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Abstract 
 Adrenergic receptors (AR) are G protein-coupled receptors (GPCRs) responsible for 
regulating physiological processes including the fight-or-flight response, muscle contraction, 
blood flow, and energy release. Numerous protein kinases play key roles in AR signaling 
cascades such as GPCR kinases (GRKs) and inflammatory kinases whose aberrant activity 
contributes to cardiovascular disease, hypertension, type 2 diabetes, and obesity. Thus, a detailed 
molecular understanding of the structure, function, and regulation of these kinases will therefore 
facilitate the development of novel therapeutic interventions. 
 Obesity results in chronic inflammation of adipocytes through increased expression of 
inflammatory kinases, namely, IKKε and TBK1, which indirectly attenuate β3 adrenergic 
receptor signaling to decrease energy expenditure and disrupt glucose homeostasis. Together, 
excessive activity of IKKε and TBK1 exacerbates the obese phenotype and leads to the 
development of type 2 diabetes. The drug amlexanox is a modest potency inhibitor of both 
kinases that produces weight loss and improves insulin sensitivity when administered to obese 
mice. Herein, I report the co-crystal structure of TBK1 in complex with amlexanox and a 
comprehensive profiling of the structure-activity relationships (SAR) of amlexanox analogs. 
Through the determination of seven co-crystal structures of TBK1 in complex with amlexanox 
and amlexanox analogs inhibitors, we uncovered mechanisms for improving potency, cellular 
efficacy, and selectivity against IKKε and TBK1. Future efforts on targeting IKKε and TBK1 
!x
should carefully consider pharmacokinetics, as we observe a stark disconnect between in vitro 
potency and efficacy in cells and animals. Taken together, amlexanox undoubtedly represents a 
pharmacophore amenable to therapeutic development whose analogs may have clinical value in 
the treatment of diabetes and obesity. 
 Heart contractility is carefully regulated through the activation of the ⍺1 adrenergic receptor 
and subsequent desensitization by GRKs. Excessive activation of ⍺1AR, such as during cardiac 
arrest, leads to abnormally high levels of intracellular Ca2+ and activation of calmodulin 
(Ca2+·CaM) which inhibits GRK5 and promotes nuclear translocation of the kinase, leading to 
maladaptive ventricular hypertrophy. I determined the architecture of the Ca2+·CaM–GRK5 
complex through small X-ray scattering and electron microscopy, which show that Ca2+·CaM 
inhibits GRK5 via bitopic bridging to two different regions of GRK5. The natural product 
calmodulin inhibitor malbrancheamide, which I showed binds exclusively to the C-terminal lobe 
of Ca2+·CaM in a co-crystal structure, was used to probe the Ca2+·CaM–GRK5 interaction. I 
establish malbrancheamide as a tool for probing the regulatory effects of half the Ca2+·CaM 
interaction. The bitopic nature of Ca2+·CaM binding to GRK5 produces different modes of 
regulation which may therefore be exploited for therapeutic development. In particular, 
disrupting the C-terminal interaction may retain GRK5 at the cell membrane and block cardiac 
hypertrophy. Together, my work suggests that natural products may serve as useful probes for 
studying Ca2+·CaM protein-protein interactions. Future efforts should consider the utility of 
screening natural product compound libraries to identify additional molecules that may be of use 
in studying maladaptive cardiac pathologies. 
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Chapter 1: Introduction 
1.1. Adrenergic receptor signaling 
 1.1.1. Structure and function of G protein-coupled receptors. G protein-coupled 
receptors (GPCRs) constitute the largest family of cell 
surface receptors in humans (>800 members) and play 
a critical role in the regulation of many physiological 
processes through the activation of the G proteins G⍺ 
and Gβγ (Pierce et al., 2002; Fredriksson et al., 2003; 
Tesmer, 2016). Different GPCRs couple to one or 
more of the four primary classes of G⍺ (Hepler and 
Gilman, 1992). The primary role of G⍺s is the 
activation of adenylyl cyclase which generates cAMP. 
Elevated levels of cAMP lead to activation of protein 
kinase A (PKA), which phosphorylates a variety of 
targets. Conversely, G⍺i/o inhibits cAMP production. 
G⍺q activates phospholipase C which hydrolyzes 
phospholipids to produce phosphatidylinositol 4,5-
bisphosphate (PIP2) and diacyl glycerol, the later of 
which activates protein kinase C (PKC) and additional 
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Figure 1.1: Structural comparison of 
activated β2AR in complex with 
nucleotide free G⍺s and Gβγ (PDB 
3SN6) and inactive β2AR (PDB 5JQH). 
Nanobodies and T4 lysozyme groups 
are omitted for clarity. The straight 
arrow indicates a clash between TM6 
in the inactive state and the helical 
domain of G⍺s. Activation of the 
receptor leads to a dramatic movement 
of TM6 (curved arrow and spheres) and 
lengthening of TM5, that make the core 
of the receptor more accessible for 
insertion of the ⍺5 helix of G⍺s.
TM5
downstream signaling events including release of stored intracellular Ca2+. G⍺t (transducin), 
which is exclusively expressed in the retina, is activated by the GPCR rhodopsin and rapidly 
reduces the levels of cGMP through the activation of phosphodiesterases (PDEs) giving rise to 
vision. Gβ and Gγ function as a constitutive heterodimer (Gβγ) and are associated with G⍺ 
subunits prior to activation by GPCRs. Free Gβγ heterodimers regulate the function of dozens of 
proteins including activation of some GPCR kinases (GRKs), PLCβ, and ion channels. 
 GPCRs are activated by a variety of ligands including small molecule hormones, 
peptides, and photons of light (Tesmer, 2016). Upon activation, GPCRs undergo a series of 
conformational changes, most notably outward movement of transmembrane helix 6 (TM6, 
Figure 1.1), that leads to the binding of and the exchange of GDP for GTP on G⍺, thereby 
activating the ⍺ subunit of the heterotrimer and leading to dissociation of the Gβγ subunits. Thus, 
GPCRs act as transmembrane guanine nucleotide exchange factors. 
 1.1.2. Adrenergic receptors in cardiomyocytes and the control of contractility. The 
adrenergic receptor (AR) subfamily of GPCRs are activated by the catecholamine hormones 
epinephrine (adrenalin) and norepinephrine (noradrenaline) and regulate the fight-or-flight 
response, smooth muscle contraction or relaxation, and energy mobilization through coupling to 
different G⍺ isoforms (Rockman et al., 2002). ⍺1- and ⍺2AR couple to G⍺q and G⍺i, 
respectively, whereas all three βARs primarily couple to Gs. Together, the combined stimulation 
of ⍺- and βARs is critical for cardiovascular function which relies on the careful activation of 
ARs in the myocardium. Stimulation of ⍺1ARs by norepinephrine leads to Ca2+ release from the 
sarcoplasmic reticulum thereby triggering muscle contraction. Simultaneously, βARs, which are 
!2
generally less potently activated by norepinephrine, will signal for an increase in heart rate and 
stroke volume. 
  1.1.3. Adrenergic receptors in adipocytes and the control of energy homeostasis. 
Adrenergic receptors also play a key role in the maintenance of proper energy balance in 
adipocytes (Cannon and Nedergaard, 2004). Activation of the β3AR in brown adipocytes by 
norepinephrine from the hypothalamus leads to increased cAMP levels through G⍺s and 
activation of PKA. PKA phosphorylates the transcription factor cAMP response element-binding 
protein (CREB) that leads to increased gene expression. Among the target genes is Ucp1 which 
encodes uncoupling protein 1 (UCP1, also known as thermogenin). UCP1 is a proton pore that 
resides in the inner mitochondrial membrane and acts to dissipate the proton gradient formed by 
oxidative phosphorylation by the electron transport chain. Thus, the uncoupling of oxidation and 
phosphorylation results in greater energy expenditure through increased β-oxidation of fatty 
acids while generating heat as a byproduct. This process, known as non-shivering thermogenesis, 
is a major component of basal metabolism and the maintenance of body temperature (Cannon 
and Nedergaard, 2004). 
1.2. Regulation of adrenergic receptor signaling cascades by kinases 
 1.2.1. Structure and function of kinases. Adrenergic receptor signaling relies heavily on 
protein kinases for the regulation and propagation of signals throughout the cell. The human 
kinome is composed of >500 kinases whose function is to transfer the g phosphate from ATP to 
substrates (Manning et al., 2002). Kinases are divided into two primary groups, Ser/Thr and Tyr 
kinases, based on the residue(s) phosphorylated by the enzyme. A third group of kinases, termed 
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pseudokinases, frequently bind ATP but lack catalytic residues or are too catalytically slow for 
their activity to have biological significance. Despite lacking activity, pseudokinase domains 
often work in tandem with an active kinase domain where they play critical roles in facilitating 
protein-protein interactions, allostery, and substrate recruitment (Zeqiraj and van Aalten, 2010). 
 The canonical kinase domain is approximately 250-300 residues in length and forms two 
lobes (Figure 1.2) (Huse and Kuriyan, 2002; Taylor and Kornev, 2011). The N-terminal “small” 
lobe is predominantly composed of β sheets and contains a glycine-rich hairpin with the 
consensus sequence of GxGxxG that forms the ATP phosphate-binding loop (P-loop) and is 
similar to the canonical Walker A motif (Figure 1.2 A,D) (Saraste et al., 1990; Walker et al., 
1982). The C-terminal “large” lobe is mostly helical and contains the so-called kinase activation 
loop and Asp-Phe-Gly (DFG) motif (Figure 1.2 D). Most kinases require phosphorylation of one 
or more residues in their activation loop for efficient catalysis. The DFG motif contains residues 
critical for the coordination of Mg2+. Connecting the small and large lobes of kinases is a flexible 
hinge region (Figure 1.2 B,C) that allows for opening and closing of the kinase domain when 
binding ATP or substrates (Madhusudan et al., 2002; Huse and Kuriyan, 2002; Taylor and 
Kornev, 2011; Yao et al., 2017). Located in the hinge region is the so-called “gatekeeper” 
residue, which is often a bulky hydrophobic residue in Ser/Thr kinases but a Thr in Tyr kinases 
(first defined as corresponding to Thr338 in c-Src) (Taylor and Kornev, 2011; Dar and Shokat, 
2011). This residue both regulates binding of ATP as well as the formation of a hydrophobic 
spine that stabilizes the active conformation of the kinase (Taylor and Kornev, 2011; Roskoski, 
2016). Also necessary for the formation of a catalytically-competent active conformation is the 
positioning of the DFG motif and small lobe ⍺C helix inward toward the ATP binding site 
!4
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Figure 1.2: Structure of the canonical kinase domain. A) Protein kinase A (PDB 1ATP), the first 
crystal structure of a protein kinase, in complex with Mn2+ (labeled as the more biologically 
relevant Mg2+), ATP, and the substrate-competitive peptide inhibitor PKI. The gatekeeper residue 
Met120 is shown in yellow spheres, the DFG residues in blue spheres, Mg2+ in dark gray, and 
phosphorylated Thr197 in the activation loop in magenta spheres. The active site tether (AST) 
loop is a conserved structural feature of AGC family kinases of which PKA is a founding 
member. B) Side view of adenine-hinge interactions. The P-loop covers the phosphate groups. 
The gatekeeper (yellow spheres) and AST loop must be properly aligned for efficient catalysis. 
C) Top-down view of the active site (P-loop omitted). The Asp residue of the DFG motif aids in 
the coordination of Mg2+ ions and phosphates. The substrate phosphorylation site is marked with 
an *, though no phosphorylatable residues exist in PKI. D) View of the activation loop and ⍺C 
helix. Phosphorylation of Thr197 (marked with an arrow) in the activation loop establishes a 
network of interactions with neighboring activation loop and ⍺C helix residues which aids in 
proper positioning of the DFG motif and ⍺C helix for catalysis. The substrate phosphorylation 
site is marked with an *.
(Treiber and Shah, 2013; Hari et al., 2013; Arencibia et al., 2013) which is aided by activation 
loop phosphorylation (Figure 1.2 D). Given their importance in regulating kinase activation and 
catalysis, the activation loop, P-loop, and gatekeeper residue are frequent sites of mutation in 
disease. 
 1.2.2. GPCR kinases and receptor desensitization. Particularly important kinases in the 
regulation of adrenergic receptors are the GPCR kinases (GRKs). GRKs are Ser/Thr kinases that 
phosphorylate the third intracellular loop and/or C-terminus of active GPCRs to initiate primary 
receptor desensitization (Figure 1.3 A) (Homan and Tesmer, 2014; Komolov and Benovic, 
2018). Arrestin proteins preferentially bind phosphorylated, activated receptors thereby sterically 
occluding the binding of heterotrimeric G proteins and arresting downstream signaling (Kohout 
and Lefkowitz, 2003; Reiter and Lefkowitz, 2006; Gurevich and Gurevich, 2006; Premont and 
Gainetdinov, 2007; Kang et al., 2015). Arrestins also associate with clathrin-coated pits resulting 
in receptor internalization thereby reducing the number of receptors at the cell surface available 
to bind ligands (Reiter and Lefkowitz, 2006; Hanyaloglu and von Zastrow, 2008). Endocytosed 
receptors are either recycled back to the membrane to resume signaling or fuse with the 
lysosome for degradation. Interestingly, whereas arrestin-bound GPCRs are largely unable to 
couple to G proteins (Tsvetanova et al., 2015), arrested receptors can continue signaling through 
alternative pathways because arrestin serves as a scaffold for the recruitment of mitogen-
activated protein kinases (MAPK) and other proteins (Lefkowitz and Shenoy, 2005; Jiyuan Sun 
and X Lin, 2008; Irannejad and von Zastrow, 2014). 
 GRKs contain a kinase domain most closely related to those of the AGC (protein kinase 
A, G, and C) family of kinases. The domain is inserted into a regulator of G protein signaling 
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homology (RH) domain (Figure 1.3 B) (Lodowski et al., 2003; Komolov and Benovic, 2018). 
They are grouped into three subfamilies each with distinct C-terminal membrane localization 
mechanisms to facilitate efficient receptor phosphorylation. Because there are >800 GPCRs and 
only seven GRKs, GRKs are fairly promiscuous and consequently phosphorylate numerous non-
receptor substrates (Gurevich et al., 2012). The visual GRK subfamily, which includes GRK1 
and 7, are irreversibly prenylated in their C-terminus (Inglese et al., 1992). The GRK2 subfamily 
includes GRK2 and 3 and binds prenylated Gβγ subunits via their C-terminal pleckstrin 
homology (PH) domain (Tesmer et al., 2005). The GRK4 subfamily encompasses GRK4, 5, and 
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Figure 1.3: GPCR desensitization canonically involves GRKs and arrestin. A) Schematic of 
GPCR desensitization and internalization. After phosphorylation of the third intracellular loop 
and C-tail by GRKs, arrestin binds the GPCR and serves as a scaffold for MAPKs or interacts 
with clathrin to facilitate receptor endocytosis. The internalized receptor can continue to signal 
through MAPKs, be recycled back to the plasma membrane, or undergo degradation. B) 
Composite GRK5/6 (PDB 4WNK and 3NYN) structure and domain layout of the three 
subfamilies of GRKs. The ⍺N helix, PIP2 binding patch, ⍺C helix, and C-tail (CT) are taken 
from GRK6 and modeled onto GRK5. *Denotes lipidation site(s) in GRK1, 4, 6, and 7.
6. GRK4 and 6 are reversibly palmitoylated in their C-terminus (Stoffel et al., 1994; Premont et 
al., 1996; Loudon and Benovic, 1997; Stoffel et al., 1998; Moepps et al., 1999; Jiang et al., 
2007). All three GRK4 subfamily members contain a membrane-binding C-terminal amphipathic 
helix that also aids in orienting the GRK at the membrane interface (Thiyagarajan et al., 2004; P 
Yang et al., 2013). In addition to these mechanisms, GRKs interact with anionic phospholipids 
which promote membrane association and kinase activation (Homan, Glukhova, et al., 2013). 
GRK4 subfamily members strongly intact with phospholipids through a basic patch at its N-
terminus (residues 22-29) with preference for PIP2 (Kunapuli et al., 1994; Pitcher et al., 1996). 
GRK5, which lacks C-terminal palmitoylation sites, relies primarily on its C-terminal 
amphipathic (⍺C) helix and interactions with phospholipids for membrane association 
(Thiyagarajan et al., 2004; Ding et al., 2014) 
 1.2.3. AMP and p38 kinases in energy homeostasis. AMP-activated protein kinase 
(AMPK) and p38 MAPK are key regulators of lipid metabolism and thermogenesis in β3AR-
regulated energy homeostasis in brown adipose tissue (BAT) (Cannon and Nedergaard, 2004; BB 
Zhang et al., 2009; Saltiel, 2012). AMPK is a heterotrimeric protein kinase composed of ⍺, β, 
and γ monomers that monitors the intracellular AMP:ATP ratio, which is an indicator of cellular 
energy levels (Oakhill et al., 2009; Lin and Hardie, 2018). When energy is deprived, the γ 
subunit cooperatively binds AMP rather than ATP, which induces an active conformation of the 
kinase leading to the phosphorylation of numerous targets, including enzymes involved in 
primary metabolism, with the net effects of reduced fatty acid synthesis and increased β-
oxidation of fatty acids, glucose uptake, glycogen synthesis, and mitochondrial biogenesis 
(Saltiel, 2012; Hardie et al., 2016). p38 MAPK is activated by increased levels of cAMP and 
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phosphorylates a variety of substrates, some which overlap with AMPK, to further regulate 
energy homeostasis (Yong et al., 2009). One downstream effect of p38 MAPK activation in 
adipocytes is the production of interleukin-6 (IL-6), which is secreted from adipocytes and 
promotes glucose uptake in hepatocytes (Reilly et al., 2015). Thus, p38 MAPK acts as a bridge 
between activation of β3AR in fat cells and insulin response in the liver. 
1.3. Pathological signaling involving kinases in adrenergic receptor cascades 
 1.3.1. Cardiac failure and hypertrophy mediated by GRK5. Cardiovascular disease is the 
leading cause of death in developed countries and includes myocardial infarction, more 
commonly known as a heart attack. Myocardial infarction is caused by reduction or blockage of 
blood supply to a portion of the myocardium leading to cell death and reduced cardiac output. In 
an attempt to restore cardiac output during a heart attack, the parasympathetic nervous system 
releases a bolus of catecholamine hormones which activate adrenergic receptors, principally 
⍺ARs, which couple to Gq and elevate intracellular Ca2+ levels to stimulate muscle contraction 
(Métayé et al., 2005; Salazar et al., 2007; Sato et al., 2015). However, excessive activation of 
adrenergic receptors leads to rapid, maladaptive desensitization by GRKs that attenuates 
cardiomyocyte contraction and prevents restoration of cardiac output. Thus, inhibition of GRKs, 
namely GRK2 and GRK5, represents a route to improving cardiac function during periods of 
cardiac stress (Waldschmidt et al., 2016). 
 A negative feedback mechanism to counteract receptor desensitization during a heart 
attack has evolved (Figure 1.4). Increased intracellular levels of Ca2+ in response to ⍺AR 
stimulation activates the small calcium sensing protein calmodulin (CaM). CaM is a key 
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regulator of dozens of proteins and is 
highly abundant, comprising >0.1% 
protein by mass in humans, and highly 
conserved between mammals and 
plants (Kursula, 2014). CaM contains 
two pairs of calcium-binding EF-
hands separated by a flexible helix. 
The formation of the Ca2+·CaM 
complex leads to conformational 
changes that result in the formation of 
two hydrophobic pockets that are 
responsible for interactions with target 
proteins (Tidow and Nissen, 2013). 
Ca2+·CaM binds to and inhibits all GRKs, but most potently GRK5, the GRK primarily 
responsible for the desensitization of ⍺ARs in cardiomyocytes. 
 Whereas moderate inhibition of GRK5 is beneficial, excessive activation of Ca2+·CaM 
leads to detrimental effects on cardiac function (Figure 1.4). The Ca2+·CaM–GRK5 complex 
dissociates from the plasma membrane and translocates to the nucleus (Gold et al., 2013), due to 
the presence of a strong nuclear localization sequence (NLS) in GRK5 (Johnson et al., 2004), 
where GRK5 phosphorylates a variety of substrates including histone deacetylase 5 (HDAC5) 
(Martini et al., 2008). Phosphorylation of HDAC5 leads to binding of 14-3-3 proteins which 
shuttle HDAC5 out of the nucleus resulting in derepression of numerous genes with profound 
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Figure 1.4: Nuclear translocation of GRK5 is 
Ca2+·CaM-dependent. Nuclear GRK5 phosphorylates 
a variety of substrates including HDAC5 to derepress 
gene transcription and promote cardiac hypertrophy.
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physiological effects. Most notably, decreased nuclear levels of HDAC5 in cardiomyocytes lead 
to the induction of genes through the transcription factor myocyte enhancer factor-2 (MEF2) 
(Gold et al., 2013; Hullmann et al., 2014) which in turn result in hypertrophic cardiomyopathy/
ventricular hypertrophy. This maladaptive process leads to enlargement or thickening of the 
ventricular walls and reduced cardiac output, counteracting the initial benefits of GRK inhibition 
and leading to an increased chance of additional episodes of cardiac arrest (Frey and Olson, 
2003; Y Zhang et al., 2011; Gold et al., 2013). Mutation of the GRK5 NLS or introduction of 
Ca2+-binding deficient CaM in mice prevented post-infarct cardiac hypertrophy by suppressing 
pathological gene activation (Johnson et al., 2004). Therefore, blocking the translocation of 
Ca2+·CaM–GRK5 to the nucleus represents a potential therapeutic strategy for suppressing 
ventricular hypertrophy. 
 1.3.2. Obesity and diabetes mediated by TBK1 and IKKε. Obesity is a leading risk factor 
for the development of cardiovascular disease. Globally, more than 2 billion people are clinically 
overweight or obese including nearly half of adults in the United States (Swinburn et al., 2011). 
Furthermore, obesity is the leading risk factor for the development of insulin resistance, or type 2 
diabetes mellitus, which affects more than 10% of Americans with an additional 25% classified 
as prediabetic. A hallmark of obesity is chronic, low-grade inflammation in a variety of tissues 
(Mowers et al., 2013). Most FDA-approved therapies for obesity focus on reducing caloric 
intake or altering the neurological reward system associated with eating (Saltiel, 2016). 
However, recognition that inflammation is involved in the progression of obesity has led to an 
interest in studying the link between inflammation, dysregulated body weight, and insulin 
resistance (Reilly and Saltiel, 2017). 
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 Chronic inflammation as the result of a high fat diet stems from elevated levels of 
circulating tumor necrosis factor alpha (TNF⍺) which induces the expression of the kinases 
inhibitor of NF-κB (IκB) kinase epsilon (IKKε) and TANK-binding kinase 1 (TBK1) (Chiang et 
al., 2009). IKKε and TBK1 are Ser/Thr kinases that share 64% sequence identity overall and 
72% identity in their kinase domains. In addition to an N-terminal canonical kinase domain, both 
kinases possess an ubiquitin-like domain (ULD) and an extensive coiled-coiled scaffolding and 
dimerization domain (SDD) (Figure 1.5 A) (Tu et al., 2013; Larabi et al., 2013; Shu et al., 
2013). The extreme C-terminus of either kinase is critical for interactions with adaptor proteins. 
 Whereas IKKε and TBK1 have been most studied for their role in interferon signaling in 
response to viral infection (Tenoever et al., 2007; Shu et al., 2013), the kinases share significant 
homology to the canonical proinflammatory kinases IKK⍺ and IKKβ and are also able to 
activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Shimada et al., 
1999; Chau et al., 2008). In addition to their contributions to chronic inflammation, 
overexpression of IKKε and TBK1 in adipocytes leads to phosphorylation and activation of 
phosphodiesterase 3B (PDE3B) that degrades cAMP to attenuate β3AR-mediated thermogenic 
signaling (Figure 1.5 B) (Chiang et al., 2009; Mowers et al., 2013). Reduced cAMP levels 
suppresses PKA and p38 MAPK activity, leading to reduced levels of UCP1 and IL-6, 
respectively. As UCP1 levels directly affect non-shivering thermogenesis, reduced levels slow 
basal metabolism to produce additional weight gain. Meanwhile, reduction in hepatic stimulation 
by IL-6 leads to dysregulated glucose metabolism and insulin response that contributes to the 
development of type 2 diabetes (Reilly et al., 2015). Furthermore, decreased levels of cAMP 
suppresses AMPK and promotes direct phosphorylation of TBK1 by Unc-51-like autophagy-
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activating kinase 1 (ULK1) at Ser172 in its activation loop leading to increased TBK1 kinase 
activity (Zhao et al., 2018). Together, increased levels and activity of IKKε and TBK1 engages a 
feed-forward mechanism that promotes additional weight gain and further reduces insulin 
sensitivity.  
 Deletion of the IKKε gene in obese mice attenuated some of the deleterious metabolic 
effects of high fat feeding resulting in reduced weight gain, lowered insulin resistance, and less 
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Figure 1.5: TBK1 and IKKε attenuate catecholamine-stimulated cAMP production. A) 
Structure and domain layout of TBK1 in complex with an ATP-competitive inhibitor (PDB 
6BNY). The C-terminal domain (CTD) is absent in the construct crystallized. B) 
Schematic of the mechanism by which TBK1 attenuates thermogenic signaling and insulin 
response. TBK1 and IKKε directly phosphorylate and activate PDE3B which decreases 
intracellular [cAMP] thereby attenuating signaling through PKA, p38 MAPK, and AMPK 
while activating a feed-forward mechanism through direct phosphorylation of TBK1 by 
ULK1 which is normally repressed by AMPK.
chronic low-grade inflammation than wild-type controls (Chiang et al., 2009). These data 
suggest IKKε and TBK1 may represent attractive therapeutic targets in the treatment of obesity 
and diabetes. 
1.4. Pharmacological targeting of protein kinases 
 1.4.1. Types of kinase inhibitors. Given their role in the regulation of fundamental 
cellular processes, extensive effort has been invested in the development of therapeutics targeting 
kinases. In fact, kinases are fourth in the overall number of current FDA-approved therapeutics 
and first in approved cancer drugs over the past two decades (Vitaku et al., 2014; Wu et al., 
2015; Jingchun Sun et al., 2017; Santos et al., 2017). The first kinase inhibitor, imatinib, was 
approved in 2001 for Bcr-Abl-driven leukemia (Figure 1.6 A) (Roskoski, 2015). Since then, 
more than 250 small molecules have progressed to human trials with nearly 40 earning FDA 
approval. 
 The vast majority of kinase inhibitors are small molecules that bind in or near the ATP 
binding pocket and are classified by their binding site and preferred kinase conformation (Dar 
and Shokat, 2011; Roskoski, 2016). Type I inhibitors are the most common and bind the DFG- 
and ⍺C helix-in conformation. As both structural elements must be positioned inward toward the 
active site for catalysis, type I inhibitors are said to bind the active conformation of kinases. Type 
II inhibitors bind the less common DFG- and ⍺C helix-out conformation (Figure 1.6 A) (Y Liu 
and Gray, 2006). Type I and II inhibitors almost always interact with the hinge and/or gatekeeper 
regions of the kinase and thus occupy the ATP binding site and are ATP-competitive.  
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Figure 1.6: Structures of different classes of small molecule kinase inhibitors. A) Crystal 
structure of Abl kinase in complex with imatinib and GNF-2 (PDB 3K5V). Imatinib, a type II 
ATP-competitive inhibitor, binds along the hinge with a portion of the molecule extending toward 
the ⍺C helix. This binding mode is only possible when the DFG motif and ⍺C helix swing out 
(indicated by an arrow) to assume the inactive conformation. GNF-2 is an allosteric inhibitor that 
binds in a distant myristate-binding pocket which interferes with kinase activation. Kinase 
coloring is consistent with Figure 1.2 A. B) Crystal structure of MEK1 in complex with the 
allosteric inhibitor PD 318088, which occupies the same binding site as PD 098059, and ATP 
(PDB 1S9J). The compound forces the DFG motif and ⍺C helix out to yield an inactive kinase 
conformation without affecting ATP binding. C) Crystal structure of Bruton's tyrosine kinase with 
the type VI covalent inhibitor ibrutinib (PDB 5P9J). The acrylamide group on ibrutinib forms a 
covalent bond with Cys481 in the large lobe of the kinase. D) GRK2 in complex with the type I 
inhibitor paroxetine (PDB 3V5W). The benzodioxole moiety forms a contact with the hinge 
while the fluorophenyl packs against the P-loop. E) Chemical structures of select kinase 
inhibitors.
 A minority of small molecule kinase inhibitors target allosteric or regulatory regions of 
the protein. Researchers at Parke-Davis identified small molecules including PD 098059, that are 
capable of inhibiting MEK without displacing ATP, representing the first reported non-ATP-
competitive kinase inhibitors (Alessi et al., 1995; Dudley et al., 1995). Such molecules bind 
adjacent to the ATP site (type III, Figure 1.6 B), at allosteric sites distant from the ATP site (type 
IV, Figure 1.6 A), or both (type V or bivalent) and often inhibit by preventing the kinase from 
assuming an active conformation, disrupting substrate binding, or altering cellular localization 
(Roskoski, 2016). Additional allosteric small molecule inhibitors include the type IV inhibitor 
GNF-2 which binds the myristate-binding pocket on Abl kinase thereby disrupting the ability of 
the kinase to assume an active conformation (Figure 1.6 A) (J Zhang et al., 2010). Type VI 
inhibitors form covalent adducts with cysteine residues within the protein often through a 
Michael acceptor group, such as an acrylamide, on the inhibitor (J Zhang et al., 2009). 
Historically avoided for potential off-target reactivity, covalent kinase inhibitors have gained 
popularity due to recent successes in animals and humans (Chaikuad et al., 2018) Consequently, 
several FDA-approved covalent kinase inhibitors, such as ibrutinib, are currently on the market 
primarily targeting tyrosine kinases in cancer (Figure 1.6 C) (J Zhang et al., 2009; Ferguson and 
Gray, 2018). 
 1.4.2. Inhibitors targeting GRKs. Most efforts to target GRKs have focused on their role 
in heart failure, hypertension, and other facets of cardiovascular disease (Homan and Tesmer, 
2014a; Homan, Larimore, et al., 2015; Waldschmidt et al., 2016). Many pan-kinase inhibitors, 
such as staurosporine and sangivamycin, inhibit GRKs as well as many other kinases. The 
natural product balanol (Figure 1.6 E) is selective for AGC-family kinases, to which GRKs 
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belong, and is nearly 100-fold selective for GRK2 over other GRK subfamilies (Tesmer et al., 
2010; Thal et al., 2011; Homan and Tesmer, 2014a). A family of structurally related inhibitors 
produced by Takeda Pharmaceuticals exhibit greater selectivity for GRK2 and appeared to be 
promising inhibitors for the treatment of heart failure (Thal et al., 2011). However, their low 
bioavailability precluded further development or clinical trials.  
 The FDA-approved antidepressant paroxetine was identified as an inhibitor of GRK2 and 
bears structural similarity to several well-characterized Rho-associated coiled-coiled containing 
kinase (ROCK) inhibitors reported by GlaxoSmithKline (Figure 1.6 D) (Thal et al., 2012; 
Homan, Wu, et al., 2013, Homan et al., 2014, Homan and Tesmer, 2014). Through structure-
based drug design (SBDD), numerous analogs of paroxetine were synthesized drawing from 
prior studies on balanol and ROCK inhibitors. Highly potent and GRK2-selective inhibitors were 
synthesized and evaluated in mouse models of heart failure and hypertrophy (Waldschmidt et al., 
2016; 2017; Bouley et al., 2017). Paroxetine and several related analogs increased cardiac 
contractility in mouse models of heart failure (Schumacher et al., 2015; Bouley et al., 2017). The 
FDA-approved anti-inflammatory drug amlexanox was also identified as a GRK inhibitor 
(Homan et al., 2014). Unlike paroxetine, amlexanox is only 5-10-fold selective for GRK5 
(Figure 1.6 E). Administration of amlexanox treatment markedly reduced the activation of 
hypertrophic genes in line with prior data indicating aberrant nuclear GRK5 activity inducing 
cardiac hypertrophy. This suggests differential cellular permeability or subcellular localization of 
amlexanox relative to paroxetine. 
 Despite advances in potent and selective inhibition, no inhibitors targeting GRKs or other 
AGC-family kinases have been approved for clinical use perhaps due to the lack of mutations 
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adversely affecting GRK activity and regulation. Indeed, most type I/II approved inhibitors, 
particularly tyrosine kinase inhibitors, target mutant forms of the enzyme with aberrant activity 
(Wu et al., 2015; Roskoski, 2015). An alternative to ATP-competitive inhibitors are those 
allosterically targeting protein-protein interactions. The overexpression of the dominant negative 
C-terminus of GRK2 (βARKct) sequesters free Gβγ and thereby suppresses GRK2 and 3 activity, 
leading to improved cardiac output during heart failure (Koch et al., 1995; Rockman et al., 
1998). Thus, small molecule inhibitors of Gβγ interactions, such as gallein, may prove useful 
inhibitors of GRK2 and 3 (Casey et al., 2010; Kamal et al., 2014). 
 1.4.3. Inhibitors targeting p38 MAPK, AMPK, and IκB kinases. Inhibitors targeting p38 
MAPK, AMPK, and IκB kinases have been aggressively pursued given the prevalence of 
inflammation in many disease states including cancer and metabolic disorders (Yong et al., 
2009). A key challenge of kinase inhibitor development is selectivity, as the ATP binding site 
among kinases is highly conserved. The groundbreaking p38 MAPK inhibitor SB 202190 
(Figure 1.6 E) proved that selective inhibition of kinases was achievable (Barancík et al., 2001). 
The selectivity of SB 202190 stems from differences in the gatekeeper residue of MAPKs, which 
forms a critical contact with the inhibitor. Several structurally related p38 inhibitors have entered 
clinical trials but, despite excellent selectivity, failed to illicit a significant response or were 
associated with toxicity (Llona-Minguez and Baiget, 2013). Unlike most kinases, therapeutic 
targeting of AMPK has focused on the development of activators rather than inhibitors, as 
substrate phosphorylation is beneficial in the context of diabetes and obesity (BB Zhang et al., 
2009; Hardie et al., 2012; Cameron and Kurumbail, 2016). AMPK-activating compounds, such 
as the widely prescribed drug metformin, indirectly activate AMPK by altering cellular levels of 
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AMP/ATP. The direct, ATP-competitive AMPK inhibitor dorsomorphin/compound C (Figure 1.6 
E) is being explored as a therapeutic option for several cancers, though off-target inhibition of 
other kinases is believed to contribute to its antiproliferative effects (Jin et al., 2009; X Liu et al., 
2014). 
 Inhibitors targeting the canonical IκB kinases, predominantly IKKβ, but also IKK⍺, 
which canonically activate proinflammatory NF-κB signaling, have been extensively explored by 
both academic and industrial groups (Llona-Minguez and Baiget, 2013). However, out of several 
thousand patented compounds and more than a dozen clinical trials, no IKK⍺ or IKKβ inhibitors 
have earned FDA-approval, typically as a result of severe side effects stemming from 
immunosuppressive effects of sustained NF-κB inhibition. Thus, there has been a significant 
decline in IKK⍺ or IKKβ inhibitors since the mid-2000s. However, interest in targeting the non-
canonical inflammatory kinases IKKε and TBK1 have dramatically increased over the past 
several years. The Medical Research Council has been at the forefront of IKKε and TBK1 
inhibitor development, first with the identification of the pyruvate dehydrogenase kinase 1 
inhibitor BX795 (Figure 1.6 E) as a potent inhibitor of IKKε and TBK1 (Clark et al., 2009; 
2011), and the synthesis of BX795 analogs which have progressed to pre-clinical trials (Llona-
Minguez and Baiget, 2013). Several pharmaceutical companies have IKKε and TBK1 inhibitors 
nearing clinical trials, primarily as antiproliferative agents, highlighting the promise of 
pharmacological targeting of these kinases (Wang et al., 2012; Hayden and Ghosh, 2012; Llona-
Minguez and Baiget, 2013). However, no reported compounds under investigation are for the 
treatment of metabolic diseases including obesity and type 2 diabetes. Thus, it is unknown 
whether any reported compounds are promising leads for these indications. 
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1.5. Summary and research goals. 
 Kinases play critical roles in many important physiological signaling cascades including 
cardiac function and basal metabolism, which are both regulated by adrenergic receptors. Herein, 
I aim to use structural biology to improve our understanding of the structure, function, and 
regulation of some of the key kinases involved in these pathways to aid in the identification and 
development of novel therapeutic strategies for the treatment of heart disease, obesity, and 
diabetes (Figure 1.7). First, I will describe my contributions to a structure-based drug design 
campaign to develop inhibitors of IKKε and TBK1 and their translation towards a clinical 
treatment for diet-induced obesity and type 2 diabetes. Through the determination of co-crystal 
structures of TBK1 in complex with amlexanox and amlexanox analogs, we uncovered 
mechanisms for improving potency, efficacy, and selectivity against IKKε and TBK1. I also 
report on the biophysical characterization of the Ca2+·CaM–GRK5 complex implicated in 
cardiac hypertrophy. Structural studies of the complex were aided by the application of a natural 
product probe that targets Ca2+·CaM and led to the identification of druggable features of the 
complex that may be exploited as a therapeutic strategy to block hypertrophy in the heart. Lastly, 
I will describe the first method for the expression and purification of human GRK5 in bacteria 
along with its biochemical characterization. 
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Figure 1.7: Summary of dissertation research centering on pathological regulation of 
adrenergic receptor signaling by kinases. Chapters 2 and 3 will describe efforts to develop 
therapeutics targeting TBK1 and IKKε for the treatment of metabolic disease. Chapters 4 and 5 
will focus on the regulation of GRK5 by Ca2+·CaM in the context of maladaptive cardiac 
hypertrophy.
Chapter 2: Characterization of Amlexanox and Carboxylic Acid Analogs as Inhibitors of 
IκB Kinases 
2.1. Introduction 
 Obesity is the leading risk factor for 
the development of type 2 diabetes, and is 
characterized by chronic, low-grade 
inflammation in liver and adipose tissues 
stemming from overexpression of the 
proinflammatory kinases TBK1 and IKKε. 
Together, these kinases attenuate the actions 
of multiple hormones to produce a 
dysregulated metabolic state (Mowers et al., 
2013; Saltiel, 2016; Reilly and Saltiel, 2017). 
Several years ago, the FDA-approved asthma and aphthous ulcer drug amlexanox (Makino et al., 
1987; Bell, 2005) was identified as an inhibitor of IKKε and TBK1 (Figure 2.1) (Reilly et al., 
2013). When administered to obese mice, catecholamine-stimulated cAMP levels are restored, 
activating p38 MAPK and inducing expression of Ucp1 in adipose tissue, which leads to weight 
loss via increased energy expenditure (Reilly et al., 2013). Insulin sensitivity and regulation of 
glucose levels were also improved due to activation of the hepatic JAK/STAT pathway by IL-6 
whose expression is regulated by cAMP levels in adipocytes (Reilly et al., 2015).  
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Figure 2.1: Schematic depicting the signaling 
cascade underlying IKKε and TBK1-induced 
obesity. Amlexanox (structure inset) inhibits 
kinase activity to restore catecholamine-
stimulated signaling cascades. 
 Given the history of safety using amlexanox (Bell, 2005), phase I and II clinical trials in 
obese and diabetic patients were conducted at the University of Michigan Medical Center in 
which a subset of patients was identified for their positive response to amlexanox treatment (Oral 
et al., 2017). Patients showed improvements in glycated hemoglobin (HbA1C), insulin 
sensitivity, and displayed a reduction in hepatic steatosis while exhibiting changes in energy 
expenditure gene expression similar to those previously noted in animal studies. Interestingly, in 
contrast to prior animal studies, no significant weight loss was observed in human patients. 
 Despite these promising results, the future use of amlexanox in the clinic for obesity and 
type 2 diabetes intervention will likely be limited by its poor aqueous solubility, moderate 
potency, and/or poor metabolic profile. We demonstrate in vitro that the carboxylic acid on 
amlexanox is critical for maintaining potency against TBK1 whereas its elimination significantly 
enhances potency toward IKKε. Replacement of the carboxylic acid with a tetrazole acid 
bioisostere results in improved potency toward both kinases, whereas a simple amide only 
displays potency toward IKKε, suggesting a potential routes for the development of IKKε-
selective inhibitors. To understand how amlexanox interacts with this family of kinases and to 
interpret these results, the co-crystal structure of amlexanox bound to TBK1 was determined. 
This structure suggested a favorable interaction between the carboxylate on amlexanox and the 
Thr156 side chain in the active site that is critical for potent inhibition of IKKε and TBK1. Three 
additional amlexanox analog co-crystal structures shed light on how carboxylate analogs either 
improve or diminish potency. Together, these results provide the first critical insights into how to 
design an amlexanox analog for type 2 diabetes and obesity.  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2.2. Materials and methods 
 2.2.1. TBK1 protein expression and purification. Catalytically-inactive human TBK1 
D135N spanning residues 1-308 (“KD”) and 1-385 (“KU”) (Ma et al., 2012) were cloned into 
the bacterial expression vectors pMCSG7 (N-terminal, tobacco etch virus (TEV) protease 
cleavable hexahistidine tag) and pMCSG9 (N-terminal, TEV cleavable hexahistidine-maltose-
binding protein (MBP)) via ligation-independent cloning (LIC). Positive clones were verified by 
Sanger sequencing, the DNA transformed into BL21 DE3 pLysS Escherichia coli. Cells were 
grown in terrific broth (TB) at 37 ºC to an optical density at 600 nm of 0.6-1.0, cooled to 18 ºC, 
and induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and grown overnight. 
Cells were pelleted the next day, resuspended in buffer containing 20 mM HEPES pH 8.0, 200 
mM NaCl, 40 mM imidazole, 1 mM DTT, 0.1 mM phenylmethanesulfonyl fluoride (PMSF), 2 
µg mL-1 leupeptin, and 2 µg mL-1 lima bean trypsin protease inhibitor and briefly sonicated to 
lyse. Cell lysate was centrifuged for 30 m at 15,000xg and the supernatant glass filtered. 
Fractions of the supernatant and resuspended cell pellet were analyzed by polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 Wild-type and inactive (K38A or D135N) TBK1 spanning residues 1-308, 1-385, and 
1-657 was cloned into the modified insect expression pFastBac vector pH7pFB (University of 
Michigan Center for Structural Biology) containing a TEV cleavable N-terminal hexahistidine 
tag via LIC. Positive clones were verified by Sanger sequencing, the DNA transformed into 
DH10Bac E. coli, and viral bacmid containing the gene of interest isolated by isopropanol 
precipitation. Recombinant baculovirus was prepared by transfecting Sf9 insect cells with 
purified bacmid and passaging several times to obtain virus of a higher titer. For expression, Sf9 
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or Hi5 insect cells at a density of 2x106 cells mL-1 were infected with baculovirus and harvested 
after 65-72 h. Cells were pelleted and flash frozen in liquid nitrogen. 
 TBK1 insect cell pellets were thawed and resuspended in lysis buffer containing 20 mM 
HEPES pH 8.0, 100 mM NaCl, 40 mM imidazole, 1 mM DTT, 0.1 mM PMSF, leupeptin, and 
lima bean trypsin protease inhibitor. Resuspended cells were homogenized with a Dounce 
homogenizer prior to brief sonication. The lysate was clarified by ultracentrifugation for 1 h at 
>200,000xg. The resulting supernatant was glass filtered prior to being slowly flowed through 
Ni-NTA resin. The resin was washed with lysis buffer and the protein eluted with lysis buffer 
supplemented with an additional 200 mM imidazole. Eluted TBK1 was further purified by anion 
exchange fast protein liquid chromatography (FPLC) using a HiTrap Q column and eluted with a 
NaCl gradient from 0.0-1.0 M at pH 8.0. Purified TBK1 was incubated at 4 ºC overnight with 
10% (w/w) TEV protease while being dialyzed against 20 mM HEPES pH 7.5, 100 mM NaCl, 
and 1 mM DTT to cleave the hexahistidine tag. The following day, the mixture was again passed 
through Ni-NTA resin to remove TEV protease and uncleaved TBK1. The cleaved TBK1 protein 
was dephosphorylated by incubating at room temperature for 4-6 h with λ phosphatase (New 
England Biolabs, Ipswich, MA) in buffer supplemented with 1 mM MnCl2. The 
dephosphorylated protein was further purified via size-exclusion chromatography (SEC) on an 
analytical Superdex200 (S200) column in buffer lacking MnCl2 (20 mM HEPES pH 7.5, 100 
mM NaCl, and 1 mM DTT). Concentrations of ≥95% pure TBK1 by coomassie staining were 
determined by absorbance at 280 nm using the TBK1 molecular weight and molar extinction 
coefficient calculated from the primary sequence. Typical final yields were <0.25 mg L-1 for 
TBK1 KD and 0.25-1.0 mg L-1 cells for TBK1 1-657. 
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 2.2.2. IKKε protein expression and purification. Catalytically-inactive human IKKε 
D135N spanning residues 1-309 (“KD”) and 1-385 (“KU”) were cloned into pMCSG7 and 
pMCSG9 and expressed in E. coli as described above for TBK1. WT and inactive (K38A or 
D135N) IKKε spanning residues 1-309, 1-385, 1-641, 1-643, and 1-655 were cloned into insect 
expression vectors and baculovirus generated also as described above for TBK1. Purification of 
IKKε from insect cells followed that previously described for TBK1. Briefly, cells were lysed in 
pH 7.5 buffer, clarified by ultracentrifugation, Ni-NTA resin, and anion exchange 
chromatography via a HiTrap Q column. Due to aggregation during concentration, IKKε was not 
purified by SEC. IKKε concentrations were determined by absorbance at 280 nm using the 
calculated molecular weight and molar extinction coefficient from the primary sequence and 
flash frozen in liquid nitrogen. Typical yields of IKKε KD and KU were 0.25-0.5 mg L-1 cells 
and 5-15 mg L-1 cells for the longer constructs. 
 2.2.3. TBK1 crystallization and structure determination. TBK1 crystal form 1 (P6522) 
was obtained with N-terminally hexahistidine-tagged TBK1 (1-657 at ~6 mg mL-1) and 0.5 mM 
MRT67307 grown at 20 ºC via hanging drop vapor diffusion in drops containing 1 µL protein 
and 1 µL well solution comprised of 0.8-1.2 M Na/KPO4 pH 6.4-7.0. Large (>200 µm along 
longest axis) hexagonal cylinders grew within 1-3 days. Crystals were harvested and briefly 
soaked in a cryoprotecting solution comprised of well solution supplemented with 20% glycerol 
and 0.5 mM inhibitor. 
 Crystallization conditions for crystal form 2 (P3221) with hexahistidine-tag cleaved 
TBK1 (1-657) were based on those previously reported with modification (Tu et al., 2013; 
Larabi et al., 2013). TBK1·amlexanox crystals were grown at 20 ºC via hanging drop vapor 
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diffusion in drops containing 1 µL of 0.1 M HEPES pH 7.5, 4% (w/v) PEG 8,000, 2 µL of 
purified wild-type human TBK1 (residues 1-657 at ~3 mg mL-1), and 0.2 µL amlexanox (10 mM 
in DMSO) over wells containing 1 mL of 0.1 M HEPES pH 7.5, 4% (w/v) PEG 8,000, and 10% 
DMSO. To obtain TBK1 crystals in complex with 224182, 224120, or 224183 analogs of 
amlexanox, TBK1 was incubated with 1 mM inhibitor (from 100 mM stock in DMSO) for 1 h on 
ice. Crystals were grown at 20 ºC via hanging drop vapor diffusion in drops containing 1 µL of 
well solution and 1 µL of purified wild-type human TBK1 (residues 1-657 at ~3 mg mL-1) over 
wells containing 1 mL of 0.1 M HEPES pH 7.0-8.5 and 1-6% (w/v) PEG 8,000. Small diamonds 
≤25 µm appeared within 1-2 days and grew for an additional 1-3 days to 50-100 µm in all 
dimensions. Crystals were harvested and briefly soaked in a cryoprotecting solution composed of 
0.1 M HEPES pH 8.5, 8% (w/v) PEG 8,000, 30% (v/v) PEG 400, and 0.5 mM inhibitor prior to 
flash freezing in liquid nitrogen. 
 Data were collected at LS-CAT (Sector 21, Advanced Photon Source, Argonne National 
Lab) under a cryostream maintained at 100 K using either MAR300 or Eiger 9M detectors. All 
individual software were used as part of the SBGrid package (Morin et al., 2013). Data were 
processed with XDS (Kabsch, 2010) and the structure solved in Phenix (Adams et al., 2010) 
through molecular replacement implemented by Phaser (McCoy et al., 2007) with a ligand-free 
structure of TBK1 (PDB 4IM0, (Tu et al., 2013) as the search model. Models were built by 
alternating rounds of manual model building in Coot (Emsley et al., 2010) with reciprocal space 
refinement in Phenix alongside validation with MolProbity (Chen et al., 2010). Ligand restraints 
were generated with eLBOW in Phenix using the AM1/RM1 semi-empirical quantum-
mechanical optimization method (Moriarty et al., 2009). Graphics were prepared with PyMol 
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(Version 2.1, Schrödinger, LLC). Coordinates and diffraction amplitudes have been deposited in 
the Protein Data Bank with the accession codes 5W5V, 6BNY, 6BOD, and 6BOE. 
 2.2.4. IC50 determination by radiometric kinase assay. Reactions containing 50 nM 
TBK1 or IKKε and 5 µM myelin basic protein (MyBP) in reaction buffer (50 mM HEPES pH 
7.5, 10 mM NaCl, 10 mM MgCl2, and 1 mM DTT) with varying concentrations of inhibitor were 
initiated with 5 µM ATP spiked with [γ-32P]-ATP and allowed to proceed for 30 min at room 
temperature in a final volume of 20 µL. Reactions were quenched with SDS gel loading dye, run 
on 4-15% SDS-PAGE gels, and imaged on phosphor screens. Band intensities corresponding to 
phosphorylated MyBP were quantified with ImageQuant and the data analyzed in GraphPad 
Prism 7 using a three parameter dose-response curve model with the Hill slope constrained to –1. 
Statistical significance determined in GraphPad Prism via Student’s two-tailed T-test using the 
amlexanox IC50 as the ideal value from a total of three experiments using protein from the same 
purification and a standardized ATP stock. 
 2.2.5. Differential scanning fluorometry thermal shift assay. Differential Scanning 
Fluorometry (DSF) was performed in either a ThermoFluor or HT7900 qPCR instrument. DSF 
via the ThermoFluor instrument was performed with 0.2 mg mL-1 TBK1 or IKKε (~5.8 µM for 
KD and KU constructs and ~2.6 µM for C-terminally truncated constructs) in assay buffer 
(20 mM HEPES pH 8.0, 5 mM MgCl2, and 1 mM DTT), 0.1 mM 8-Anilino-1-
naphthalenesulfonic acid (ANS) dye, and 200 µM ligand. DSF via qPCR instrument was 
performed with 0.2 mg mL-1 (2.6 µM) TBK1 or IKKε in assay buffer (20 mM HEPES pH 8.0, 5 
mM MgCl2, and 1 mM DTT), SYPRO Orange protein gel stain (5000x stock in DMSO), and 200 
µM ligand. Melt curves were obtained by increasing the temperature from 25-60 ºC at a rate of 1 
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ºC min-1 with a fluorescence reading every degree (ThermoFluor) or a rate of 2 ºC min-1 with 
continuous data acquisition (qPCR). Data were plotted in GraphPad Prism 7 with the inflection 
point of the sigmoidal curve representing the melting point (Tm) of the protein. 
2.3. Results 
 2.3.1. Kinase domain purification and crystallographic studies. Initial attempts at 
purifying TBK1 and IKKε focused on constructs spanning the kinase domain (KD) or kinase-
ubiquitin-like domains (KU), as these constructs of TBK1 had been previously crystallized (Ma 
et al., 2012). Expression of either wild-type (WT) or catalytically inactive (D135N or K38A) 
variants in E. coli yielded insoluble protein. Co-expression with chaperones or solubility tags did 
not improve soluble protein quantities (data not shown). Expression in insect cells yielded small 
amounts KD and KU constructs, with the best yields from the IKKε KD construct (Figure 2.2 
A).  
 Purified IKKε KD was extensively screened for appropriate crystallization conditions 
with amlexanox and other potent pan-kinase inhibitors. Only one condition yielded crystals that 
diffracted to 2.7 Å with MRT67307 (Figure 2.3 A). However, the unit cell dimensions (56.3, 
56.3, 81.9 Å, space group P6) is too small to accommodate the IKKε KD (Figure 2.3 B). Drops 
of protein from the same sparse-matrix screen were analyzed by SDS-PAGE and revealed a 
protein band at 15-20 kDa, suggesting degradation of the protein (Figure 2.3 C). Therefore, the 
crystals obtained were either a degraded form of IKKε or a minor contaminant that was not 
observed during prior purification steps. 
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Figure 2.2: Expression and purification of IKKε. A) Purification of IKKε KD from insect 
cells. Arrows indicate insoluble and soluble kinase domain. B) Purification of C-terminally 
truncated and full-length IKKε. Only IKKε 1-655 WT and D135N yield soluble protein. C) 
IKKε 1-655 D135N elutions from Ni-NTA resin demonstrating protein purity without gel 
filtration. D) Representative anion exchange chromatogram from a HiTrap Q column. The blue 
trace is UV absorbance at 280 nm and the red trace is conductivity. At pH≤7.5 IKKε 1-655 
elutes as a broad plateau indicated by a line under the UV trace.
 2.3.2. Purification and crystallization of C-terminally 
truncated IKKε and TBK1. Given the poor expression and 
potential for degradation, longer constructs of TBK1 and 
IKKε were pursued. C-terminally truncated TBK1 (residues 
1-657) had been previously crystallized and better expressed 
and purified from insect cells (Tu et al., 2013, Larabi et al., 
2013). Analogous C-terminally truncated constructs of IKKε were also generated and expressed 
exceptionally well with typical yields >10 mg L-1 (Figure 2.2 B) but was prone to aggregation 
when concentrated or passed over chromatography columns. Interestingly, the aggregates formed 
microscopic sheets that stain with methylene blue dye similarly to protein crystals (Figure 2.4). 
However, these small plates did not diffract X-rays and attempts to image these objects via 
negative stain electron microscopy were unsuccessful.  
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Figure 2.3: Attempted structure elucidation of IKKε KD. A) Diffraction pattern from crystals 
grown at 4 ºC in 0.1 M Bis-Tris pH 5.5 and 25% (v/v) PEG 3,350. Diffraction extends to 2.7 Å 
spacings. B) Matthews coefficient analysis plotting probability (out of total structures in the 
PDB) vs. solvent content (%) for the unit cell volume. Example protein masses are indicated. 
The mass of IKKε KD (34.5 kDa) does not lie on the distribution and cannot occupy such a 
small volume. C) SDS-PAGE analysis of protein from crystallization screen drops. IKKε KD is 
near 37 kDa. The bands below 20 kDa are degradation products or minor contaminants. 
Figure 2.4: Aggregates of 
IKKε (residues 1-655) stained 
with methylene blue after 
concentrating >2 mg mL-1.
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Figure 2.5: Purification of TBK1. A) Eluted TBK1 from Ni-NTA resin is indicated by an 
arrow. After S200 SEC and λ phosphatase treatment, homogeneous TBK1 was obtained. B) 
Representative anion exchange chromatogram from a HiTrap Q column. The blue trace is UV 
absorbance at 280 nm and the red trace is conductivity. C) Representative SEC chromatogram 
from an analytical S200 column. Eluted TBK1 is indicated by a bar under the peak.
!33
Figure 2.6: Crystallization of TBK1. A) Crystal form 1 (P6522). Crystals grown in 1.0 M Na/
KPO4 pH 6.4 with MRT67307. B) Crystal lattice with a solvent content of 82%. TBK1 
crystallizes as a dimer in the asymmetric unit (ASU). One homodimer is colored. C) Crystal 
form 2 (P3221) grown in 0.1 M HEPES pH 7.5, 5% PEG 8,000, and 10% DMSO with 
MRT67307.
Table 2.1: Crystallographic data collection 
statistics
TBK1·MRT67307
Wavelength (Å) 1.0332
Resolution range 49.45 - 5.36 
(5.45 - 5.36)*
Space group P 65 2 2
Unit cell constants (Å, ˚) 248.9 248.9 239.8 
90 90 120
Total reflections 604583 (29982)
Unique reflections 15936 (771)
Multiplicity 37.9 (38.9)
Completeness (%) 100.0 (100.0)
Mean I/σ(I) 15.0 (1.5)
Wilson B-factor 521
Rmeas 0.181 (3.52)
CC1/2 0.999 (0.621)
*Statistics for the highest-resolution shell are 
shown in parentheses
 Despite poorer expression, TBK1 was not prone to aggregation but appeared 
phosphorylated by SDS-PAGE due to the presence of two broad bands. Indeed, treatment with λ 
phosphatase resulted in a tight, single band by SDS-PAGE (Figure 2.5). In light of this 
observation, catalytically inactive TBK1 K38A was focused on, as the extent of phosphorylation 
was markedly decreased. Crystals of a previously reported form (form 1, P6522, Table 2.1, 
Figure 2.6 A) were obtained under new conditions with the inhibitor MRT67307. However, 
diffraction only extended to ~5.36 Å spacings due to an solvent content of 82% (Figure 2.6 B).  
 Given the poor resolution of crystal form 1, a better diffracting crystal form was sought. 
Cleavage of the N-terminal hexahistidine tag yielded crystal form 2 (P3221) under previously 
published conditions that diffracted to ~3 Å spacings with inhibitor MRT67307. However, 
crystals with amlexanox could not be obtained. Soaking amlexanox into TBK1 
K38A·MRT67307 was unsuccessful, as the potency of MRT67307 is approximately two orders 
of magnitude greater than amlexanox and crystals rapidly degraded during soaking. 
 2.3.3. Characterization of amlexanox and co-crystal structure with TBK1. Efforts to 
obtain a co-crystal structure with a better-expressing, inactive form of TBK1 (K38A) were 
unsuccessful, but differential scanning fluorometry (DSF) with wild-type (WT) and TBK1-K38A 
revealed that the WT protein was significantly stabilized whereas the K38A variant was 
significantly destabilized by amlexanox (Figure 2.7 A). Using WT protein, the TBK1·amlexanox 
crystal structure was determined to 3.65 Å spacings (Figure 2.7 B, Table 2.2). The structure 
features strong density for amlexanox binding along the hinge of the kinase domain, mimicking 
the interactions made by the adenine ring of ATP. The type I binding mode is similar to that 
observed in the GRK1·amlexanox complex (Figure 2.8) (Homan et al., 2014). The amine forms 
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Table 2.2: TBK1 crystallographic data collection and refinement statistics
Ligand Amlexanox 224120 224182 224183
Wavelength (Å) 0.97857 0.97872 0.97857 1.03312
Resolution range 39.2 - 3.65 
(3.78 - 3.65)*
44.1 - 3.34
(3.46 - 3.34)*
40.0 - 3.20
(3.31 - 3.20)*
35.4 - 3.60
(3.73 - 3.60)*
Space group P 32 2 1 P 32 2 1 P 32 2 1 P 32 2 1
Unit cell constants (Å, ˚) 135.0 135.0 84.9 
90 90 120
134.8 134.8 85.3
90 90 120
134.3 134.3 85.3
90 90 120
134.5 134.5 85.5
90 90 120
Total reflections 76280 (6549) 145201 (13401) 245551 (24305) 201857 (20642)
Unique reflections 10120 (923) 13238 (1305) 14970 (1463) 10626 (1055)
Multiplicity 7.5 (7.1) 11.0 (10.3) 16.4 (16.6) 19.0 (19.5)
Completeness (%) 98.0 (90.6) 99.5 (96.2) 99.6 (99.3) 99.5 (98.7)
Mean I/σ(I) 12.60 (1.09) 16.24 (1.63) 18.17 (1.60) 16.37 (1.25)
Wilson B-factor 166.0 112.4 121.9 166.0
Rmeas 0.102 (2.23) 0.143 (1.66) 0.113 (2.14) 0.145 (1.91)
CC1/2 0.999 (0.403) 0.999 (0.599) 1 (0.548) 1 (0.553)
Reflections used in refinement 10087 (907) 13206 (1277) 14926 (1458) 10592 (1050)
Reflections used for Rfree 1011 (91) 1321 (127) 1495 (145) 1061 (105)
Rwork 0.229 (0.350) 0.227 (0.352) 0.223 (0.412) 0.244 (0.428)
Rfree 0.290 (0.371) 0.286 (0.382) 0.271 (0.454) 0.267 (0.416)
Number Non-hydrogen atoms 4887 4956 4960 4895
   Protein 4865 4932 4936 4868
   Ligand 22 24 24 27
RMSD bonds (Å) 0.003 0.002 0.002 0.002
RMSD angles (˚) 0.77 0.50 0.41 0.41
Ramachandran favored (%) 98.6 91.0 96.3 95.6
Ramachandran allowed (%) 1.4 8.7 3.7 4.1
Ramachandran outliers (%) 0 0.3 0 0.3
Rotamer outliers (%) 0 0 0 0
Clashscore 7.0 6.9 4.2 5.1
Average B-factor 185 133 142 182
   Protein 185 133 142 182
   Ligand 158 97 184 187
PDB Entry 5W5V 6BNY 6BOD 6BOE
*Statistics for the highest-resolution shell are shown in parentheses
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Figure 2.7: Structural analysis of the TBK1·amlexanox complex. A) Amlexanox (200 µM) 
only stabilizes the wild-type (WT) form of TBK1, as indicated by a positive shift in the melting 
temperature Tm (average ± SEM, n=2, two-way ANOVA with Bonferroni correction for 
multiple comparisons, **p≤0.01, ***p≤0.001). B) TBK1·amlexanox crystal structure at 3.65 Å. 
Amlexanox binds along the kinase hinge and forms specific interactions with the backbone of 
Glu87 and Cys89 and the side chain of Thr156. Mesh represents positive |Fo| - |Fc|  density 
contoured at 3.0 σ.
P-loop
AmlexanoxHinge
GRK1
TBK1
Figure 2.8: Alignment of the 
small lobe of the kinase domain 
of GRK1·amlexanox (4WBO, 
green) and TBK1·amlexanox 
(5W5V, cyan).
a hydrogen bond with the backbone carbonyl of Glu87 whereas the pyridine nitrogen interacts 
with the backbone nitrogen of Cys89. The side chain of Leu15 in the phosphate-binding loop (P-
loop) packs against the tricyclic core of the drug. The carboxylic acid on amlexanox is 4.1 Å 
away from Thr156 and thus, considering the low resolution, either forms a weak hydrogen bond 
or favorable electrostatic interaction with the Thr156 hydroxyl. Indeed, TBK1 T156A displays a 
significant decrease in amlexanox potency but, interestingly, displays a slight but significant 
increase in potency toward IKKε T156A (Table 2.3, Figure 2.9). No electron density is however 
observed for the side chain of Lys38, which was critical for obtaining the co-crystal structure, 
indicating a high degree of mobility. Regardless, the Lys38 side chain would complement the 
negative charge of the carboxylate of amlexanox and, together with Thr156, help direct the 
compound into the active site. 
 2.3.4. Structure-activity relationships of carboxylic acid analogs of amlexanox. 
Amlexanox displays an in vitro IC50 of 0.8 ± 0.1 and 5.8 ± 0.8 µM toward TBK1 and IKKε, 
respectively (Table 2.4, Figure 2.9). All analogs reported within were synthesized by Xinmin 
Gan, Ph.D. in the University of Michigan Vahlteich Medicinal Chemistry Core. Two analogs of 
amlexanox were synthesized in which the carboxylic acid was reduced to a primary alcohol 
(258167) or removed (232340). Reduction of the carboxyl in 258167 decreased potency 30-fold 
whereas elimination of the carboxylic acid in 232340 decreased potency 40-fold toward TBK1. 
Reduction of the carboxylate to a hydroxyl however only modestly reduced potency toward 
IKKε, whereas elimination of the group enhanced potency two-fold. These data show that the 
carboxylic acid of amlexanox plays an important role in inhibition of TBK1, but that inhibition 
of IKKε appears less dependent upon the carboxylate. 
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Table 2.3: Potency of carboxylic acid analogs against TBK1 and IKKε variants
Compound # Amlexanox 224120 224253 224254
R –COOH
aSolubility  
(mg mL-1) ≥20 ≥2.5 <1 <<0.5
bIC50 (µM)
TBK1 0.8 ± 0.1 0.4 ± 0.05 2.9 ± 1.0 >100
TBK1 T156A 10 ± 1.5*** 0.06 ± 0.06 1.9 ± 1.4 n.i.
IKKε 5.8 ± 0.8 0.2 ± 0.03 1.6 ± 0.7 >100
IKKε M86L 1.0 ± 1.0*** 0.03 ± 0.02 0.04 ± 0.03* n.i.
IKKε T156A 1.9 ± 1.4*** 0.02 ± 0.01 0.3 ± 0.2* n.i.
aThermodynamic solubility determined by first dissolving each compound at a basic pH (dilute NaOH 
solution) and adjusting to pH 7.4-7.6 with buffer. bIn vitro potency (IC50, µM) towards TBK1 and IKKε 
variants (mean ± SEM, n=3). TBK1 M86L did not express in insect cells. Statistical significance 
relative to WT variant determined via two-way ANOVA with Bonferroni correction for multiple 
comparisons (*p<0.05, ***p<0.001). n.i. no inhibition up to 200 µM.
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Figure 2.9: Representative dose-response curves and gels. A) Representative dose-response 
curves (Hill slope = -1) for selected analogs from Table 2.4. Data are shown as mean ± S.D. 
(N=3) and normalized to no inhibitor (100%) and background (0%). B) Representative SDS-
PAGE gels imaged from phosphor screens. Darker bands indicate greater substrate 
phosphorylation in the presence of the indicated inhibitor. Inhibitor concentrations (left to right, 
µM): 40, 10, 2.5, 0.63, 0.16, 0.08, 0.02, 0.
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Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
7273 32867 24020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
2
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
Amlexanox
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
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Table 2.4: Potency of C-3 modified 5-Oxo-5H-[1]benzopyrano[2,3-b]pyridines
CCG # R acLogP bTBK1 IC50 (µM) bIKKε IC50 (µM) Selectivity for IKKε
Amlexanox –COOH 3.65 0.8 ± 0.1 5.8 ± 0.8 0.2
224182 –COOEt 4.63 55 ± 29*** 65 ± 47*** 0.8
258167 –CH2OH 2.58 24 ± 5.7*** 18 ± 8.2 1.3
224183 3.43 2.9 ± 0.5 1.6 ± 0.4 1.8
223900 3.07 >100*** 17 ± 13 >5.9
223920 3.80 36 ± 14*** 14 ± 8.6 2.6
223921 2.87 73 ± 26*** 57 ± 23*** 1.3
257636 4.02 4.5 ± 0.8** 5.4 ± 2.0 0.8
232340 –H 3.35 33 ± 18*** 2.6 ± 1.1 13
224120 3.22 0.4 ± 0.05 0.2 ± 0.03*** 2.0
224253 3.04 2.9 ± 1.0 1.6 ± 0.7 1.8
224254 3.39 >100*** >100*** 1
aCalculated partitioning coefficient assuming an unionized molecule (calculated via Marvin, 
ChemAxon). Larger values suggest enhanced cellular permeability. bIn vitro potency (IC50) towards 
TBK1 and IKKε (n=3, mean ± SEM). Statistical significance from amlexanox determined by two-way 
ANOVA with Dunnett’s multiple comparison correction,*p≤0.05, **p≤0.01, ***p≤0.001.
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 Methyl (223900), 2-(diethylamino)ethyl (223920), and morpholine (223921) amide 
derivatives were synthesized to expand the SAR around the carboxylic acid moiety. Potency of 
223920 and 223921 toward TBK1 was decreased by nearly 50-fold and 90-fold, respectively. 
Similar decreases in potency were observed toward IKKε. A selective loss in potency of more 
than 125-fold for TBK1 was observed for the simple methyl amide analog 223900. These data 
suggest that the conversion of the carboxylic acid to an amide is responsible for decreased 
potency toward TBK1 rather than the steric bulk associated with the other amide derivatives. 
IKKε is however more tolerant to short modifications of the carboxylic acid. 
 A pair of related ester analogs were next synthesized because they better mimic the parent 
carboxylic acid and thus might be less detrimental to compound binding. An ester-linked 2-
(dimethylamino)ethyl analog 257636, similar to the amide-coupled amine 223920, displayed a 
significant 5-fold decrease in potency but only toward TBK1. To test whether the length of the 
modification could underlie the observed decrease in potency, a short ethyl ester analog (224182) 
was synthesized which decreased potency by more than 65-fold toward TBK1 and 10-fold 
toward IKKε, similar to the change observed for the related analog 223900. 
 Given the decrease in potency resulting from the elimination or derivatization of the 
carboxylic acid group, a series of bioisosteres was next investigated. Analogs of amlexanox 
containing tetrazole (224120), oxadiazolone (224253), or oxadiazole (224254) groups in place of 
the carboxylic acid were synthesized. The tetrazole analog 224120 displayed significantly 
improved potency of 400 and 200 nM against TBK1 and IKKε, respectively. Despite reduced 
solubility, installation of an oxadiazolone moiety (224253) reduced potency toward TBK1 to 2.9 
± 1.0 µM and improved potency to 1.6 ± 0.7 µM toward IKKε, consistent with IKKε being able 
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to accept a wider variety of C-3 modifications. The oxadiazole analog 224254 was essentially 
inactive against both TBK1 and IKKε, likely due to its extremely poor aqueous solubility (Table 
2.3). Given the significant enhancement in potency of the tetrazole analog, an analog bearing a 
tetrazole attached to the core of amlexanox through an amide linkage, 224183, was synthesized. 
224183 displayed a three-fold reduction in potency toward TBK1 but significantly improved 
potency by three-fold toward IKKε. 
 2.3.5. Co-crystal structures of amlexanox C-3 derivatives. To investigate the molecular 
basis for the loss in potency observed for 224182 and 223900, the crystal structure of TBK1 in 
complex with the ethyl ester analog 224182 was determined to 3.2 Å spacings (PDB 6BOD, 
Table 2.2). Relatively weak ligand density is observed, consistent with its relatively weak 55 µM 
IC50 value, but the planar density is situated along the hinge of the kinase domain analogous to 
the parent compound amlexanox (Figure 2.10 A). A shift of the P-loop and neighboring strand 
(residues 37-42) in the N-terminal lobe of the kinase domain is also observed, resulting in a more 
open active site (Figure 2.10 B). Compared to the TBK1·amlexanox structure, additional density 
is observed for residues 160-163 adjacent to the DFG motif of the kinase domain. Thus, it seems 
that steric clashes introduced by the addition of an ethyl group induce a twisting motion of the N-
lobe of the kinase domain that leads to less favorable binding interactions with the ligand. 
 To investigate the binding mode of the tetrazole analog 224120, its crystal structure in 
complex with TBK1 was solved at 3.3 Å spacings (PDB 6BNY). The compound again binds 
similarly to amlexanox, forming specific interactions with the kinase hinge (Figure 2.10 C). 
Compared to the co-crystal structure with 224182, the kinase domain of TBK1 adopts a more 
closed conformation. Unlike amlexanox, which forms a relatively long hydrogen bond with 
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Figure 2.10: Crystallographic analysis of TBK1 in complex with carboxylic acid analogs. A) 
TBK1·224182 crystal structure at 3.2 Å. Mesh represents positive |Fo| - |Fc| omit map density 
contoured at 2.0 σ. B) Alignment of TBK1·224182 (green) and TBK1·amlexanox (gray) 
complexes. The rotation in the P-loop is denoted by spheres at the Cα positions of Thr20 and 
Val39. C) TBK1·224120 crystal structure at 3.3 Å with mesh representing 3.0 σ positive |Fo| - |
Fc| omit density. D) TBK1·224183 crystal structure at 3.6 Å with mesh representing 3.0 σ 
positive |Fo| - |Fc| omit density.
Thr156, the side chain of Thr156 rotates to accommodate the tetrazole ring, which allows a 3.2 Å 
hydrogen bond to form between the sulfur of the gatekeeper residue Met86 and the tetrazole 
moiety. The TBK1 variant M86L, another common gatekeeper residue in Ser/Thr kinases, did 
not express in insect cells but 224120 displayed an increase in potency toward IKKε M86L 
(Table 2.3). The related compound 224253 displays increased potency toward IKKε M86L. 
Additionally, 224120 and 224253 display increased potencies against both TBK1 T156A and 
IKKε T156A, perhaps through the reduction of steric clashes as Thr156 is forced to rotate away 
from the cyclic bioisosteres. 
Because other amide derivatives were significantly less potent than amlexanox, the 
molecular basis for the retained potency of 224183 was assessed via a 3.6 Å co-crystal structure 
with TBK1 (PDB 6BOE). The core of the molecule again binds along the hinge (Figure 2.10 D). 
Weak positive |Fo| - |Fc| omit map density is observed for the amide linker and terminal tetrazole 
ring. The amide arm assumes a cis conformation relative to the amide bond and core of the 
inhibitor, and packs between Met142 and Val23. Residues 18-21 in the P-loop are disordered, 
disrupting P-loop crystal contacts observed in the other reported TBK1 structures and possibly 
accounting for the decreased resolution of the diffraction data. The loss in carboxylate 
interactions with Thr156 and Lys38 and disordering of the P-loop turn may partially be 
compensated for by the packing of the planar tetrazole ring under the ordered portion of the P-
loop. 
 2.3.6. Cellular efficacy of selected carboxylic acid analogs. To determine whether 
carboxylic acid modifications improve cellular efficacy, 3T3-L1 adipocytes were treated with the 
highest-potency tetrazole analog 224120 and the related oxadiazolone bioisostere 224253. TBK1 
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Figure 2.11: Adipocyte cellular responses upon treatment with amlexanox and selected 
analogs. A) Western blot for phosphorylation of TBK1 and p38 MAPK after incubation of 3T3-
L1 adipocytes with 2-50 µM amlexanox, 224120, or 224253 for 1 h. Quantified results for 
pTBK1 and p-p38 are displayed below the blot (average ± SD, n=2 technical replicates, 
**p≤0.01, ***p≤0.001, two-way ANOVA with Dunnett’s correction for multiple comparisons 
relative to amlexanox). B) Expression of Il6 as determined by qPCR in 3T3-L1 adipocytes 
treated with 50 µM compound for 4 h. Expression was quantified with and without 
pretreatment with the p38 MAPK inhibitor SB203580 (average ± SD, n=3 biological replicates, 
two-way ANOVA with Dunnett’s correction for multiple comparisons relative to DMSO 
control, ***p≤0.001). C) Secreted Il-6 from 3T3-L1 adipocytes treated with 50 µM compound 
for 4 h as determined by ELISA (average ± SD, n=2 technical replicates, two-way ANOVA 
with Dunnett’s correction for multiple comparisons relative to DMSO control, **p≤0.01, 
***p≤0.001).Experiments performed by Shannon Reilly and Louise Chang in the Saltiel lab 
(University of California – San Diego and University of Michigan).
mediates negative feedback regulation of AMP-activated protein kinase (AMPK) whereas IKKε, 
and to a lesser extent TBK1, directly activate phosphodiesterase 3B and thereby reduce 
intracellular cAMP levels to attenuate catecholamine-stimulated adrenergic receptor signaling. 
Thus, inhibition of both kinases produces a unique readout consisting of increased TBK1 
phosphorylation at Ser172 as a consequence of the AMPK mediated negative feedback loop 
(Zhao et al., 2018; Reilly et al., 2013; Clark et al., 2009), and phosphorylation and activation of 
p38 MAPK (Reilly et al., 2015), and production of IL-6 (Reilly et al., 2015) downstream of 
cAMP signaling. Treatment of adipocytes with 224120 or 224253 simultaneously stimulated 
TBK1 and p38 phosphorylation in a dose-dependent manner (Figure 2.11 A). However, neither 
224120 nor 224253 significantly increased pTBK1 response compared to amlexanox. 
Furthermore, although 224253 more potently induces p38 phosphorylation, the maximum 
response is not greater than amlexanox. Compound 224120 was worse than amlexanox at 
stimulating p38 phosphorylation, likely as a result of decreased permeability, assessed by cLogP 
(Table 2.4), and poor compound solubility in the assay medium (Table 2.3). Adipocytes treated 
with amlexanox or 224253 display significantly increased Il6 expression (Figure 2.11 B). In 
agreement with previous studies, induction of Il6 is blocked by pretreatment with the p38 MAPK 
inhibitor SB203580, confirming that the observed response to 224253 is through activation of 
p38 (Barancík et al., 2001; Reilly et al., 2015). The tetrazole analog 224120 did not induce Il6 
gene expression. Secretion of IL-6 from treated adipocytes was also assessed by ELISA (Figure 
2.11 C). In line with Il6 expression, only treatment with analog 224253 resulted in a significant 
increase in IL-6 secretion, though the increase was less robust than that produced by amlexanox. 
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2.4. Discussion  
 Amlexanox shows promise as a therapeutic lead for the 
treatment of obesity and type 2 diabetes via inhibition of kinases that 
are effectors of chronic low-grade inflammation in hepatic and adipose 
tissues. Initial characterization showed inhibition by amlexanox to be 
through an ATP-competitive mechanism, however the precise binding 
mode and molecular interactions leading to inhibition were unknown 
(Reilly et al., 2013). The elucidation of the structure of TBK1 bound 
to amlexanox reveals a canonical ATP-competitive binding along the 
hinge of the kinase in space occupied by the adenine ring on ATP. 
Compared to previously reported TBK1 structures in complex with the nanomolar inhibitors 
BX795 and MRT67307 (Ma et al., 2012; Tu et al., 2013; Larabi et al., 2013; Shu et al., 2013), 
the small lobe of the kinase domain appears less ordered in complex with amlexanox, 
particularly residues 15-19 in the P-loop. This finding is not unexpected because amlexanox is a 
lower potency inhibitor and occupies only the region along the hinge, whereas the more extended 
BX795 and MRT67307 inhibitors (Figures 2.12, 2.13) also pack under the P-loop.  
 The interaction between the carboxylate on amlexanox and the side chain hydroxyl of 
Thr156 or Lys38 amine seems important for potent inhibition of TBK1, but less so in the context 
of IKKε where removal of the carboxylic acid moiety in 232340 instead improves potency. 
Reduction of the carboxylic acid to a primary alcohol in 258167 also only perturbs inhibition of 
TBK1. As TBK1 and IKKε are >70% identical in their kinase domains, the potency exhibited 
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Figure 2.12: Chemical 
structures of BX795 
and MRT67307.
toward IKKε by 232340 and 223900 is surprising. One notable difference between the two 
kinases lies at position 90 in the hinge, which is a proline in TBK1 and a serine in IKKε. The 
presence of a proline in the hinge of TBK1 may restrict the relative orientation of its kinase 
domain lobes. Thus, the loss of the carboxylate interactions in TBK1 could result in decreased 
potency because the kinase is unable to optimally interact with inhibitors lacking the carboxylate. 
Verification of this model will await determination of atomic structures of IKKε. Taken together, 
disruption of the carboxylate-Thr156 interaction appears a viable strategy for improving 
selectivity and often potency toward IKKε. 
 All amide and ester modifications of the carboxylic acid significantly decreased potency 
toward TBK1 relative to amlexanox whereas only 223921 significantly decreased potency 
toward IKKε, suggesting that extensions to the carboxylic acid introduce steric clashes in TBK1 
that further impede ligand binding. Indeed, the co-crystal structure of TBK1 bound to 3 reveals 
that esterification of amlexanox does not change the binding position of the core of the inhibitor 
along the kinase hinge, but the introduction of an ethyl group clearly leads to a twist in the P-
loop and a more open conformation of the kinase domain. Interestingly, the amide- and ester-
coupled amines 223920 and 257636, respectively, and the short methyl amide 223900, display no 
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Figure 2.13: Comparison of inhibitor packing under the P-loop. A) TBK1·MRT67307 (PDB 
4IM0), B) TBK1·BX795 (4IM2), and C) TBK1·CCG-224183 (6BOE).
significant reduction in potency toward IKKε, possibly as a result of increased hinge flexibility 
in this enzyme. The coupling of a 5-membered tetrazole ring through an amide linkage in 224183 
improves IKKε inhibition but only exhibits a modest decrease in potency toward TBK1, whereas 
the 6-membered 2-morpholinoethyl analog 223921, bearing a 6-membered ring, is a poor 
inhibitor of both kinases. These results further suggest that there is a steric size limit for packing 
under the P-loop. Indeed, other potent TBK1 and IKKε inhibitors such as BX795 and 
MRT67307 pack 4- and 5-membered thiophene and cyclobutyl rings under the P-loop (Figure 
2.13) (Ma et al., 2012; Tu et al., 2013; Larabi et al., 2013). 
 Because TBK1 and IKKε may play different roles in chronic inflammation associated 
with obesity, the development of inhibitors selective for either kinase would enable 
pharmacological interrogation of the signaling pathways associated with each enzyme. The SAR 
around the carboxylic acid moiety of amlexanox reveals that IKKε is more tolerant to 
modifications at the C-3 position. Simple decarboxylation of amlexanox (7) improves selectivity 
toward IKKε by more than one order of magnitude. Other modifications, such as conversion of 
the carboxylic acid to a methyl amide (223900), also improve selectivity toward IKKε. Coupled 
with modifications at other positions, such as the C-7 isopropyl, these and related carboxylic acid 
derivatives represent possible routes to the generation of IKKε-selective inhibitors. 
 The lack of cellular activity observed for the tetrazole analog of amlexanox is not 
surprising, as tetrazole modifications have been reported to decrease cellular permeability 
(Lassalas et al., 2016). Despite a decrease in potency toward TBK1 and solubility (Table 2.3), 
the oxadiazolone analog 224253 produces a significant cellular response, albeit less than 
amlexanox, perhaps due to increased cellular permeability (cLogP) of oxadiazolones (Table 2.4) 
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compared to carboxylic acids (Lassalas et al., 2016). Since amlexanox and related analogs are 
type I kinase inhibitors with a general ATP-competitive mechanism, we cannot exclude the 
possibility of off-target effects, especially given the indirect nature of measuring p-TBK1, p-p38 
MAPK, and IL-6. However, this particular combination of readouts has been extensively 
validated in the context of amlexanox (Reilly et al., 2013, Reilly et al., 2015, Zhao et al., 2018). 
Given the modest nature of the C-3 modifications and expected effects in all three readouts, 
analogs 224120 and 224253 are likely predominantly on-target, at least in the context of cultured 
adipocytes. The selectivity of analogs exhibiting more promising cellular efficacy should be 
thoroughly assessed prior to studies in vivo to predict and minimize deleterious off-target effects 
stemming from inhibition of kinases prevalent in other cell types. 
Because free carboxylic acid groups are prone to glucuronidation during phase II 
metabolism (Sakaguchi et al., 2004), installation of less acidic bioisosteres may improve 
metabolic properties of amlexanox. However, in assays with cultured adipocytes metabolism is 
expected to be insignificant due to a lack of hepatic drug metabolizing enzymes. Difficulties 
solubilizing 224120 and 224253 (Table 2.3) prohibited testing in obese mice and highlights 
another PK property that may be improved through the installation of alternative bioisosteres. 
The co-crystal structure with the tetrazole analog 224120 will serve as a guide towards 
identifying alternative bioisosteres that maintain or improve potency while also improving 
cellular response. In particular, the related thiadiazolone and isoxazole bioisosteres are 
significantly more cell permeable and are targets for future exploration (Vitaku et al., 2014; 
Lassalas et al., 2016). 
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 The co-crystal structures and in vitro SAR analysis presented herein will enable future 
development of TBK1 and IKKε inhibitors based on the amlexanox pharmacophore. Significant 
improvements in potency have been achieved through the installation of acid bioisosteres, 
whereas other carboxylic acid modifications suggest possible routes for improving inhibitor 
selectivity for IKKε. Despite improved potency, improving cellular efficacy remains a challenge 
because modification of the carboxylic acid may alter PK properties that hamper drug 
distribution and cellular permeability.  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Chapter 3: Analysis of A Ring and Truncated Pharmacophore Analogs of Amlexanox as 
Inhibitors of IκB Kinases 
3.1. Introduction  
 Elucidation of the TBK1·amlexanox structure revealed the amino pyridine moiety on 
amlexanox binds the kinase hinge and a critical interaction between the C-3 carboxylate and the 
sidechain of Thr156 in TBK1. Inhibition of IKKε is not dependent upon this carboxylate 
interaction and modification of the corresponding position is largely tolerated. Despite 
improvements in potency upon the installation of a tetrazole at the C-3 position, significant 
enhancements to efficacy and selectivity remain elusive. To remedy these concerns, we sought to 
modify additional positions on the amlexanox pharmacophore to improve potency, solubility, and 
efficacy.  
 Guided by prior structures and SAR, amlexanox analogs bearing conservative 
modifications at the C-7 position alongside a small set of C-6 and C-8 derivatives that may 
stabilize the P-loop or interact with the kinase hinge, respectively, were evaluated for their ability 
to inhibit either kinase. A large series of cyclic C-7 modifications were also examined due to 
their synthetic accessibility along with crystallographic data showing space to accommodate 
bulkier modifications. Drawing from previous analogs, bioisostere derivatives of the C-3 
carboxylic acid were combined with C-7 modifications to assess the effect of dual modification 
of the pharmacophore. Lastly, in pursuit of a novel pharmacophore, a truncated form of 
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amlexanox lacking the solvent exposed A ring was prepared and a small subset of analogs tested 
to demonstrate future utility of this pharmacophore. Taken together, this extensive series of 
analogs reveals mechanisms for the selective and potent inhibition of IKKε which has recently 
been shown to play a distinct role in obesity and diabetes.  
3.2. Materials and methods 
 3.2.1. Protein expression and purification. WT TBK1 (1-657) and IKKε (1-655) for 
assays and crystallography were purified as described previously in sections 2.2.1. and 2.2.2. 
 3.2.2. IC50 determination by radiometric kinase assay. Single-dose inhibition assays 
were performed for TBK1 and IKKε with either 1 or 5 µM inhibitor, respectively. Percent 
inhibition was determined by normalizing substrate phosphorylation in the presence of inhibitor 
to a no inhibitor (0% inhibition) or background (100% inhibition) control. Dose-response assays 
were carried out as described previously in 2.2.4. Statistical significance from amlexanox was 
determined by a Student’s two-tailed t-test from three independent experiments. 
 3.2.3. Crystallization. Crystallization conditions were based off those previously reported 
with modifications (Tu et al., 2013; Larabi et al., 2013). TBK1 crystals were grown at 20 ºC via 
hanging drop vapor diffusion in drops containing 1 µL of 100 mM HEPES pH 7.5, 4% (w/v) 
PEG 8,000, 2 µL of purified human TBK1 (residues 1-657 at ~3 mg mL-1), and 0.2 µL inhibitor 
(10 mM in DMSO) over wells containing 1 mL of 100 mM HEPES pH 7.5, 4% (w/v) PEG 
8,000, and 10% DMSO. Small diamonds appeared within 1-2 d and grew for an additional 1-2 d. 
Better diffracting and larger crystals were obtained through microseeding. Crystals of form 2 
(P3221) were harvested and briefly soaked in a cryoprotecting solution containing 100 mM 
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HEPES pH 8.5, 8% (w/v) PEG 8,000, 30% (v/v) PEG 400, and 0.5 mM inhibitor prior to flash 
freezing in liquid nitrogen. Data were collected and processed as described in 2.2.3. Coordinates 
and diffraction amplitudes have been deposited in the Protein Data Bank with the accession 
codes 6CQ0, 6CQ4, and 6CQ5. 
 3.2.4. Virtual docking. Docking was performed with PyRx (Dallakyan and Olson, 2015) 
using the Autodock Vina (Trott and Olson, 2010) algorithm. All docking was rigid body for the 
protein and side chains and flexible for the ligand. Docking grid space encompassed the entire 
active site.  
3.3. Results 
 3.3.1. Structure-activity relationships of acyclic A ring analogs of amlexanox. All 
analogs reported within were synthesized by Xinmin Gan in the University of Michigan 
Vahlteich Medicinal Chemistry Core. Potency of simple amlexanox analogs was assessed in vitro 
by radiometric kinase assays (Table 3.1). Analogs 259012, 262485, 258073, 258702 bearing a 2-
propenyl substituent at the C-7 or C-8 positions generally show significantly reduced potency 
toward TBK1 while significantly improving potency toward IKKε when located at the C-7 
position. The addition of a methylene spacer(s) (258961 and 258762) had no significant effect on 
potency. The introduction of an alkyne spacer (258759) markedly reduced potency with the data 
likely compromised due to poor solubility in the assay medium. To improve the solubility of 
amlexanox, the isopropyl group was replaced with a dimethyl amino moiety in 232482 which 
improved potency two- and three-fold toward TBK1 and IKKε, respectively. 
 Moving the isopropyl group to the C-6 position in 262826, in an attempt to stabilize the 
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P-loop by packing against Leu15 and Gly16, reduced potency toward TBK1 while displaying no 
detrimental effect on inhibition of IKKε. Shifting the isopropyl to the C-8 position in 259043 
significantly improved potency toward TBK1. The introduction of fluorine at the C-8 position in 
262501 enhanced potency toward either kinase relative to des-fluoro congener amlexanox, and 
slightly improved potency of the C-7 2-propenyl analog 262485 for TBK1 compared to the non-
fluorinated 258702. Installation of a nitrogen in place of carbon at the 8-position of amlexanox in 
258101 enhanced potency toward both kinases. In contrast, making the same replacement for the 
C-7 2-propenyl congener 258702 to give 258073 negated the potency increase of the 2-propenyl 
substituent toward IKKε. 
 Analogs bearing more extensive modifications at the C-7 and C-8 positions which may 
dramatically affect potency were first evaluated at a single concentration of 1 or 5 µM near the 
amlexanox IC50 toward TBK1 and IKKε, respectively (Tables 3.1, 3.2). The vast majority of 
analogs displayed decreased potency relative to amlexanox. Selected analogs displaying 
!54
Figure 3.1: Representative dose-response curves and gels. A) Representative dose-response 
curves (Hill slope = -1) for selected analogs from Table 2.4. Data are shown as mean ± S.D. 
(N=3) and normalized to no inhibitor (100%) and background (0%). B) Representative SDS-
PAGE gels imaged from phosphor screens. Darker bands indicate greater substrate 
phosphorylation in the presence of the indicated inhibitor. Inhibitor concentrations (left to right, 
µM): 40, 10, 2.5, 0.63, 0.16, 0.08, 0.02, and 0 except for 263758 and 262826 which are (left to 
right, µM): 400, 100, 25, 6.3, 1.6, 0.4, 0.1, and 0.
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Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 23 680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 23 867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Response Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
2 4483 224481 224183
2 4081 23 643 257394
257961 259043 257685
62826
 
Amlexanox #1 Amlexanox #2 257635
232681 232680 232607
257131 224181 257344
32P Dose-Re ponse Assays
Concentrations: 40 µM, 10 µM, 2.5 µM, 0.625 µM, 0.156 µM, 0.078 µM, 0.019 µM, 0 µM
257273 232867 224020
258045 257174 257466
224120 232780 232482
224483 224481 224183
224081 232643 257394
257961 259043 257685
63758
Amlexanox
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM)
40  10  2.5  0.63  0.16 0.08 0.02  0Cmpd. (µM) 40  10  2.5  0.63  0.16 0.08 0.02  0
400  100  25  6.3 1.6  0.4  0.1   0
400  100  25  6.3 1.6  0.4  0.1   0
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Table 3.1: Potency of Synthesized 5-Oxo-5H-[1]benzopyrano[2,3-b]pyridines 
CCG# R7 R8
Aq. sol. 
(µM)a
bSingle Concentration % Inhibition 
c(IC50, µM)
TBK1
IC50 
Fold 
Change IKKε
IC50 
Fold 
Change
Amlexanox i-Pr H 172 50 ± 1.3 (0.85 ± 0.14)
29 ± 7.4 
(5.1 ± 1.6)
258702 CH2=C(CH3)- H 259 (1.3 ± 0.1*) 0.7 (1.3 ± 0.5**) 3.9
259043 H i-Pr 19 (0.30 ± 0.03**) 2.8 (4.7 ± 2.3) 1.1
259012 H CH2=C(CH3)- n.d. (2.3 ± 0.1**) 0.4 (7.2 ± 2.0) 0.7
262826 C-6 Amlex 229 (1.1 ± 0.02**) 0.8 (6.0 ± 0.5) 0.9
262501 i-Pr F 14 (0.40 ± 0.08) 2.1 (5.4 ± 0.7) 0.9
262485 CH2=C(CH3)- F n.d. (0.79 ± 0.07) 1.1 (1.7 ± 0.3*) 3.0
258101 i-Pr 8-aza 78 (0.57 ± 0.02**) 1.5 (3.1 ± 1.1) 1.6
258073 CH2=C(CH3)- 8-aza 373 (2.0 ± 0.3*) 0.4 (5.3 ± 0.5) 1.0
232482 Me2N H n.d. (0.40 ± 0.09*) 2.1 (1.6 ± 0.5) 3.2
232241 Me2N(CH2)3- H n.d. 35 ± 2.2 21 ± 1.8
232240 H n.d. 20 ± 3.4 17 ± 2.0
258961 i-Bu H 179 (0.55 ± 0.08) 1.5 (4.9 ± 2.0) 1.0
258762 i-pentyl H 119 (0.83 ± 0.08) 1.0 (3.4 ± 0.4) 1.5
258759 H n.d. (12 ± 1*) 0.1 (20 ± 9) 0.3
262706 i-pentyl F n.d. 32 ± 0.7 -5.7 ± 4.7
258727 t-BuCH2CH2 H n.d. 14 ± 4.8 0.6 ± 11
258726 t-BuCH=CH- H n.d. 8.7 ± 4.2 -3.1 ± 3.2
aThermodynamic solubility determined by Analiza Inc, Cleveland, OH 44114. b'TBK1, (1 µM); IKKε (5 
µM) (n=3, mean ± SEM). c Concentration for 50% inhibition in radiometric kinase assays using purified 
protein. Reported as IC50 (µM) ± SEM (n=3). Significance relative to amlexanox determined by a two-
tailed Student’s T-test (*p<0.05, **p<0.01). n.d. = not determined
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equivalent or improved potency were further tested in dose-response assays. Introduction of 
conformational restriction in amlexanox to give cyclopropyl analog 223901 resulted in reduced 
potency toward both kinases. A decrease in inhibition was observed as the ring size at the C-7 
position was increased from c-Bu to c-heptyl (232960, 224081, 232643, and 257042) with IKKε 
inhibition the most adversely affected. However, unsaturation of the cyclohexyl ring in 232780 
improved inhibition of IKKε while decreasing TBK1 inhibition, consistent with prior 
observation that unsaturated 2-propenyl substituents preferentially improve IKKε inhibition. 
When the C-7 cyclohexyl and cyclohex-2-enyl modifications are combined with fluorination at 
the 8 position or appended to the 8-aza scaffold a large decrease in inhibition is observed 
similarly to the decrease observed for 262501 and 258101. The phenyl analog 232925 displayed 
a similar trend in inhibition of TBK1 and IKKε.  
 3.3.2. Structure-activity relationships of cyclic A ring analogs of amlexanox. Based off 
preliminary cellular results with 232643, we choose to focus on C-7 c-hexyl analogs (Table 3.2). 
Fluoro, methyl, or trifluoromethyl modifications were made at the para position (257089, 
257082, 232900, 257134, 257133, 257783, and 257685). These modifications decreased 
compound solubility and reduced inhibition. Hydroxylation of the para position in 257273 also 
reduced potency, but the introduction of a double bond in 257226 improved IKKε inhibition to 
that of amlexanox while further decreasing TBK1 inhibition. Installation of a cyclohexanonyl 
ring at the C-7 position in 257635 significantly improved potency toward TBK1. Conversion to a 
ketal in 257366 significantly improved potency toward both kinases while the introduction of a 
double bond in the ring only significantly improved potency toward IKKε. 
 Next, nitrogen, oxygen, and sulfur containing heterocycles were examined. The 
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installation of a piperidinyl group at the C-7 position in 232606 and 232781 reduced inhibition 
Table 3.2: Potency of C-7, C-8 cyclic and alkcyclic 5-Oxo-5H-[1]benzopyrano[2,3-b]pyridines 
CCG# R7 R8
Aq. sol. 
(µM)a
bSingle Concentration % Inhibition 
c(IC50, µM)
TBK1
IC50 Fold 
Change IKKε
IC50 Fold 
Change
Amlexanox i-Pr H 172 50 ± 1.3 (0.85 ± 0.14)
29 ± 7.4 
(5.1 ± 1.6)
223901 c-Pr H 148 (2.3 ± 0.1**) 0.4 (10.6 ± 0.4**) 0.5
232960 c-Bu H n.d. 44 ± 3.7 (4.6 ± 3.6) 0.2
25 ± 3.4 
(3.1± 0.7*) 1.6
224081 c-Pentyl H n.d. 67 ± 4.1 (1.8 ± 0.3*) 0.5
9.2 ± 1.9 
(6.3 ± 1.0) 0.8
232643 c-Hexyl H 94 34 ± 1.6 (1.9 ± 0.6) 0.5
9.0 ± 3.1 
(>100)
232780 H n.d. 44 ± 0.2 (1.7 ± 0.5) 0.5
41 ± 4.9 
(5.4 ± 1.5) 0.9
257042 c-Heptyl H n.d. 32 ± 8.5 9.2 ± 4.1
262457 H c-Hexyl n.d. 11 ± 9.6 8.2 ± 6.3
259142 H n.d. 15 ± 3.7 15 ± 4.7
232925 H n.d. 34 ± 2.9 33 ± 6.4
257089 H n.d. 14 ± 3.8 11 ± 2.1
257082 H n.d. 27 ± 3.8 19 ± 5.6
232900 H n.d. 19 ± 5.6 3.2 ± 2.9
257134 H n.d.
33 ± 8.0 11 ± 2.3 
!
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257133 H n.d. 4.0 ± 4.0 0.4 ± 0.4
257783 H n.d. 15 ± 6.5 -0.7 ± 7.5
257685 H n.d. 38 ± 4.5 22 ± 2.4
257273 H n.d. 37 ± 2.8 12 ± 2.2
257226 H n.d. 27 ± 2.8 26 ± 3.6
257635 H < 1 52 ± 6.2 (0.45 ± 0.07*) 1.9
27 ± 4.9 
(1.5 ± 1.3) 3.4
257366 H n.d. 63 ± 1.1 (0.44 ± 0.05*) 1.9
30 ± 8.1 
(3.2 ± 0.03**) 1.6
257344 H n.d. 54 ± 2.4 (0.75 ± 0.06) 1.1
63 ± 4.6 
(2.1 ± 0.8*) 2.4
232606 H n.d. 12 ± 8.7 7.9 ± 8.6
232781 H n.d. 22 ± 3.4 23 ± 2.7
232867 H n.d. 68 ± 1.1 (0.49 ± 0.05*) 1.7
34 ± 8.4 
(5.2 ± 2.9) 1.0
232681 H 121 66 ± 1.3 (0.27 ± 0.03**) 3.1
26 ± 7.5 
(1.9 ± 2.6) 2.7
 232607 H n.d. 46 ± 0.4 (0.75 ± 0.22) 1.1
32 ± 13 
(11 ± 5.5) 0.5
232680 H n.d. 46 ± 4.0 (0.86 ± 0.56) 1.0
50 ± 2.3 
(2.0 ± 0.6*) 2.6
257174 H 61 46 ± 1.8 (0.29 ± 0.10*) 2.9
18 ± 2.5 
(1.2 ± 0.4**) 4.3
HO
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257466 H n.d. 57 ± 4.1 (0.83 ± 0.12) 1.0
23 ± 2.3 
(11 ± 6.7) 0.5
224020 H n.d. 32 ± 5.9 3.5 ± 10
262621 F n.d. 26 ± 8.4 8.2 ± 3.0
262562 F n.d. 10 ± 6.8 -0.5 ± 1.3
258045 8-aza n.d. 14 ± 4.9 7.0 ± 1.1
258028 8-aza n.d. -1.2 ± 6.6 3.0 ± 1.4
257973 H n.d. 31 ± 6.0 7.7 ± 1.9
257972 H n.d. 29 ± 4.8 10 ± 6.8
258451 H n.d. 11 ± 3.2 -6.0 ± 8.0
258907 H n.d. 26 ± 4.9 8.7 ± 6.8
257962 H n.d. 3.2 ± 10 4.8 ± 5.5
257961 H n.d. 44 ± 1.0 13 ± 4.6
259141 H n.d. 4.7 ± 7.1 5.2 ± 2.0
259112 H n.d. 8.8 ± 2.5 6.5 ± 2.3
262549 F n.d. -4.4 ± 7.2 -7.1 ± 4.0
262502 F n.d. 2.9 ± 3.2 -0.2 ± 2.4
257303 H n.d. -1.9 ± 2.3 -4.1 ± 3.7
257300 H n.d. 13 ± 1.3 4.3 ± 0.7
(CH2)2-
O
N
(CH2)2-
(CH2)2-
(CH2)2-
(CH2)2-
O2S
(CH2)2-
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toward both kinases. Surprisingly, formylation or acetylation of the heterocyclic nitrogen in 
232867 and 232681, respectively, significantly improved potency toward TBK1. The installation 
of a tetrahydropyranyl group had no significant effect on potency whereas introduction of a 
double bond in 232680 significantly improved potency toward IKKε. In contrast to 232607, the 
presence of a sulfur in 257174 significantly improved potency toward both kinases while no 
improvement was observed for the sulfone-containing ring 257466. The morpholinyl containing 
analog 224020 displayed a decrease in inhibition toward TBK1 and was essentially inactive 
toward IKKε. 
 A series of analogs bearing saturated rings appended to the C-7 or C-8 positions through 
short linkers were examined. All analogs were poor inhibitors of either kinase, likely due to poor 
solubility in the assay conditions. Installation of saturated or monounsaturated 6 membered rings 
at the C-8 position diminished inhibition possibly due to the introduction of steric clashes with 
the kinase hinge. 
 3.3.3. Structure-activity relationships of dual C-3 and C-7 modified analogs of 
amlexanox. We previously reported that the installation of tetrazole acid bioisosteres at the C-3 
position enhances potency toward both kinases (Table 3.3). The combination of a tetrazole and 
C-7 cyclohexyl moiety in 257407 exhibited the same potency toward TBK1 as the cyclohexyl-
only 232643. However, the potency of 257407 against IKKε was significantly increased relative 
to 232643. A more than 20-fold increase in potency to 210 nM toward IKKε was observed for 
aThermodynamic solubility determined by Analiza Inc, Cleveland, OH 44114. b TBK1, (1 µM); IKKε (5 
µM) (n=3, mean ± SEM). c Concentration for 50% inhibition in radiometric kinase assays using purified 
protein. Reported as IC50 (µM) ± SEM (n=3). Significance relative to amlexanox determined by a two-
tailed Student’s T-test (*p<0.05, **p<0.01).
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Table 3.3: Potency of C-3 and C-7 Substituted 5-Oxo-5H-[1]benzopyrano[2,3-b]pyridines
CCG# R7 R3
Aq. sol. 
(µM)a
bSingle Concentration % Inhibition 
c(IC50, µM)
TBK1
IC50 Fold 
Change IKKε
IC50 
Fold 
Change
Amlexanox i-Pr CO2H 172 50 ± 1.3 (0.85 ± 0.14)
29 ± 7.4 
(5.1 ± 1.6)
257407 n.d. 64 ± 1.5 (1.9 ± 0.2*) 0.4
30 ± 2.2 
(1.0 ± 0.3*) 5.1
257394 n.d. 52 ± 3.3 (0.49 ± 0.05*) 1.7
79 ± 2.1 
(0.21 ± 0.06***) 24
257393 Me2N n.d. 33 ± 0.6 (0.53 ± 0.16) 1.6
65 ± 1.3 
(0.58 ± 0.2***) 8.8
224481 916 34 ± 3.6 (0.54 ± 0.10) 1.6
70 ± 1.1 
(0.31 ± 0.14***) 16
224483 n.d. 49 ± 0.5 (0.76 ± 0.11) 1.1
57 ± 1.7 
(1.2 ± 0.4**) 4.3
aThermodynamic solubility determined by Analiza Inc, Cleveland, OH 44114. b'TBK1, (1 µM); IKKε (5 µM) 
(n=3, mean ± SEM). c Concentration for 50% inhibition in radiometric kinase assays using purified protein. 
Reported as IC50 (µM) ± SEM (n=3). Significance relative to amlexanox determined by a two-tailed Student’s 
T-test (*p<0.05, **p<0.01, ***p<0.001).
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257394 which contained a cyclohexenyl substitution, consistent with prior observations that 
IKKε favors an unsaturated bond on C-7 modifications. Significant increases in potency were 
also observed for the dimethyl amine and morpholinyl analogs bearing tetrazole or amide-linked 
tetrazole modifications. Interestingly, analog 224181 was a potent 310 nM inhibitor of IKKε 
despite the morpholinyl-only analog 224020 having no inhibitory effect on IKKε, suggesting the 
tetrazole moiety is the primary driver of potency in this class of analogs. 
 3.3.4. TBK1 co-crystal structures with C-7 modified analogs. To verify the binding 
mode of analogs, select inhibitors were co-crystallized with TBK1 (Figure 3.2, Table 3.4). To 
represent the series of analogs with extended non-cyclic C-7 modifications such as 258762 and 
258727, the more soluble analog 232241 was co-crystallized with TBK1 and the structure 
determined to 3.19 Å spacings (PDB 6CQ0, Figure 3.2 A). The core of the inhibitor binds 
identically to amlexanox along the kinase hinge. Weak density is observed for the dimethyl 
amino tail upon refinement which is positioned near Pro90 and Cys91. The placement of the C-7 
tail in solvent may explain why no significant changes in potency are observed, however these 
analogs are generally less soluble which may also contribute to reductions in potency. The 
placement of the tail near Cys91, which is likely in the thiolate form due to its proximity to 
Arg143, suggests that incorporation of an acrylamide in place of the dimethyl amine in 232241 
may serve as a strategy for covalent inhibitor design targeting Cys91. 
 To represent cyclic C-7 analogs, we determined the structure of TBK1 in complex with 
257089 at 3.2 Å and 257466 at 3.35 Å resolution (PDB 6CQ4 and 6CQ5, Figure 3.2 B,C). Both 
structures reveal binding along the hinge as observed for all inhibitors bearing the amlexanox 
pharmacophore. The C-7 rings extend into solvent between the kinase and dimerization domains 
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of TBK1. The lack of interaction between the 4,4-difluorocyclohexyl modification on 257089 
and TBK1 and decreased solubility explains why the analog displays decreased inhibition of 
both kinases. The sulfone-containing ring on 257466 also does not interact with the kinase but is 
within range of Lys567 and Lys568 which may form favorable electrostatic interactions with the 
sulfone carbonyl. 
 3.3.5 Efficacy of select C-7 modified analogs. Cellular and in vivo efficacy was assessed 
by the Saltiel Lab (University of California - San Diego) first assayed in cultured adipocytes and 
IL-6 secretion, a biomarker of TBK1 and IKKε inhibition (Reilly et al., 2015), assessed with 
additional testing for promising compounds in obese mice (Figure 3.3). A subset of the results 
are reported here for the C-7 2-propenyl analog of amlexanox (258702), vinylcyclopentyl 
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Figure 3.2: TBK1 co-crystal structures with A) 232241, B) 257089, and C) 257466. Mesh 
represents positive |Fo| - |Fc| omit density contoured at 3 σ. The amino pyridine portion of the 
inhibitor core interacts with the backbone of Glu87 and Cys89 in the hinge of the kinase and 
the carboxylate with Thr156 adjacent to the DFG motif. The structures have been deposited in 
the PDB with the accession codes 6CQ0, 6CQ4, and 6CQ5, respectively.
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Table 3.4: TBK1 Crystallographic data collection and refinement statistics.
Ligand 232241 257089 257466
Wavelength (Å) 0.97857 1.03312 0.97857
Resolution range 48.2 - 3.19  (3.30 - 3.19)*
48.0 - 3.20  
(3.31 - 3.20)*
44.1 - 3.35  
(3.47 - 3.35)*
Space group P 32 2 1 P 32 2 1 P 32 2 1
Unit cell constants (Å, º) 134.8 134.8 85.5  90 90 120
134.6 134.6 84.5  
90 90 120
134.8 134.8 85.2  
90 90 120
Total reflections 237693 (19958) 300633 (29913) 99937 (9694)
Unique reflections 15107 (1359) 14851 (1454) 12948 (1269)
Multiplicity 15.7 (14.7) 20.2 (20.6) 7.7 (7.6)
Completeness (%) 98.9 (90.2) 99.6 (98.0) 98.7 (97.7)
Mean I/σ(I) 18.98 (1.53) 16.59 (1.94) 16.61 (1.80)
Wilson B-factor 112.8 117.6 115.9
Rmeas 0.122 (2.07) 0.124 (1.71) 0.108 (1.41)
CC1/2 0.999 (0.49) 0.999 (0.79) 0.999 (0.50)
Reflections used in refinement 15093 (1355) 14823 (1450) 12931 (1269)
Reflections used for Rfree 762 (71) 737 (71) 651 (64)
Rwork 0.238 (0.394) 0.233 (0.387) 0.231 (0.363)
Rfree 0.293 (0.468) 0.273 (0.452) 0.275 (0.374)
Number of non-hydrogen atoms 4902 4910 4899
   Protein 4877 4883 4872
   Ligand 25 27 27
RMS bonds (Å) 0.001 0.002 0.002
RMS angles (º) 0.36 0.41 0.43
Ramachandran favored (%) 96.1 96.3 95.8
Ramachandran allowed (%) 3.7 3.5 4.0
Ramachandran outliers (%) 0.2 0.2 0.2
Rotamer outliers (%) 0.56 0.00 0.00
Clashscore 3.9 4.8 4.5
Average B-factor 140 149 135
   Protein 140 150 135
   Ligand 123 103 103
PDB Entry 6CQ0 6CQ4 6CQ5
*Statistics for the highest-resolution shell are shown in parentheses.
(257961), and cyclohexyl (232643). Despite 258702 displaying improved potency toward IKKε, 
cellular response to treatment was equivalent to that of amlexanox (Figure 3.3 A). The 
vinylcyclopentyl analog displayed a significant increase in IL-6 secretion in cultured cells and 
was also tested in obese mice (Figure 3.3 B). Treatment with 257961 produced no significant 
weight loss in a short time course (Figure 3.3 C) but did significantly improve insulin sensitivity 
as determined by blood glucose testing after sugar administration (Figure 3.3 D). The cyclohexyl 
analog 232643 robustly stimulated IL-6 secretion (data not shown) and was evaluated in obese 
mice over four weeks. Significant weight loss was observed (Figure 3.3 E) but was not greater 
than amlexanox treatment. Taken together, it appears that the weight loss effect of amlexanox 
treatment may represent the ceiling for response through engagement of TBK1 and IKKε. 
 3.3.6. Design and evaluation of truncated amlexanox pharmacophore analogs. As the 
solvent exposed A ring on amlexanox is not involved in any direct interactions with the kinase, 
elimination of the ring from the inhibitor core may yield an inhibitor with improved ligand 
efficiency and will explore new chemical space. In collaboration with Hollis Showalter and 
Xinmin Gan in the Vahlteich Medicinal Chemistry Core, a truncated form of the amlexanox 
pharmacophore was designed based off manual modeling and docking into the TBK1·amlexanox 
structure (PDB 5W5V, Figure 3.4, Table 3.5). The core, which is not reported previously and 
required the development of a novel synthesis, retains the critical amino pyridine hinge binding 
moiety and carboxylate. The primary derivatization point is the C-3 position that is analogous to 
the C-7 position in amlexanox. Introduction of a C-3 trans-2-i-pentyl group results in a close 
mimic to amlexanox, whereas a shorter i-Bu resembles the C-6 isomer of amlexanox (262826). 
 At the present time, preparation of analogs based off the truncated amlexanox core is 
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Figure 3.3: Cellular and in vivo response to select C-7 modified amlexanox analogs. A, B) 
Secreted IL-6 from 3T3-L1 adipocytes treated with 100 µM compound for 4 hr. C) Mean 
weight loss relative to starting weight and D) blood glucose levels after sugar injection in obese 
mice treated with compound for 2 weeks. E) Time course weight loss in obese mice treated 
with compound. F) Chemical structures of analogs assayed. Assays were performed by 
Shannon Reilly in the Saltiel Lab. Cellular experiments were performed three times and animal 
studies once with three animals. Statistical significance determined by one-way ANOVA 
(*p<0.05, ** p<0.01). Significance in A-C was determined relative to the vehicle control, D at 
each time point, and E at the final time point.
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Table 3.5: Potency of pyrano[2,3-b]pyridines 
CCG# R3 R6
aSingle Concentration % Inhibition 
b(IC50, µM)
TBK1
IC50 Fold 
Change IKKε
IC50 Fold 
Change
Amlexanox 50 ± 1.3 (0.85 ± 0.14)
29 ± 7.4 
(5.1 ± 1.6)
263758 i-Pr COOH 2.9 ± 3.2 (11) 0.1
6.1 ± 0.2 
(11) 0.5
263869 i-pentyl COOEt 0.2 ± 3.2 9.1 ± 4.5
263870 COOEt -5.7 ± 7.1 10.8 ± 2.9
263882 i-pentyl COOH 10.1 ± 2.6 5.6 ± 0.4
a'TBK1, (1 µM); IKKε (5 µM) (n=3). b Concentration for 50% inhibition in radiometric kinase assays using 
purified protein. Reported as IC50 (µM) ± SEM (n=3 for amlexanox, n=1 for 263758).
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Figure 3.4: Docking of truncated amlexanox analog 263870 with deprotected carboxylate. A) 
AutoDock Vina docking pose assuming identical hinge contacts as with amlexanox. The 
pyridine nitrogen is predicted to interact with the sidechain of either Ser93 or Thr96. B) 
Surface representation of deprotected 263870 docked along the kinase hinge. Docking was 
performed with PyRx using the AutoDock Vina algorithm.
difficult due to the base sensitivity of the electrophilic dihydropyran ring, especially during 
deprotection of the carboxylic acid. Therefore, a limited number of analogs have been 
synthesized to assess the inhibitory potential of this ring system. Installation of an i-Pr or i-pentyl 
group diminished potency by an order of magnitude likely due to decreased buried hydrophobic 
surface area. The ethyl ester congener of 263882 also displayed little inhibition towards either 
kinase, in line with prior observations regarding the modification of the carboxylate on 
amlexanox. Docking indicated that the addition of a pyridine at the R3 position may form 
favorable contacts with the large lobe of the kinase domain while simultaneously packing against 
the P-loop. Unfortunately, deprotection of the carboxylate was not achieved and thus the 
compound was supplied as the protected ethyl ester which displayed very poor inhibition as 
anticipated from compound 224182. 
3.4 Discussion 
 We are utilizing the clinically approved drug amlexanox, a modest inhibitor of TBK1 and 
IKKε, as a starting point for analog synthesis in order to develop inhibitors to test a novel 
hypothesis about the role of inflammation in the generation of insulin resistance and type 2 
diabetes during obesity. I previously determined the TBK1·amlexanox crystal structure which 
revealed canonical ATP-competitive binding along the kinase hinge and demonstrated the 
importance of the carboxylic acid for potent inhibition. Here, we extensively modified the 
solvent exposed A ring of amlexanox to improve potency and pharmacokinetic properties and 
investigate the effects of simultaneous substitution at two positions.  
 Analogs with a 2-propenyl substituent favor binding to IKKε relative to isopropyl 
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congeners, possibly due to the planarity of the sp2 carbon center (compare 258702 vs amlexanox, 
262485 vs 262501, and 259012 vs 259043). The presence of a Ser residue in the hinge of IKKε, 
in contrast to a Pro in TBK1, should affect the flexibility of the hinge region and, in conjunction 
with the planar 2-propenyl, may allow for more kinase domain closure and improved binding. 
This trend is in line with prior SAR surrounding the C-3 position of amlexanox in which more 
extensive modifications were only accommodated by IKKε. This trend does not apply to 8-aza 
analogs (258073 vs 258101) in which the isopropyl congener 258101 shows a greater fold 
change in binding relative to amlexanox. For binding to 8-aza analogs, the hinge region may 
assume a conformation that allows for a hydrogen bond to form with the kinase backbone. This 
possibility is supported by the TBK1·amlexanox crystal structure wherein the hinge would need 
to change conformation in order for an 8-nitrogen to interact with the kinase backbone. 
 Based off prior structural studies with amlexanox, analogs bearing cyclic C-7 
modifications were predicted to assume an unusual binding mode for a kinase inhibitor in which 
the modification extends through solvent and contacts the neighboring dimerization domain. As 
such a binding mode is uncommon, a completely different binding mode along the hinge was 
envisioned wherein the cyclic modification would be positioned under the P-loop. Docking 
experiments also indicated the potential for global rearrangement of the inhibitor binding mode. 
However, two independent co-crystal structures confirmed that the inhibitor core binds 
identically to amlexanox along the hinge. Rings containing heteroatoms at the 4 position may 
interact with Tyr564, Lys570, or Lys576 such as with 257174 and 257466. More extended ring 
modifications such as acetylated piperidine in 232681 and ketal in 257366 and 257344 may 
begin to form contacts with the backbone of the dimerization domain.  
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 The installation of saturated hydrocarbon rings at the C-7 position is tolerated in size up 
to cyclohexyl after which potency markedly decreases likely as a result of poor solubility and 
excessive bulk near the kinase hinge and P-loop. In line with the prior observation that IKKε 
prefers unsaturated bonds adjacent to the C-7 position, analogs 232780 and 232925 retain 
inhibition of IKKε while TBK1 inhibition is decreased. Appending saturated rings via short 
aliphatic linkers was detrimental to inhibition due to extremely poor solubility. However, analogs 
containing C-7 saturated ring substitutions display enhanced cellular response and in vivo 
efficacy likely as a result of their lipophilicity enhancing cellular permeability.  
 Among the most striking results from the C-7 modified analogs are dual modification 
with C-3 acid bioisosteres previously described. The analog 224120 bearing a tetrazole at the C-3 
position was previously described to display a potency of 200-300 nM toward both TBK1 and 
IKKε. When combined with a 6-membered hydrocarbon ring, dimethyamine, or morpholine 
there is no significant change in potency relative to amlexanox. Strikingly, potency toward IKKε 
is significantly improved by nearly 25-fold compared to amlexanox to 210 nM in the case of a 
C-7 cyclohexene, as IKKε prefers planarity near the hinge, and a C-3 tetrazole. This potency is 
comparable to the tetrazole only analog 224120 suggesting that interactions with the gatekeeper 
Met86 drives potency even when unfavorable modifications such as a C-7 morpholine are 
present. Selectivity toward IKKε for dually modified analogs may stem from potentially 
increased hinge flexibility allowing for the accommodation of two additional rings off the 
amlexanox pharmacophore. Conversely, the installation of an amide linked tetrazole at the C-3 
position was previously shown to decrease potency toward TBK1. However, when combined 
with a C-7 morpholine, potency is comparable to that of amlexanox. Thus, it appears that 
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modifications at the C-3 and C-7 positions influence each other in both directions to overcome 
unfavorable modifications at the opposite end of the inhibitor. 
 In an attempt to optimize the pharmacophore of amlexanox, a novel truncated ring system 
was designed with the assistance of available co-crystal structures wherein the A ring of 
amlexanox was eliminated. As the A ring does not make any polar contacts, elimination should 
not significantly perturb binding while entering novel chemical space. However, synthesis of this 
ring system is challenging and most analogs contained a protected carboxylate group which 
display poor potency. Interestingly, 263758 and 263882 which contain a free acid group and 
hinge binding atoms are poor inhibitors of either kinase. Loss of the A ring of the pharmacophore 
may destabilize the P-loop of the kinase by reducing Van der Waals contacts between Leu15 and 
the inhibitor core. Thus, a pyridine containing analog was designed which docking suggests may 
stabilize the P-loop by packing the hydrophobic side of the pyridine ring against Leu15 while 
simultaneously hydrogen bonding with side chains in the large lobe of the kinase domain. 
Unfortunately, deprotection of the carboxylate on the designed pyridine analog was not achieved, 
though the protected analog 263870 displayed weak inhibition against IKKε suggesting future 
promise for the deprotected version once synthesized.  
 In light of the surprising results of combining C-3 and C-7 modification on amlexanox, 
dual modification of the truncated pharmacophore warrants exploration. One such target is the 
pyridine analog 263870 bearing a tetrazole in place of the ethyl ester. Docking indicates such an 
analog would retain an amlexanox-style binding mode while greatly improving potency (data not 
shown). As the pyridine and dual modification analogs are more potent toward IKKε, additional 
selectivity may be achieved while improving potency to <200 nM. 
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 Taken together, structural and pharmacological characterization of amlexanox as an 
inhibitor of TBK1 and IKKε has yielded insights into the SAR of the amlexanox pharmacophore. 
In addition to the observations made in Chapter 2 regarding the necessity of the carboxylate for 
TBK1 inhibition and dramatic potency improvements through the installation of acid 
bioisosteres, we have determined that the introduction of saturated hydrocarbon rings at the C-7 
position greatly improve efficacy and that the modification of both the C-3 and C-7 positions 
yields potent IKKε inhibitors. This work has produced several analogs, namely 232643, with 
clinical potential that are undergoing preclinical profiling.  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Chapter 4: Biophysical Characterization and Perturbation of the Ca2+·CaM–GRK5 
Interaction 
4.1. Introduction 
 G protein-coupled receptors (GPCR) are the largest family of cell-surface receptors in 
humans and regulate numerous physiological processes through the activation of heterotrimeric 
G proteins, GPCR kinases (GRKs) and arrestins. To maintain proper physiology, mechanisms to 
attenuate or cease downstream signaling have evolved. The principal desensitization mechanism 
is initiated by GRKs which phosphorylate the third intracellular loops or C-terminal tails of 
active GPCRs, thereby facilitating the recruitment of arrestin which sterically occludes G protein 
binding and promotes receptor internalization (Tesmer, 2016).  
 As membrane localization and recognition of activated receptors is critical for efficient 
receptor desensitization, several regulatory mechanisms have evolved to attenuate GRK activity 
and prolong receptor activation.  The ubiquitous calcium-sensing protein calmodulin (CaM) 
binds all GRKs and inhibits both membrane localization and receptor phosphorylation in a Ca2+-
dependent manner (Chuang et al., 1996; Pronin et al., 1997; Levay et al., 1998; Iacovelli et al., 
1999) without significantly affecting phosphorylation of most soluble substrates (Chuang et al., 
1996). The interaction between Ca2+·CaM and GRK5 has been the most studied due to its high 
affinity (Kd=8 nM by surface plasmon resonance) and 50-fold greater potency (IC50=40-60 nM 
toward rhodopsin phosphorylation) compared to other GRKs (Chuang et al., 1996; Pronin et al., 
1997). Pulldown experiments showed Ca2+·CaM affinity toward GRK5 was mediated by 
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contacts with the N-terminal helix (residues 1-17), C-terminal amphipathic helix (residues 
552-561, Figure 1.3 B), and a phospholipid-interacting patch of basic residues (residues 20-39) 
near the junction between the kinase domain and regulator of G protein signaling homology 
(RH) domains (Pronin et al., 1997; Levay et al., 1998). More recently, Ca2+·CaM was shown to 
directly strip peptides corresponding to the GRK5 N- and C-terminal regions from model 
membranes (Ding et al., 2014). Interestingly, the binding of Ca2+·CaM promotes GRK5 
autophosphorylation at non-canonical C-terminal sites that further reduce the ability of GRK5 to 
associate with membranes and may represent a mechanism prolong GRK5 inhibition after 
Ca2+·CaM has dissociated (Pronin et al., 1997; Levay et al., 1998). 
 Conflicting models for the Ca2+·CaM–GRK5 complex have been proposed. One depicts 
two Ca2+·CaM simultaneously binding distal N- and C-terminal elements of GRK5 in a fashion 
that would interfere with its membrane binding and receptor phosphorylation. (Levay et al., 
1998). Alternatively, recent structures of GRK5 have revealed the N- and C-terminal elements to 
be in close proximity to one another, and thus a single Ca2+·CaM may bind both simultaneously, 
although this would likely require a non-canonical interaction where each lobe binds to a 
separate element. (Komolov et al., 2015; Homan, Waldschmidt, et al., 2015; Beyett et al., 2016). 
 GRK5 inhibition by Ca2+·CaM is of growing interest because is plays a role in the 
development of cardiac hypertrophy during heart failure. To better understand the molecular 
mechanism of inhibition of GRK5 by Ca2+·CaM, we used multi-angle light scattering (MALS), 
small-angle X-ray scattering (SAXS) and negative stain electron microscopy (EM) to determine 
the architecture of the Ca2+·CaM–GRK5 complex. Our data reveal that a single Ca2+·CaM binds 
at the junction of the regulator of G protein signaling homology (RH) and kinase domains of 
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GRK5 where Ca2+·CaM is poised to interact with elements of the kinase critical for receptor 
recognition and allosteric activation, but also within reach of the C-terminal membrane-binding. 
We confirm that the binding of Ca2+·CaM promotes an active conformation of GRK5 resulting in 
increased phosphorylation of non-receptor substrates. We investigated the outcome of disrupting 
the Ca2+·CaM–GRK5 interaction through the application of the natural product 
malbrancheamide, a known Ca2+·CaM inhibitor believed to block the C-lobe of the protein 
(González-Andrade et al., 2016). Co-crystallization of malbrancheamide in complex with 
Ca2+·CaM confirmed that the natural product stabilizes an unusual conformation of Ca2+·CaM by 
binding to the C-terminal lobe while leaving the N-terminus exposed in a state that is free to 
interact with other proteins. This binding mode allows malbrancheamide to suppress Ca2+·CaM-
stimulated GRK5 membrane dissociation, and hence autophosphorylation, without relieving the 
ability of Ca2+·CaM to suppress receptor phosphorylation. 
4.2. Materials and methods 
 4.2.1. Calmodulin protein expression and purification. Human calmodulin (CaM) was 
inserted into pMCSG7 using ligation-independent cloning, confirmed with Sanger sequencing, 
and transformed into E. coli BL21 DE3 pLysS cells. Cells were grown at 37 ˚C in TB to an 
optical density at 600 nm of 0.6-1.0, cooled to 20 ˚C, and induced with 0.5 mM IPTG overnight. 
Cells were harvested by centrifugation were resuspended in lysis buffer composed of 20 mM 
HEPES pH 8.0, 200 mM NaCl, 40 mM imidazole, 5 mM CaCl2, 1 mM DTT, leupeptin, lima 
bean trypsin protease inhibitor, and 0.1 µM PMSF and lysed by sonication. Lysate was clarified 
by centrifugation for 30 min at 15,000xg. After centrifugation, the supernatant was glass filtered 
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and slowly flowed through Ni-NTA resin. The resin was washed with lysis buffer and CaM 
eluted with lysis buffer supplemented with an additional 200 mM imidazole. Eluted CaM was 
further purified via size exclusion chromatography (SEC) on an analytical S75 column in 20 mM 
HEPES pH 8.0, 200 mM NaCl, 5 mM CaCl2, and 1 mM DTT. CaM of ≥95% purity by SDS-
PAGE was aliquoted, flash frozen, and stored at -80 ºC. Calmodulin protein concentrations were 
determined by absorbance at 280 nm using a calculated molecular weight of 19,580 Da and 
extinction coefficient of 4,470 M-1 cm-1. His-tagged N- or C-terminal lobes (residues 1-75 and 
78-149, respectively) of CaM were expressed and purified as described above for full-length 
CaM. 
 4.2.2. GRK5 protein expression and purification. Human GRK5 with a C-terminal 
hexahistidine tag was cloned into a modified pFastBac HTB lacking the N-terminal hexahistidine 
tag and verified by Sanger sequencing. High-titer recombinant baculovirus was prepared using 
the Bac-to-Bac protocol and used to infect Sf9 or Hi5 insect cells at a density of 2x106 cells mL-1 
for 48-60 hrs. Cells were pelleted and flash frozen in liquid nitrogen. GRK5 insect cell pellets 
were resuspended in lysis buffer containing 20 mM HEPES pH 8.0, 100 mM NaCl, 40 mM 
imidazole, 1 mM DTT, and 0.1 µM PMSF, leupeptin, and lima bean trypsin protease inhibitor 
and briefly sonicated. Lysis was verified by examination of the cells under a microscope. Lysate 
was clarified by ultracentrifugation for 1 h at >200,000xg. After centrifugation, the supernatant 
was glass filtered and slowly flowed through Ni-NTA resin. The resin was washed with lysis 
buffer and GRK5 eluted with lysis buffer supplemented with an additional 200 mM imidazole. 
Eluted GRK5 was further purified via cation exchange chromatography on a HiTrap S column 
with a gradient of 0.0-1.0 M NaCl at pH 8.0. Fractions containing GRK5 were combined and run 
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over an S200 SEC column in 20 mM HEPES pH 8.0, 200 mM NaCl, and 1 mM DTT. GRK5 of 
≥95% purity by SDS-PAGE was aliquoted, flash frozen, and stored at -80 ˚C. GRK5 protein 
concentrations were determined by absorbance at 280 nm using a calculated molecular weight of 
70,660 Da and extinction coefficient of 60,280 M-1 cm-1. Lyophilized terminal peptides 
encompassing the N-terminal helix (⍺N, residues 2-31) and C-terminal helix (⍺C, residues 
546-565) were prepared via solid-phase peptide synthesis as described previously and 
resuspended in DMSO (Ding et al., 2014). 
 4.2.3. Determination of Ca2+·CaM·malbrancheamide structure. Ca2+·CaM at 10-12 mg 
mL-1 was incubated at room temperature with 2 molar equivalents of malbrancheamide in buffer 
containing 5 mM CaCl2 for 30 min. Sitting drop sparse-matrix screens with 0.5 µL well solution 
and 0.5 µL Ca2+·CaM·malbrancheamide were set and incubated at 20 ˚C. Small rod-like crystals 
appeared after 1-3 d in well D6 of the Qiagen JCSG+ screen which contains 0.1 M Tris pH 8.5, 
0.2 M MgCl2, and 20% (w/v) PEG 8,000. The best diffracting crystals were harvested directly 
from the drop without cryoprotection. Diffraction data to 1.96 Å spacings was collected at LS-
CAT (Sector 21, Advanced Photon Source, Argonne National Lab) on an Eiger 9M detector at 
100 K. Data were indexed, integrated, and scaled using xia2, DIALS, and AIMLESS (Winn et 
al., 2011; Winter et al., 2018; Winter 2010.). Molecular replacement was performed with Phaser 
(McCoy et al., 2007) in Phenix (Adams et al., 2010) using one chain of PDB 4HEX. Ligand 
restraints were prepared using eLBOW (Moriarty et al., 2009). Reciprocal space refinement was 
carried out in Phenix Refine with real space refinement and model building in coot (Emsley et 
al., 2010). Graphics were prepared with PyMol (Version 2.1, Schrödinger LLC). 
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 4.2.4. Isothermal titration calorimetry (ITC). ITC was performed with a NanoITC 
instrument. Malbrancheamide at 600 µM in 20 mM HEPES pH 8.0, 200 mM NaCl, 5 mM CaCl2, 
and 5% DMSO was slowly titrated into a solution of 80 µM Ca2+·CaM in an identical buffer. The 
heat of binding was analyzed using Nano Analyze software and fit to a sigmoidal binding curve 
to obtain the binding affinity (Kd) and stoichiometry. ITC was repeated three times and statistical 
significance determined via Student’s two-tailed T-test. 
 4.2.5 Radiometric kinase assays. Kinase assays were performed with 50 nM purified 
human GRK5 and 5 µM light activated bovine rhodopsin in native membranes, 5-10 µM porcine 
tubulin monomer, or 7 µM bovine myelin basic protein (MyBP) in buffer containing 20 mM 
HEPES pH 8.0, 10 mM MgCl2, 0.5 mM CaCl2, and 1 mM DTT. CaM, peptides, and/or 
malbrancheamide were added and the reactions initiated with 10 µM ATP spiked with [γ-32P]-
ATP and allowed to proceed for 2-5 min at room temperature prior to quenching with SDS 
loading dye. Samples were separated on 4-15% polyacrylamide gels, dried, and exposed 
overnight on phosphor screens. Screens were imaged on a Typhoon imager, band intensities 
quantified using ImageQuant, and fit to a three parameter dose-response model in GraphPad 
Prism. Data were normalized such that the background intensity = 0% kinase activity and a 
sample lacking calmodulin and/or inhibitors = 100% kinase activity.  
 4.2.6 Complex formation and light scattering. Purified GRK5 and Ca2+·CaM were 
mixed in a 1:3 molar ratio, supplemented with 5 mM CaCl2, and incubated at 4 ˚C for 30 min 
prior to separation by size exclusion chromatography using an analytical S200 10/300 column. 
Approximately 500 µg of GRK5 or Ca2+·CaM–GRK5 complex was injected onto Shodex 
KW-804 liquid chromatography column coupled to a Dawn-Helios multi-angle light scattering 
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(MALS) detector to determine the molecular weight and stoichiometry of the complex from a 
standard curve. 
 4.2.7. Differential scanning fluorometry (DSF). Protein thermal stability was assessed 
with an HT7900 qPCR instrument using 0.25 mg mL-1 GRK5 or Ca2+·CaM–GRK5 complex in 
assay buffer containing 20 mM HEPES pH 8.0, 5 mM MgCl2, 5 mM CaCl2, and 1 mM DTT, 
SYPRO Orange protein gel stain (5000x stock in DMSO), and 200 µM ATP or CCG-215022 
(Homan, Waldschmidt, et al., 2015; Waldschmidt et al., 2016), Melt curves were obtained by 
increasing the temperature from 25-60 ˚C at a rate of 2 ˚C min-1. Data were plotted in GraphPad 
Prism 7 with the inflection point of the sigmoidal curve representing the melting point (Tm) of 
the protein. 
 4.2.8. Small-angle X-ray scattering (SAXS). SEC-SAXS analysis was performed on 
purified Ca2+·CaM–GRK5 complex at Bio-CAT (Sector 18, Advanced Photon Source, Argonne 
National Lab). Approximately 600 µg of GRK5 or complex was injected onto a Superdex-200 
10/300 column and the eluted peak corresponding to the complex directly flowed through a 12 
keV X-ray beam. Diffraction data were collected on a Pilatus 1M detector with a sample to 
detector distance of 3.5 m. The achievable Q range for this experimental setup is 0.004-0.33 Å-1. 
 PRIMUS QT as part of the ATSAS software package was used to process raw SAXS data 
including data averaging, buffer subtraction, and data merging (Svergun, 1992; Franke et al., 
2017). DAMMIN and DAMAVER (Svergun, 1999; Volkov, 2003) was used to generate ab initio 
envelopes containing dummy atoms through iterative rounds of simulated annealing which were 
averaged together to obtain an unbiased average envelope (Franke and Svergun, 2009). The 
envelope was then filtered using DAMFILT (Volkov, 2003) to obtain a final, most probable 
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envelope. GASBOR was also used to generate an ab initio envelope by filling space with a 
dummy peptide containing the same number of C⍺ atoms as found in the protein sample 
(Svergun et al., 2001). CRYSOL (Svergun et al., 1995) as part of the ATSAS PyMol plugin 
SASpy (Panjkovich and Svergun, 2016) was used to score models against the raw SAXS data. 
PyMol (version 2.1, Schrödinger LLC.) was used to manipulate structure coordinates and 
generate figures. 
 4.2.9. Electron microscopy (EM). The Ca2+·CaM–GRK5 complex was isolated by SEC 
as described under Complex formation and Light Scattering. For negative stain imaging, protein 
samples were diluted with buffer (20 mM HEPES, 200 mM NaCl, 5 mM CaCl2, 1 mM DTT) to 
0.02-0.05 mg mL-1. The negative staining samples were prepared using conventional negative 
staining protocol (Peisley and Skiniotis, 2015), and imaged at room temperature with a Technai 
T12 electron microscope operated at 120 kV using low dose procedures. Images were recorded at 
a magnification of 71,138x and a defocus value of approximately -1.4 µm on a Gatan US4000 
CCD camera. All images were binned (2x2 pixels) to obtain a pixel size of 4.16 Å on the 
specimen level. Particles were manually picked using e2boxer.py (part of the EMAN2 software 
suite) (Tang et al., 2007). 2D reference-free alignment and classification of particle projections 
was performed using ISAC (Z Yang et al., 2012). To simulate 2D projections from the SAXS 
model, a 20 Å low-pass filter was applied to the high resolution model of Ca2+·CaM–GRK5 
docked into SAXS envelope in Chimera (Pettersen et al., 2004) and the project3d.py script of 
EMAN2 suite was used to generate 2D projections with 10˚ rotational spacings. 
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4.3. Results 
 4.3.1. Binding, thermal stabilization, and stoichiometry of CaM–GRK5. To better 
understand how each lobe of Ca2+·CaM differentially regulates GRK5 function, we determined 
the architecture of the Ca2+·CaM–GRK5 complex. GRK5 was incubated with excess CaM and 
saturating Ca2+ prior to separation via analytical size exclusion chromatography (SEC) coupled 
to a multi-angle light scattering (MALS) detector. MALS analysis of the peak indicated a 
molecular weight for the complex of approximately 90 kDa indicating a 1:1 stoichiometry 
(Figure 4.1 A,B).  
 The effect of Ca2+·CaM binding on the stability of GRK5 was next assessed by 
differential scanning fluorometry (DSF) (Figure 4.1 C). The addition of Ca2+·CaM increased the 
melting temperature (Tm) of GRK5 by 2 ˚C. The addition of ATP or the potent GRK5 inhibitor 
CCG-215022 (Homan, Waldschmidt, et al., 2015; Waldschmidt et al. 2016) increased the Tm of 
GRK5 by approximately 5 and 6 ˚C, respectively. The same increases in melting temperature 
were observed for the Ca2+·CaM–GRK5 complex, demonstrating that Ca2+·CaM does not 
interfere with ligand binding and has an overall stabilizing effect on GRK5.  
 4.3.2. Small-angle X-ray scattering studies of Ca2+·CaM–GRK5. Attempts to crystallize 
the Ca2+·CaM–GRK5 complex were unsuccessful, likely due to the highly dynamic nature of the 
termini of GRK5 and CaM. To determine the arrangement of Ca2+·CaM and GRK5 in complex, 
we performed small-angle X-ray scattering (SAXS). Purified GRK5 or complex were separated 
via SEC immediately prior to in-line SAXS analysis, eliminating contaminating aggregates and 
excess Ca2+·CaM  (Figure 4.2, Table 4.1). Ab initio envelopes were generated through simulated 
annealing with two distinct data processing methods which revealed extra density upon the 
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Figure 4.1: Isolation of Ca2+·CaM–GRK5 complex and determination of stoichiometry. A) 
Representative chromatogram of GRK5 and Ca2+·CaM mixed in a 1:3 molar ratio passed over 
an S200 SEC column. A shift toward a lower elution volume was observed upon the addition of 
Ca2+·CaM. MALS was used to determine the molecular weight of the complex and is indicated 
by a solid line inside the peak. The dotted line corresponds to 90 kDa, the approximate weight 
of a 1:1 complex (n=2). B) SDS-PAGE analysis of the chromatogram peak corresponding to 
the Ca2+·CaM–GRK5 complex. Both proteins co-elute indicating complex formation. 
Molecular weight ladder is shown on the left with relevant weights indicated. C) DSF thermal 
shift assay of GRK5 in the presence of Ca2+·CaM and/or small molecule ligands. Error bars 
represent ± standard error of mean (SEM) (n=3, significance between the presence or absence 
of CaM determined by two-way ANOVA with correction for multiple comparisons, **p≤0.01).
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Figure 4.2: SAXS data processing for GRK5 and the Ca2+·CaM–GRK5 complex. A) SEC-
SAXS chromatogram of S200 SEC column. A cluster of scans with Rg between 20-35 Å 
indicates the elution of the injected protein. Scans with Rg<0.1 Å were omitted for clarity. B) 
Scattering plot of the scans corresponding to the complex. C) Guinier plot for the qRg<1.3 
region of the scattering curve. The best-fit line used to calculate I(0) through extrapolation is 
shown. D) Pair-distance distribution [P(r)] for the scattering curve.
Table 4.1: Data collection statistics for SAXS experiments. 
Zero angle intensity [I(0)], radius of gyration (Rg), and quality 
of fit/Pearson correlation coefficient derived from Guinier and 
Pair-distance [P(r)] analyses are displayed. The maximum 
particle size Dmax was determined from the largest radius in the 
P(r) plot (Figure 4.2 D). Estimated molecular weight was 
calculated by dividing the Porod volume by 1.7.55 Guinier 
results are reported as average ± SD.
SAXS Data Collection Statistics
GRK5 Ca2+·CaM–GRK5
Guinier I(0) 27.4 ± 0.3 17.2 ± 0.4
Guinier Rg (Å) 31.8 ± 0.5 37.3 ± 1.7
Guinier Pearson CC 0.84 0.86
P(r) I(0) 27.0 15.2
 P(r) Rg (Å) 31.2 32.2
P(r) Quality of Fit 0.81 0.83
Dmax (Å) 94 108
Estimated Molecular Weight (kDa) 68 85
Actual Molecular Weight (kDa) 70.7 90.3
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Figure 4.3: Generation of ab initio SAXS envelopes. A) Filtered envelopes for GRK5 (gray) 
and Ca2+·CaM–GRK5 (blue) generated using space filling dummy beads in DAMMIN. 
Envelope fits against raw data are χ 2=0.89 for GRK5 and χ 2=0.96 for Ca2+·CaM–GRK5. Extra 
density upon the addition of Ca2+·CaM is indicated by an arrow. B) Mock polyglycine chains 
(only C⍺ displayed) of the correct length generated in GASBOR representing the approximate 
shape of GRK5 (gray) and Ca2+·CaM–GRK5 (blue). Envelope fits against raw data are χ 2=0.90 
for GRK5 and χ 2=1.02 for Ca2+·CaM–GRK5. Extra density upon the addition of Ca2+·CaM is 
indicated by an arrow. C) Comparison of Ca2+·CaM–GRK5 envelope from DAMFILT (gray 
mesh) and polypeptide model from GASBOR (blue spheres).
addition of Ca2+·CaM (Figure 4.3). Estimated molecular weights calculated from the envelope 
volumes agree well with the actual molecular weights of GRK5 and a 1:1 Ca2+·CaM–GRK5 
complex (Table 4.1). 
 The published crystal structure of GRK5 (PDB 4WNK) (Homan, Waldschmidt, et al., 
2015) with a modeled N-terminal helix, a known site of Ca2+·CaM binding, and active site tether 
(AST) loop from GRK6 (PDB 3NYN) (Boguth et al., 2010) was manually placed in the 
envelope alongside Ca2+·CaM (PDB 5J03) (Strulovich et al., 2016). Ca2+·CaM lies along the 
small lobe of GRK5 near the N-terminus with its acidic surface adjacent to the basic 
phospholipid binding patch (Figure 4.4). The AST loop (approximately residues 462-492) 
conformation observed in recent GRK5 structures (PDB 4TNB, 4TND) (Komolov et al., 2015) is 
strongly influenced by crystal contacts and clashes with Ca2+·CaM in our SAXS model, whereas 
the AST conformation observed in GRK4 and 6 structures, which are not influenced by crystal 
contacts, are compatible with this Ca2+·CaM binding mode. In this conformation, the 
phospholipid binding patch (residues 20-39) projects basic side chains toward several acidic 
residues on Ca2+·CaM, likely forming an extensive salt bridge network. Modeling of a C-
terminus onto GRK5 projects the ⍺C helix toward the density for one lobe of Ca2+·CaM. The 
positioning of Ca2+·CaM along the surface of the small lobe of the kinase domain does not 
obscure the substrate or ATP binding pockets, which is consistent with the observation that 
GRK5 retains catalytic activity toward soluble substrates and autophosphorylation when in 
complex (Chuang et al., 1996). 
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 4.3.3. Negative stain electron microscopy Ca2+·CaM–GRK5. We next characterized 
GRK5 and the Ca2+·CaM–GRK5 complex by negative stain electron microscopy (EM). Particles 
of the Ca2+·CaM–GRK5 complex revealed additional protein density corresponding to 
Ca2+·CaM (Figure 2 C), modeled in similar position to the SAXS experiments, along the surface 
spanning the junction between the RH domain (residues 29-181) and N-lobe of the kinase 
domain (residues 182-267). To compare the class averages to our SAXS experiments, high-
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Figure 4.4: SAXS envelopes and modeling. A) Manual modeling of GRK5 and Ca2+·CaM into 
the DAMFILT envelope. B) Manual modeling of the Ca2+·CaM–GRK5 complex in the 
GASBOR envelope. C) CRYSOL analysis of the manually modeled complex against the raw 
data.
resolution models fitting the SAXS envelopes were low-pass filtered and simulated class 
averages were generated. The SAXS simulated projections align well with those determined by 
negative stain electron microscopy (Figure 4.5 C,D), providing orthogonal confirmation of the 
architecture of the Ca2+·CaM–GRK5 complex. However, the low resolution of the envelope in 
either technique prohibits definitive orientation of the two lobes of Ca2+·CaM or their specific 
contributions to the regulation of GRK5. 
 4.3.4. Activation and autophosphorylation of GRK5 by Ca2+·CaM. We sought to 
determine the effect of Ca2+·CaM binding on the activity of GRK5. As previously reported, 
Ca2+·CaM inhibits GRK5-mediated receptor phosphorylation while simultaneously promoting 
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Figure 4.5: Ca2+·CaM–GRK5 negative stain electron microscopy. A) Reference-free class 
averages of GRK5 alone. B) Reference-free class averages of the Ca2+·CaM–GRK5 complex. 
C) Selected class averages compared to simulated projections from SAXS models. Density 
likely corresponding to Ca2+·CaM is indicated by an arrow. D) Selected class averages (marked 
* in panel C) with SAXS models fitting the DAMFILT and GASBOR models overlaid. 
autophosphorylation (Figure 4.6 A,B) (Kunapuli et al., 1994). Our structural analysis suggests 
inhibition of receptor phosphorylation is likely the result of Ca2+·CaM interacting with regions of 
GRK5 critical for both receptor interaction and membrane association. However, 
autophosphorylation is not the consequence of membrane dissociation as Ca2+·CaM stimulates 
autophosphorylation in the absence of membranes or other substrates (Figure 4.6 C). 
Interestingly, while Ca2+·CaM inhibits receptor phosphorylation, GRK5 activity toward soluble 
substrates is enhanced suggesting that Ca2+·CaM binding stabilizes an active kinase 
conformation (Figure 4.6 D-E). Ca2+·CaM is even able to promote phosphorylation of myelin 
basic protein which is not phosphorylated at all by GRK5 in the absence of Ca2+·CaM (Figure 
4.6 F-G) further demonstrating the activating effect of Ca2+·CaM.  
 Our structural results are consistent with binding to both the N-terminus and C-terminus 
of GRK5 by a single molecule of Ca2+·CaM. To dissect the roles of the individual domains of 
Ca2+·CaM, we studied the effects of its independent N- and C-terminal lobes (residues 1-75 and 
78-149, respectively). Both less potently inhibited receptor phosphorylation than full-length 
Ca2+·CaM, consistent with the fact that interfering with membrane association or receptor 
binding would diminish receptor phosphorylation (Figure 4.6 H). Interestingly, addition of both 
independent lobes of Ca2+·CaM was not sufficient to stimulate autophosphorylation (Figure 4.6 
I), suggesting that full-length Ca2+·CaM induces an autophosphorylation-prone conformation 
mediated by covalently linked lobes, and also that phosphorylation occurs in cis and not in trans. 
This effect is not limited to receptor substrates, as the independent lobes of Ca2+·CaM are also 
unable to stimulate autophosphorylation in the presence of soluble substrates (Figure 4.6 J,K). 
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Figure 4.6: Substrate phosphorylation in the presence of calmodulin. A) Rhodopsin (5 µM, 
light activated) phosphorylation and B) accompanying GRK5 (50 nM) autophosphorylation in 
the presence of Ca2+·CaM. C) Stimulation of GRK5 (50 nM) autophosphorylation by 
Ca2+·CaM in the absence of membranes or other substrates. D) Tubulin (10 µM) and E) 
corresponding GRK5 autophosphorylation in the presence of Ca2+·CaM. F) Phosphorylation 
of myelin basic protein (7 µM) and G) accompanying GRK5 autophosphorylation in the 
presence of Ca2+·CaM. H) Rhodopsin phosphorylation and I) accompanying GRK5 
autophosphorylation in the presence of the N-lobe, C-lobe, or 1:1 combination of N- and C-
lobes of Ca2+·CaM. J) Tubulin phosphorylation and K) accompanying GRK5 
autophosphorylation in the presence of the N-lobe, C-lobe, or 1:1 combination of N- and C-
lobes of Ca2+·CaM. All experiments were performed three times and reported as mean ± SD. 
Data were normalized to either substrate or GRK5 phosphorylation in the absence of small 
molecule inhibitor and/or Ca2+·CaM (100%) and an SDS-PAGE background (0%) 
measurement.
 4.3.5. Binding analysis of malbrancheamide with Ca2+·CaM and its effects on the 
Ca2+·CaM–GRK5 interaction. To discern which lobe of CaM is involved in binding each GRK5 
binding site, we turned to malbrancheamide, a halogenated fungal indole alkaloid that 
antagonizes Ca2+·CaM (Figure 4.7 A) (Figueroa et al., 2011) and is predicted through docking 
studies to bind to the C-terminal lobe (González-Andrade et al., 2016). However, prior binding 
experiments suggested a 2:1 malbrancheamide to Ca2+·CaM stoichiometry (Figueroa et al., 
2011). We first used isothermal titration calorimetry (ITC) to confirm the binding affinity and 
stoichiometry of malbrancheamide, provided by Amy Fraley of the Sherman lab, for Ca2+·CaM. 
The affinity (Kd) of malbrancheamide was determined to be 5.2 ± 0.8 µM, consistent with prior 
reports (Figueroa et al., 2011), and binds Ca2+·CaM with a 1:1 stoichiometry (Figure 4.7 B,C). 
The congener isomalbrancheamide D with a Br atom in place of the C-9 Cl (Fraley et al., 2017) 
was also assessed by ITC and displayed an affinity of 1.8 ± 0.3 µM and a stoichiometry of 1:1 
(Figure 4.7 B,C). 
We next determined the crystal structure of the Ca2+·CaM·malbrancheamide complex to 
1.96 Å spacings (Figure 4.8 A-C and Table 4.2), wherein a single malbrancheamide molecule is 
observed bound with its dichlorinated indole buried in the hydrophobic pocket of the C-lobe of 
Ca2+·CaM (Figure 4.8 B,C). Malbrancheamide forms a pair of hydrogen bonds with a 
neighboring molecule in a crystallographic symmetry mate (Figure 4.8 D). The C-8 chlorine 
packs against Phe93 while the indole is positioned between Leu106, Met125, and Met145. 
Malbrancheamide buries approximately 250 Å2 of surface area in the hydrophobic pocket (via 
PISA server, Krissinel and Henrick, 2007), consistent with ligands of similar affinities 
(Waldschmidt et al., 2016). The observed Ca2+·CaM conformation is rare and only reported one 
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other time our of several hundred Ca2+·CaM structures (Kumar et al., 2013). In this open 
conformation, the canonical binding site on the N-lobe of Ca2+·CaM is free to interact with other 
substrates while the C-lobe is bound to malbrancheamide. 
Addition of malbrancheamide to phosphorylation reactions containing Ca2+·CaM–GRK5 
did not recover rhodopsin phosphorylation, but inhibited GRK5 autophosphorylation (Figure 4.9 
A-D). Malbrancheamide also had no effect on the stimulation of phosphorylation of soluble 
substrates mediated by Ca2+·CaM (Figure 4.9 E), but similarly inhibited stimulation of 
autophosphorylation (Figure 4.9 F). This results indicates that the C-lobe of Ca2+·CaM is 
involved in phosphorylation of the C-terminus of GRK5, and that the N-lobe is responsible for 
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Figure 4.7: Binding analysis of malbrancheamide to Ca2+·CaM. A) Representative ITC 
binding curve for malbrancheamide (Mal) and Ca2+·CaM and chemical structure of 
malbrancheamide (inset). B) Binding affinity and C) stoichiometry. Isomalbrancheamide D 
(IsoMalD) contains a bromine atom in place of the C-9 chlorine. Data represented as mean ± 
SD (n=3). Statistical significance determined by Student’s two-tailed T-test (**p<0.01).
stimulation of GPCR and soluble substrates, 
likely via direct interactions with the small lobe 
of the kinase domain. 
 4.3.6. Perturbation of Ca2+·CaM lobe 
interactions with terminal regions of GRK5. In 
another approach, peptides spanning the known 
Ca2+·CaM binding sites on GRK5, ⍺N (residues 
2-31) and ⍺C (residues 546-565), were evaluated 
for their ability to disrupt regulation of GRK5 by 
Ca2+·CaM. Titration of either peptide inhibited 
autophosphorylation (Figure 4.9 H,J). However, 
whereas the addition of the ⍺N peptide recovered 
receptor phosphorylation, addition of the ⍺C 
peptide did not, mimicking the effect observed 
upon addition of malbrancheamide (Figure 4.9 
G,I). Neither peptide affected soluble substrate 
phosphorylation (Figure 4.9 I), although similar 
inhibition of autophosphorylation was observed 
(Figure 4.9 J). Thus, the C-terminus of GRK5 likely binds the C-lobe of Ca2+·CaM in the same 
manner as malbrancheamide. 
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Table 4.2: Crystallographic Data Collection 
and Refinement Statistics for the 
Ca2+·CaM·Mal Complex
Wavelength (Å) 1.03315
Resolution range 35.42 - 1.96 
(2.03 - 1.96)*
Space group C 2 2 21
Unit cell constants (Å, ˚) 49.1 56.9 116.8 
90 90 90
Total reflections 158616 (16218)
Unique reflections 12096 (1184)
Multiplicity 13.1 (13.7)
Completeness (%) 99.8 (99.8)
Mean I/σ(I) 7.47 (1.73)
Wilson B-factor 29.7
Rmeas 0.200 (0.831)
CC1/2 0.995 (0.944)
Reflections used in refinement 12080 (1181)
Reflections used for Rfree 1207 (118)
Rwork 0.216 (0.366)
Rfree 0.243 (0.386)
Number Non-hydrogen atoms 1221
  Protein 1127
  Ligand 32
  Solvent 62
RMSD bonds (Å) 0.002
RMSD angles (˚) 0.41
Ramachandran favored (%) 99.3
Ramachandran allowed (%) 0.7
Ramachandran outliers (%) 0
Rotamer outliers (%) 0.8
Clashscore 3.6
Average B-factor 54.0
  Protein 53.7
  Ligand 85.4
  Solvent 43.3
PDB Entry TBD
*Statistics for the highest-resolution shell are shown in 
parentheses
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Figure 4.8: Ca2+·CaM·malbrancheamide crystal structure. A) Rainbow ribbon representation 
of the Ca2+·CaM·Mal structure. Ca2+ are shown as yellow spheres. B) Surface representation 
of Ca2+·CaM with malbrancheamide shown in spheres bound to the C-lobe. C) C-lobe 
hydrophobic pocket with malbrancheamide bound. Black dotted line represents a hydrogen 
bond with a water molecule. Ca2+ is shown as a yellow sphere. Mesh represents |2Fo| - |Fc| 
electron density contoured at 1 σ. D) Interactions between malbrancheamide molecules in 
crystallographic symmetry mates.
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Figure 4.9: Effects of malbrancheamide and GRK5 peptides on Ca2+·CaM modulation of 
GRK5 activity. A) Rhodopsin (5 µM, light activated) phosphorylation and B) accompanying 
GRK5 (50 nM) autophosphorylation in the presence of 500 nM Ca2+·CaM and increasing 
concentrations of malbrancheamide. In these assays, Ca2+·CaM was either preincubated with 
malbrancheamide or with GRK5prior to the addition of malbrancheamide (“no preincubation”). 
C) Effect of malbrancheamide on rhodopsin phosphorylation and D) autophosphorylation in 
the absence of Ca2+·CaM. E) Tubulin (5 µM) phosphorylation and F) accompanying GRK5 
autophosphorylation in the presence of 500 nM Ca2+·CaM and varying concentrations of 
malbrancheamide. G) Rhodopsin phosphorylation and H) accompanying GRK5 
autophosphorylation in the presence of 500 nM Ca2+·CaM and varying concentrations of 
GRK5 ⍺N or ⍺C peptides. I) Tubulin phosphorylation and J) accompanying GRK5 
autophosphorylation in the presence of 500 nM Ca2+·CaM and varying concentrations of 
GRK5 ⍺N or ⍺C peptides. All experiments were performed three times and reported as mean ± 
SD. Data were normalized to either substrate or GRK5 phosphorylation in the absence of small 
molecule inhibitor and/or Ca2+·CaM (100%) and an SDS-PAGE background (0%) 
measurement.
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4.4. Discussion 
The role of GRK5 in heart failure and cardiac hypertrophy has spurned interest in both 
therapeutic development and the underlying molecular mechanisms of disease. Several recent 
studies have shed light on the role of GRK5 regulation by Ca2+·CaM at the cellular and 
physiological levels (Martini et al., 2008; Gold et al., 2013). However, the molecular basis of the 
interaction remains understudied. Prior pulldown assays showed that Ca2+·CaM affinity toward 
GRK5 was mediated by contacts with the N-terminal helix (residues 1-17), the basic 
phospholipid binding patch (residues 20-39), and the C-terminal amphipathic helix (residues 
552-561) (Pronin et al., 1997; Levay et al., 1998). Two primary models for the Ca2+·CaM–GRK5 
complex have been proposed, including one in which two Ca2+·CaM molecules bind distinct 
sites on GRK5 and one in which a single Ca2+·CaM molecule binds multiple elements 
simultaneously. Here, I present light scattering, SAXS, and negative stain EM data that reveal a 
single Ca2+·CaM binds in a manner that is in agreement with the latter model (Figure 4.10). 
The architecture of the complex reveals Ca2+·CaM binding near and likely interacting 
with the ⍺N and ⍺C helices simultaneously. Indeed, numerous structures of Ca2+·CaM bound to 
two helices have been reported in which Ca2+·CaM the pair of helices are positioned between the 
lobes containing Ca2+-bound EF-hands (Tidow and Nissen, 2013). The ⍺N helix has been 
proposed in some models to dock into the hydrophobic core of activated GPCRs and is well 
known to be critical for receptor recognition and phosphorylation (Pao et al., 2009; Huang and 
Tesmer, 2011). Thus, Ca2+·CaM binding to the ⍺N partially explains the inability of GRK5 to 
efficiently phosphorylate receptor substrates. Furthermore, the basic patch on GRK5 (residues 
20-39) that interacts with PIP2 to aid in membrane localization and allosteric activation of the 
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Figure 4.10: Proposed model of the regulation of GRK5 by Ca2+·CaM. Features critical for 
receptor docking and membrane association are sequestered by Ca2+·CaM but also induce an 
active conformation of the kinase. However, addition of the two independent lobes Ca2+·CaM 
does not promote an activated state of GRK5. The addition of ⍺N and ⍺C peptides or 
malbrancheamide (Mal) are able to relieve various aspects of regulation through differential 
binding to Ca2+·CaM.
kinase enhances Ca2+·CaM affinity when added to peptides of the ⍺N helix (Levay et al., 1998). 
In our model, this patch is adjacent to multiple acidic residues on Ca2+·CaM and would project 
basic residues toward the acidic surface of Ca2+·CaM which would engage in favorable 
electrostatic interactions and sterically occlude PIP2 binding (Figure 4.11). Because GRK5 is not 
lipid modified like other GRK4 subfamily members, its C-terminal amphipathic helix 
significantly contributes to membrane association. Sequestration of the ⍺C helix by Ca2+·CaM as 
suggested by our model would lead to impaired membrane association or altered orientation 
along the membrane surface further disrupting interactions with GPCRs.5 Together, this 
architecture is consistent with a kinase that would have difficulty interacting with membranes 
and receptor substrates when bound to Ca2+·CaM. 
Substrates of Ca2+·CaM often contain positively charged amphipathic helices with bulky 
hydrophobic side chains that anchor in the hydrophobic pockets of each lobe of Ca2+·CaM 
(Bhattacharya et al., 2004; Kursula, 2014). The terminal helices and basic patch of GRK5 
resemble canonical Ca2+·CaM substrates such as the well characterized myristoylated alanine-
rich protein kinase C substrate (MARCKS) (Pronin et al., 1997; Arbuzova et al., 1998; Yamauchi 
et al., 2003). With only minor manual movement of the terminal regions of GRK5 in our SAXS 
models, the ⍺N and ⍺C helices can both be placed in a canonical Ca2+·CaM binding mode with 
potential hydrophobic anchoring residues positioned near the hydrophobic pockets of Ca2+·CaM 
(Figure 4.11). 
Interestingly, although Ca2+·CaM potently inhibits receptor phosphorylation, the activity 
of GRK5 toward soluble substrates is enhanced. It has been previously reported that Ca2+·CaM 
stimulates phosphorylation of certain cytosolic proteins such as synucleins (Pronin et al., 2000), 
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but this appears to apply to all soluble substrates suggesting that Ca2+·CaM binding stabilizes an 
activated state of GRK5. As suggested by the GRK6·sangivamycin crystal structure (Boguth et 
al., 2010), the activated state of GRKs is stabilized by a network of contacts between the ⍺N 
helix, AST loop, and RH domains (Lodowski, Tesmer, and Benovic, 2006; Pao et al., 2009; 
Huang et al., 2009; Boguth et al., 2010; Huang et al., 2011). Because one lobe of Ca2+·CaM 
binds near these features based on our SAXS and EM data, stabilization of this interaction 
network likely explains the increase in GRK5 activity towards its soluble substrates. Addition of 
the isolated lobes of Ca2+·CaM, however, did not similarly activate kinase activity at any 
concentration tested, indicating that full-length Ca2+·CaM is required for stabilizing this active 
conformation of GRK5. 
 Unlike other members of the AGC family of protein kinases, GRKs do not require 
activation loop autophosphorylation for efficient catalysis. However, GRK5 undergoes PIP2-
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Figure 4.11: Potential docking residues in the GRK5 termini. Modeled termini for the A) 
DAMFILT and B) GASBOR SAXS models. Hydrophobic residues Leu3, Ile6, Val7, Leu554, 
and Phe555 are shown in spheres positioned near canonical hydrophobic binding pockets on 
Ca2+·CaM.
stimulated autophosphorylation at Ser484 and Thr485 in the AST loop (Kunapuli et al., 1994). 
Ca2+·CaM-stimulated autophosphorylation has been mapped to non-canonical residues in the 
extreme C-terminus of GRK5 (residues 579-590) that, similarly to phosphorylation by protein 
kinase C (PKC), further reduces the ability of GRK5 to associate with membranes and may 
represent a mechanism to prolong GRK5 inhibition after Ca2+·CaM has dissociated (Pronin and 
Benovic, 1997; Levay et al., 1998; Penn et al., 2000). Cleavage of the helix connecting the two 
lobes of Ca2+·CaM abolished Ca2+·CaM-stimulated autophosphorylation, suggesting that intact 
Ca2+·CaM positions the terminal elements of GRK5 in a specific conformation that allows for 
robust cis-autophosphorylation. A likely mechanism for this “repositioning” may simply be loss 
of membrane shielding of the C-terminal region of the kinase via the binding of Ca2+·CaM, 
which would free this disordered region to instead be acted on by the active site of the kinase 
domain, but it is also possible that Ca2+·CaM redirects the path of the C-terminus towards the 
active site. In addition to a shorter C-tail, the C-terminus of other GRK4 subfamily members is 
often palmitoylated (Stoffel et al., 1994; Premont et al., 1996; Sallese et al., 1997; Loudon and 
Benovic, 1997) and may remain membrane anchored when bound to Ca2+·CaM, explaining why 
GRK4 and 6 do not display Ca2+·CaM-induced autophosphorylation. 
 Despite a lack of high-resolution structures, our model, in combination with prior 
biochemical studies, allude to mechanisms of selectivity. The ⍺N helix is bound to one lobe of 
Ca2+·CaM in our model is variable across GRKs but is highly conserved within the GRK4 
subfamily, which are most potently inhibited by Ca2+·CaM. Likewise, the ⍺C helix and basic 
phospholipid binding patch are absent in the GRK1 and GRK2 subfamilies (Figure 1.3 B). Thus, 
these evolutionary differences may explain the preference for GRK4 subfamily members. 
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However, while GRK1 is inhibited by Ca2+·CaM in vitro, the primary regulator in cells is the 
related neuronal Ca2+-sensing protein recoverin further supporting evolutionary divergence 
between GRK subfamilies (Kawamura et al., 1993; Levay et al., 1998; Torisawa et al., 2008; 
Komolov et al., 2009). The potency of Ca2+·CaM for GRK4 subfamily members directly 
correlates with the number of basic residues in this patch which interacts with acidic residues on 
Ca2+·CaM in our model. Despite similarities in their ⍺C helices, GRK4 and 6 tend to be lipid 
modified which may limit accessibility of this region for binding to one lobe of Ca2+·CaM. 
Determination of the roles of the individual lobes of Ca2+·CaM were aided by the natural 
product malbrancheamide, which we showed to stabilize an unusual conformation of Ca2+·CaM 
and bind solely to the C-lobe. This implies that addition of the compound would mimic the 
action of a GRK5 that binds to the C-lobe. Indeed, the addition of malbrancheamide or the ⍺C 
peptide inhibited kinase autophosphorylation but did not affect receptor phosphorylation. 
Therefore, the C-lobe of Ca2+·CaM interacts with the C-terminus of GRK5 to dissociate the 
kinase from membranes, whereas the N-lobe interacts with the ⍺N helix to interfere with 
receptor phosphorylation. It has been previously noted that rhodopsin phosphorylation is 
similarly inhibited by an antibody that recognize epitopes in the N-terminus of GRK1 without 
affecting soluble substrate phosphorylation. (Palczewski et al., 1993). While not tested, the 
increased binding affinity of isomalbrancheamide D may more potently inhibit Ca2+·CaM 
interactions with GRK5. 
 Extraction of GRK5 from the plasma membrane by Ca2+·CaM is thought to allow the 
nuclear localization sequence located in the large lobe of the kinase (Johnson et al., 2004) to 
promote nuclear translocation and pathological gene activation. The fact that Ca2+·CaM activates 
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GRK5 against soluble targets would augment this ability. Pharmacological disruption of the 
interaction of the C lobe of Ca2+·CaM with GRK5 may represent a therapeutic strategy for 
attenuating Ca2+·CaM–GRK5-induced cardiac hypertrophy without attenuating the ability of 
Ca2+·CaM to repress receptor phosphorylation and hence downregulation (Figure 4.12). Several 
FDA-approved antipsychotics are known to bind Ca2+·CaM, though often with low affinity and 
with various side-effects due to inhibition of other targets (Feldkamp et al., 2015; González-
Andrade et al., 2016). Furthermore, Ca2+·CaM inhibitors often assume multiple binding poses, as 
is the case with the antipsychotic drug trifluoperazine which has been observed to bind in various 
orientations in either or both lobes of Ca2+·CaM (Vandonselaar et al., 1994; Feldkamp et al., 
2015; González-Andrade et al., 2016; Cook et al., 1994).  
 Our elucidation of the binding mode of malbrancheamide at the C-terminal lobe of 
Ca2+·CaM and its successful application in probing the Ca2+·CaM–GRK5 interaction highlights 
its potential as both a chemical probe and lead molecule for rational design. Milligram quantities 
of malbrancheamide can be readily obtained from small-scale fungal cultures (Fraley et al., 
2017). The elucidation of the biosynthetic pathway and more recent structural studies of the late-
stage halogenase have enabled the generation of novel analogs through chemoenzymatic 
synthesis using engineered enzymes (Fraley et al., 2017). One such analog, isomalbrancheamide 
D bearing a C-9 bromine in addition to C-8 chlorine, displays significantly higher affinity. 
Analysis of the Ca2+·CaM·Mal structure reveals additional space in the binding pocket near the 
C-9 position which the bulkier bromine may better occupy. However, the majority of reported 
malbrancheamide analogs and structurally similar natural products have yet to be evaluated for 
their ability to modulate the Ca2+·CaM–GRK5 interaction. Nonetheless, recent studies on 
!101
manipulating the biosynthetic pathways for malbrancheamide and structurally related natural 
products, along with our co-crystal structure and inhibition data, provide a starting point for the 
development of new products for use in selectively blocking C-lobe interactions of Ca2+·CaM.  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Figure 4.12: Scheme depicting the mechanism by which 
malbrancheamide may prevent nuclear translocation by 
releasing the C-terminus of GRK5 from Ca2+·CaM.
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Chapter 5: Recombinant Production of Human GRK5 in a Bacterial System 
5.1. Introduction 
 As highlighted in Chapters 1 and 4, GRK5 is an important kinase in the progression of 
cardiovascular pathologies and an attractive therapeutic target (Métayé et al., 2005; Hullmann et 
al., 2014). Thus, efficient expression and purification of GRK5 is needed to supply high-quality 
protein for structural and pharmacological studies. GRK5 is almost exclusively recombinantly 
purified from insect cells using engineered baculovirus (see 4.2.2) with small quantities obtained 
through mammalian cell expression systems. Both expression systems are more expensive and, 
in the case of insect cells, time consuming than recombinant expression in standard bacterial 
systems. Kinases in general are not often purified from bacterial systems due to cytotoxicity, 
resulting from phosphorylation of intracellular substrates, or misfolding. However, considerable 
success has been achieved using truncated or catalytically inactive kinases (Shrestha et al., 
2012), though such variants have limited use in biochemical assays. To date, there is only one 
report of a GRK being expressed and purified from a bacterial system. Gan et al. reported 
purification of soluble human GRK2, but the result was not reproducible in our lab.  
 To facilitate future studies of GRK5, we sought to develop a method for the rapid and 
cost-effective purification of full-length, human GRK5 from E. coli. In addition to cost and time 
savings, expression in bacterial systems affords other advantages. The production of isotopically 
labeled proteins for nuclear magnetic resonance (NMR) studies is significantly easier in bacterial 
expression systems. Additionally, the production of numerous protein variants in bacteria is 
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streamlined as time-consuming recombinant baculovirus does not need to be produced for each 
variant. 
 Previous attempts to purify GRK5 from bacterial systems yielded insoluble protein, even 
in the presence of solubilizing tags such as MBP. A GRK5 construct and purification protocol 
was devised to produce full-length human GRK5 in E. coli with comparable yields to insect 
expression systems. Characterization of the bacterially expressed kinase revealed extensive 
autophosphorylation that leads to a slight reduction in Vmax compared to GRK5 purified from 
insect cells which is restored upon mutation of a single phosphorylation site. 
5.2. Materials and methods 
 5.2.1. GRK5 cloning, expression, 
and purification. The human GRK5 gene 
was amplified with the addition of a C-
terminal Val-Asp spacer directly followed 
by a hexahistidine tag (Figure 5.1, see 
peptide sequence in Figure 5.5 F). 5’ NdeI 
and 3’ EcoRI restriction sites were also 
introduced to the gene fragment via PCR. 
The bacterial expression vector 
pMalC2H10T was digested with NdeI and 
EcoRI to remove the MBP-polyhistidine-TEV features and the GRK5 gene ligated into the 
modified vector to produce plasmid pMalEL17. 
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Figure 5.1: Vector map of human GRK5 in a 
modified pMalC2H10T (pMalEL17). Cloning was 
performed with the assistance of Emily Labudde 
(University of Michigan).
 5.2.2. GRK5 protein expression and purification. GRK5 was expressed in BL21 Rosetta 
cells containing the pRARE plasmid encoding rare tRNAs. Cells were grown in TB at 37 ºC until 
OD600 of ~0.6, cooled to 18 ºC, induced with 0.2 mM IPTG at OD600 = 1.0-1.2 , and grown 
overnight at 18 ºC. Cells were pelleted and resuspended in lysis buffer containing 20 mM 
HEPES pH 8.0, 200 mM NaCl, 40 mM imidazole, 5 mM MgCl2, 5 mM CaCl2, 1 mM DTT, 
leupeptin, lima bean trypsin protease inhibitor, and 2 µg mL-1 DNaseI and lysed with a 
EmulsiFlex-C3 cell homogenizer. Alternatively, DNaseI can be replaced with 0.02% (v/v) Triton-
X100 but should be omitted from later wash and elution buffers. Lysate was incubated on ice for 
30 m to allow for digestion of DNA prior to ultracentrifugation at >200,000xg for 1 h. The 
resulting supernatant was glass filtered, flowed through Ni-NTA resin, washed with lysis buffer, 
and eluted with lysis buffer containing and additional 200 mM imidazole. Eluted GRK5 was 
further purified by cation exchange chromatography with a HiTrap S column and eluted with a 
gradient of 0.0-1.0 M NaCl at pH 8.0. Anion exchange can also be used to purify GRK5 but 
removal of the lower band of truncated kinase is not as easily achieved. Eluted GRK5 was 
subsequently purified via SEC in a buffer containing 20 mM HEPES pH 8.0, 200 mM NaCl, and 
1 mM DTT with an analytical S200 column. GRK5 concentrations were determined by 
absorbance at 280 nm using the calculated molecular weight and molar extinction coefficient 
from the primary sequence and flash frozen in liquid nitrogen. Typical yields of ≥95% purity 
GRK5 by SDS-PAGE from E. coli. were 2 mg L-1. 
 5.2.3. Western blotting. Protein samples were separated via SDS-PAGE and transferred 
to nicrocellulose membranes overnight. The membrane was blocked with 5% (w/v) bovine serum 
albumin (BSA) in Tris-buffered saline Tween (TBST, 50 mM Tris pH 7.4, 150 mM NaCl, 0.1% 
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(v/v) Tween 20), incubated overnight with primary antibody (anti-hexahistidine [H3, Santa Cruz 
Biotechnology] or anti-N-terminus of GRK5 [LS-A3470-50, LifeSpan Biosciences]), washed 
with TBST, incubated with appropriate secondary antibody conjugated to horseradish 
peroxidase, washed with TBST, and protein detected via chemiluminescence on film. 
 5.2.4. Mass spectrometry and phosphosite mapping. Intact protein mass spectrometry 
(MS) was performed on an Agilent quadrupole time-of-flight tandem mass spectrometer (QTOF-
MS/MS) with an 1-3 µL injection volume of GRK5 at 1 mg mL-1 in buffer containing 1% (v/v) 
formic acid. Protein was desalted on a C18 chromatography column prior to mass analysis with 
positive electrospray ionization (ESI+). Phosphosite mapping was performed through the Purdue 
University Proteomics Facility. Briefly, purified GRK5 was digested with trypsin, the fragments 
analyzed via high-resolution MS without TiO2 enrichment, and phosphorylation sites identified 
through peptide ionization patterns compared to the nonphosphorylated primary amino acid 
sequence. 
 5.2.5. Kinetic analysis. Steady-state kinetic parameters were determined as previously 
described (Yao et al., 2017). Briefly, 50 nM GRK5 expressed and purified from insect cells or E. 
coli and 5 µM bovine rhodopsin in native membranes were combined in assay buffer containing 
20 mM HEPES, 10 mM MgCl2, and 1 mM DTT. Reactions were initiated with 2-200 µM ATP 
spiked with [γ-32P]-ATP and allowed to proceed for 5 min at room temperature prior to 
separation by SDS-PAGE and image analysis on phosphor screens. Standard curves for 
quantification were prepared using a serial dilution of [γ-32P]-ATP given the initial specific 
activity and number of half-lives passed. The maximum reaction velocity (Vmax) and apparent 
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Michaelis constant (Km) were determined via GraphPad Prism using a classic Michaelis-Menten 
plot. 
 5.2.6. Crystallization. GRK5 from E. coli at 9-11 mg mL-1 was incubated for 1 hr on ice 
with 2 mM ATP, 5 mM MgCl2 after which sitting-drop sparse-matrix screens were set with drops 
containing 0.5 µL protein and 0.5 µL well solution. Screens were incubated at either 4 or 20 ºC. 
After 1 wk at 4 ºC, rod-like crystals ranging from 25-250 µm in length appeared in Hampton 
Research Index HT E8 (0.2 M KCl, 0.05 M HEPES pH 7.5, 35% v/v pentaerythritol propoxylate 
(5/4 PO/OH)), C4 (35% v/v tacsimate pH 7.0), C9 (1.1 M sodium malonate pH 7.0, 0.1 M 
HEPES pH 7.0, 0.5% v/v Jeffamine ED-2001 pH 7.0), and Qiagen ProComplex G10 (1.6 M Na/
KPO4 pH 6.5). Crystals from Index C4 were reproduced in hanging-drop form after 1 mo at 4 ºC 
in 0.1 M Bis-Tris pH 5.8 and 35% (v/v) tacsimate. Crystals from ProComplex G10 were 
reproduced at 20 ºC in hanging-drop form under identical conditions. Diffraction data were 
collected at either LS-CAT or GMCA beamlines (Advanced Photon Source, Argonne National 
Lab). 
5.3. Results 
 5.3.1. Optimization of expression and purification in E. coli. Human GRK5 was cloned 
with a C-terminal hexahistidine tag, as N-terminal tags interfere with receptor phosphorylation, 
separated by a Val-Asp linker. Initial attempts to purify recombinant GRK5 from E. coli yielded 
insoluble protein. Expression in E. coli cell lines co-expressing different chaperones or the use of 
slower promoters such as Trc did not yield soluble protein (data not shown). Screening buffer 
additives revealed the addition of 0.02% (v/v) Triton-X100 or DNase to yield soluble protein 
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Figure 5.2: Purification of full-length, human GRK5 from E. coli. A) Comparison of small-
scale expression tests with either Triton X-100 or DNase added to the lysis buffer. Flow-
through (FT). GRK5 is indicated with an arrow. B) Further purification via anion exchange 
chromatography. Truncated kinase (left arrow) elutes prior to full-length GRK5 (right arrow). 
C) Representative anion exchange chromatogram from a HiTrap Q column. The blue trace is 
UV absorbance at 280 nm and the red trace is conductivity. The far right peak is composed of 
nucleic acid (by absorbance at 260 nm), D) Representative SEC chromatogram from an 
analytical S200 column. Eluted GRK5 is indicated by a bar under the peak. 
(Figure 5.2). Because soluble protein was obtained through the addition of DNase, it is likely 
that GRK5 associates with genomic DNA and pellets during ultracentrifugation, as GRK5 
contains a DNA-binding element in the large lobe of its kinase domain (residues 388-395) 
(Johnson et al., 2004). Furthermore, purification via anion exchange chromatography (Figure 
5.2 C) results in a large elution peak composed of nucleic acid, presumably short, digested 
genomic DNA associated with GRK5. 
 Western blotting with an antibody for the N-terminus of GRK4/5/6 revealed the presence 
of significant truncated kinase, especially in the C-terminus as the majority of the bands are 
nearly full-length (Figure 5.3 A,B). However, since the hexahistidine affinity tag is C-terminal, 
any prematurely truncated kinase will not bind Ni affinity resin and is easily separated from full-
length GRK5. Analysis of the codon abundance in E. coli suggests the smaller N-terminal 
fragments of GRK5 are the result of premature termination of protein translation, as a groups of 
rare codons are located in the human GRK5 gene that would yield truncation products of the 
approximate sizes observed (Figure 5.3 C). Expression was attempted in Rosetta E. coli 
containing the pRARE plasmid which encodes rare tRNAs without a reduction in truncated 
kinase. Furthermore, neither reduction of the expression temperature or IPTG concentration 
reduced the quantity of truncated GRK5. Codon optimization of the GRK5 gene also did not 
improve overall yields or reduce the prevalence of truncated product. 
 5.3.2. Thermal stability of bacterially expressed GRK5. To ensure GRK5 purified from 
E. coli was properly folded, DSF was performed to measure the thermal melting point (Tm) of 
the protein (Figure 5.4). No statistically significant difference is observed between GRK5 
purified from insect cells and from bacteria. Bacterially expressed GRK5 is thermally stabilized 
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Figure 5.3: Codon usage and premature termination of GRK5. A) SDS-PAGE analysis of 
GRK5 expressed in E. coli. The gel was stained with coomassie stain. B) Western blotting with 
an antibody recognizing the N-terminus of GRK4/5/6 reveals that most bands observed by 
coomassie staining are N-terminal fragments of GRK5. C) Codon usage analysis reveals 
several patches of low-abundance codons (underlined in red) that likely produce the bands 
observed in panels A and B.
by 5-7 ºC upon the addition of Mg2+·ATP or CCG-215022 similarly to GRK5 purified from 
insect cells. A slight but significant increase in melting temperature is observed for bacterially 
expressed GRK5 in the presence of ATP suggesting an increased affinity for the ligand. 
 5.3.3. Identification of unusual phosphorylation sites in GRK5. While confirming the 
identity of the purified GRK5 by western blotting, it was observed that bacterially expressed 
GRK5 is a slightly higher molecular weight than insect expressed GRK5 (Figure 5.5 A). 
Suspecting autophosphorylation, GRK5e was treated with λ phosphatase and a decrease in 
molecular weight was observed (data not shown), suggesting that the kinase was indeed 
phosphorylated. To confirm phosphorylation, bacterially expressed GRK5 was analyzed via 
intact protein mass spectrometry using QTOF-MS/MS (Figure 5.5 A). MS analysis revealed all 
protein to be phosphorylated between two and eight times with the most common being three to 
five phosphates. 
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Figure 5.4: Thermal stability of GRK5 assessed by DSF. A) Melt curves for GRK5 expressed 
and purified from E. coli. Data points represent mean ± SD (n=3). B) Melting temperature (Tm) 
for human GRK5 expressed and purified in insect or E. coli cells in the presence or absence of 
ligand. ΔTm relative to the corresponding apo Tm. Data reported as mean ± SD (n=3). Statistical 
significance determined via two-way ANOVA with Bonferroni correction for multiple 
comparisons  between bacterially and insect expressed GRK5 (**p<0.01). 
Tm (ºC) ΔTm (ºC)
Insect GRK5 40.0 ± 0.2
Insect+ATP 45.4 ± 0.1 +5.4
Insect+ CCG-215022 46.3 ± 1.0 +6.3
Bacterial GRK5 39.2 ± 0.1
Bacterial+ADP 43.5 ± 0.1 +4.3
Bacterial+ATP 46.6 ± 0.2 +7.4
Bacterial+CCG-215022 46.7 ± 0.1 +7.5
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 To identify which sites on GRK5 are phosphorylated, phosphosite analysis was 
performed. The data show extensive phosphorylation, primarily in the disordered C-terminus 
(Figure 5.5 B-F, Table 5.1). The two highest scoring phosphorylated peptides contain the 
canonical AGC kinase autophosphorylation sites Ser484 and Thr485 in the AST loop. Other 
frequently modified sites included Thr10 in the ⍺N helix and Thr404 in the large lobe of the 
kinase domain. Despite very low abundance, simultaneous phosphorylation was identified at 
Thr73, Ser86, and Thr93 in the RH domain and Thr494 and Ser500 in the AST/kinase domain. A 
series of phosphorylation sites were identified in the C-terminus following the ⍺C helix (residues 
565-590). Between one and eleven phosphorylation sites were identified in this region with the 
most prominent being four. Interestingly, several unusual types of phosphorylation were 
observed including phosphorylated histidine, cysteine, and aspartate residues. While histidine 
phosphorylation is uncommon, but well documented, in both prokaryotes and eukaryotes, 
phosphorylation of cysteine and aspartate residues is rare and only usually observed in 
prokaryotes. Taken together, our data suggest that GRK5 purified from E. coli is phosphorylated 
at the canonical sites Ser484 and Thr485 are with additional modification(s) primarily in the 
disordered, serine-rich C-terminus.  
 5.3.4. Kinetic analysis of bacterially expressed GRK5. To demonstrate that GRK5 
purified from E. coli was catalytically active and to determine the effect of hyperphosphorylation 
on the activity of GRK5, phosphorylation kinetics were determined through radiometric assays 
using purified rhodopsin in native membranes or soluble tubulin monomers as the substrate. 
Bacterially expressed and purified GRK5 has a significantly lower Vmax and apparent Km, ATP 
compared to insect expressed GRK5 in rhodopsin phosphorylation assays (Figure 5.6 A,B). 
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Figure 5.5: Representative mass spectrometry peptide fragment ions. A) Western blotting for 
the C-terminal hexahistidine tag showing a size difference between kinase from two expression 
systems (inset) and intact protein MS revealing multiple phosphorylated species for GRK5 
purified from E. coli. Exact mass of unphosphorylated GRK5 is 68,823.65 Da. B) 
Phosphorylated peptides spanning GRK5 residues 1-14, C) 140-154, D-E) 476-487, and F) 
571-590+hexahistidine tag.
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Table 5.1: Phosphosite Mapping of GRK5 purified from E. coli
Peptide (# hits with PTM) GRK5 Residue Range Type of Phosphorylation
Phosphorylation 
Site Scorea
MELENIVANTVLLK (1) 1-14 Thr 66
TIDRDYCSLCDKQPIGR (1) 48-64 Cys 35
QFCETRPGLECYIQFLDSVAEYEV
TPDEKLGEK (1) 69-101 2x Thr, 1x Ser 3
ELFSACAQSVHEYLR (1) 140-154 Cys 45
VLETEEVYSHK (1) 401-411 Thr 14
LGCQEEGAAEVK (1) 432-443 Cys 47
LGCQEEGAAEVKR (1) 432-444 Cys 79
DVLDIEQFSTVK (1) 476-487 Thr 74
DVLDIEQFSTVK (1) 476-487 Ser, Thr 51
DVLDIEQFSTVKGVNLDHTDDDF
YSK (2) 476-501 Ser, Thr 89
DVLDIEQFSTVKGVNLDHTDDDF
YSK (2) 476-501 Ser 77
DVLDIEQFSTVKGVNLDHTDDDF
YSK (2) 476-501 Thr 47
DVLDIEQFSTVKGVNLDHTDDDF
YSK (1) 476-501 His 11
SSPSSKTSFNHHINSNHVSSNSTG
SSVDHHHHHH (1) 565-590+hexahistidine Ser, Thr 25
SSPSSKTSFNHHINSNHVSSNSTG
SSVDHHHHHH (1) 565-590+hexahistidine 11x Ser 6
TSFNHHINSNHVSSNSTGSSVDH
HHHHH (1) 571-590+hexahistidine 4x Ser 67
TSFNHHINSNHVSSNSTGSSVDH
HHHHH (5) 571-590+hexahistidine Ser 33
TSFNHHINSNHVSSNSTGSSVDH
HHHHH (3) 571-590+hexahistidine 2x Ser 32
TSFNHHINSNHVSSNSTGSSVDH
HHHHH (1) 571-590+hexahistidine Asp 23
TSFNHHINSNHVSSNSTGSSVDH
HHHHH (1) 571-590+hexahistidine Asp, His 21
aPhosphorylation Site Score indicates both relative abundance and confidence in PTM assignment. The 
largest score for the group of peptides is shown. Phosphorylatable residues of the type identified are 
underlined. Scores ≥40 indicate definitive assignment of the indicated PTM to the corresponding 
peptide. Multiple hits for the same PTM on a peptide suggests a heterogeneous population (i.e., 
phosphorylation of different residues when multiple of the same type of site exist on a peptide).
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Figure 5.6: Steady-state kinetic analysis of GRK5 variants. A) Representative Michaelis-
Menten kinetic curves from one experiment with rhodopsin in native membranes in substrates. 
B) Vmax and C) Km (for ATP) values for GRK5 protein variants purified from insect or E. coli 
cells (n=3-4). Assays performed with the assistance of Qiuyan Chen (Purdue University and 
University of Michigan). Statistical significance determined via one-way ANOVA with Tukey’s 
correction for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001, n.s.=not significant 
p>0.05).
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Table 5.2: Crystallographic data collection statistics
GRK5·ATP
Wavelength (Å) 1.03315
Resolution range 65.42 - 8.22 
(8.51 - 8.22)*
Space group C 2 2 21
Unit cell constants (Å, ˚) 375.7 456.3 351.2 
90 90 90
Total reflections 393667 (38492)
Unique reflections 29590 (2871)
Multiplicity 13.3 (13.4)
Completeness (%) 99.7 (98.7)
Mean I/σ(I) 8.6 (2.3)
Rmeas 0.274 (1.26)
CC1/2 0.992 (0.832)
*Statistics for the highest-resolution shell are shown in 
parentheses
However, no significant difference in either kinetic parameter is observed for tubulin 
phosphorylation (Yao et al., 2017). Analysis of the phosphorylation sites led to the identification 
of p-Thr10 and p-Ser500 as possible causes for the observed decrease in activity. Thr10 and 
Ser500 are among the most common phosphorylation sites beyond the canonical Ser484 and 
Thr485. Thr10 is located in the ⍺N helix that has been proposed to interact with activated 
receptors and may explain the kinetic differences only toward receptor substrates (Noble et al., 
2003; Huang and Tesmer, 2011). Ser500 is located in a region of the AST loop near the 
membrane interface for GRKs and thus, phosphorylation may repel acidic phospholipid 
headgroups. Phospho-null GRK5 S500A further decreased Vmax toward rhodopsin and had no 
effect on Km (Figure 5.6 C). GRK5 T10A significantly increased Vmax to that of insect expressed 
GRK5 without affecting Km. 
 5.3.5. Crystallization of hyperphosphorylated GRK5. To determine if non-canonical 
phosphorylation has an effect on the structure of GRK5, bacterially expressed GRK5 with 
hyperphosphorylation was crystallized. A variety of ligands including ADP, AMP-PNP, ATP, 
sangivamycin, and CCG-215022 were tested with only Mg2+·ATP yielding crystals. Four 
different sets of conditions yielded crystals, two of which were reproducible with GRK5 from 
different purifications (Figure 5.7 A,B). The diffraction of all crystals was poor with the best 
yielding weak and highly anisotropic diffraction that processes to 7.7-8.5 Å in XDS in space 
group C222 or C2221 (Figure 5.7 C, Table 5.2). The extremely large volume (375.6, 456.3, 
351.2 Å; a, b, c) of the unit cell and weak diffraction suggests a high solvent content and/or many 
protein copies (Figure 5.7 D). Furthermore, the unit cell volume yields a broad Matthew’s 
coefficient distribution which makes determination of the probable number of protein copies in 
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Figure 5.7: Crystallization and diffraction of bacterially expressed GRK5 with 
hyperphosphorylation. A) Crystals grown of GRK5 with 5 mM Mg2+ and 2 mM ATP in 0.2 M 
KCl, 0.05 M HEPES pH 7.5, 35% pentaerythritol propoxylate (5/4 PO/OH) at 4 ºC or B) 0.1 M 
Bis-Tris pH 5.5 and 35% tacsimate. C) Diffraction image of GRK5 crystals shown in panel A. 
Diffraction extends to ~8 Å spacings and is highly anisotropic. D) Unit cell and single GRK5 
(~70 kDa, bottom right) placed via MR. The space group is likely C222 with unit cell 
dimensions of 375.6, 456.3, 351.2 Å (a, b, c).
the unit cell difficult but is likely >20 protomers. 
 Molecular replacement (MR) with the highest resolution data set was attempted with 
Molrep, Phaser, MoRDa, Balbes, and MrBUMP (Vagin et al., 1997; McCoy et al., 2007; Long et 
al., 2008; Winn et al., 2011; Keegan et al., 2018). Phaser easily generated solutions with 1-4 
copies of GRK5 per asymmetric unit (ASU) (Figure 5.7 D). While these solutions were 
statistically definitive (translation function Z score >8), much of the unit cell remained 
unoccupied and searching for more than a few copies or trying to identify non-crystallographic 
symmetry (NCS) operators were extremely time consuming with routine computing resources. 
MoRDa, Balbes, and MrBUMP were run through the ccp4 online servers which have additional 
computational resources for use on complex MR jobs. Only MoRDa yielded possible MR 
solutions containing 28-36 copies of either GRK1 or GRK6 per ASU. Additionally, refinement of 
such a large solution was similarly computationally intensive. Thus, the online PDB Redo server 
utilizing a modified Refmac protocol was used for refinement. Unfortunately, identifying an MR 
solution that appropriately refines (decrease in R factors and improvement in map quality) has 
not been possible. 
5.4. Discussion 
 Bacterial expression and purification represents a faster and more cost effective route to 
obtain GRK5. While prior attempts to purify GRK5 from E. coli led to insoluble protein, we 
show that the simple addition of detergent or DNase is sufficient to obtain quality protein, the 
latter of which suggests the protein associates with genomic DNA. Indeed, GRK5 contains both 
a NLS and DNA binding element as a small fraction of endogenous GRK5 is nuclear and 
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involved in the regulation of gene expression (Johnson et al., 2004). When purified from insect 
cells, nuclei are not often disrupted and thus GRK5 does not pellet with nucleic acids. 
Interestingly, the presence of the C-terminal Val-Asp-hexahistidine tag was required for 
purification. Placing the affinity purification tag on the N-terminus yielded soluble protein 
without activity toward receptors, but for an unknown reason, omission of the Val-Asp spacer on 
the C-terminal tag yielded insoluble protein. Attempts to purify soluble GRK2 as previously 
reported (Gan et al., 2000) or GRK1 in E. coli have been unsuccessful. Perhaps, GRK5 is 
uniquely suited for bacterial expression, however expression and purification other GRKs in E. 
coli need to be attempted before such a conclusion can be made. 
 Interestingly, the resulting GRK5 displays an unusual pattern of phosphorylation that has 
a significant effect on catalytic activity towards receptor but not soluble substrates. As bacteria 
lack canonical Ser/Thr kinases, most phosphorylation events are likely the result of GRK5 
autophosphorylation. Autophosphorylation at some sites may occur during expression in insect 
and mammalian cells but are removed by phosphatases which bacteria lack. The presence of 
uncommon and rare phosphorylation events on histidine, cysteine, and aspartate highlights the 
differences in cell physiology between prokaryotes and eukaryotes. Histidine and aspartate 
phosphorylation are often coupled, as phosphates are typically attached to histidine residues 
during the intermediate steps of aspartate phosphorylation which is common in two-component 
signaling in bacteria (Swanson et al., 1994; West and Stock, 2001). Cysteine phosphorylation is 
remarkably common in prokaryotes and is essential for the phosphotransferase system used to 
phosphorylate glucose during transport (Guan and Dixon, 1991; Stuckey et al., 1994; Pannifer et 
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al., 1998; Sun et al., 2012). However, phosphorylation of histidine, cysteine, and aspartate 
residues outside of the aforementioned biological processes is rare and not well understood. 
 The majority of observed phosphorylation sites are located in the C-terminus and might 
be expected to repel the membrane binding ⍺C helix from membranes thereby reducing the 
efficiency of receptor phosphorylation. The decrease in activity towards receptors is less 
dramatic than expected from hyperphosphorylation, possibly due to the phosphorylation sites 
being in the extreme C-terminus rather than adjacent to the membrane binding ⍺C helix. Indeed, 
analysis of the C-terminus of GRK6 revealed that residues immediately following the ⍺C helix 
(561-567) enhance membrane association and receptor phosphorylation while residues in the 
extreme C-terminus act in an autoinhibitory fashion (Vatter et al., 2005). Since the residues 
responsible for enhancing membrane association include serine residues that were 
phosphorylated in our analyses, these residues warrant further investigation via mutagenesis and 
kinetic analysis. 
 Mutation of selected phosphorylation sites elsewhere in GRK5 identified Thr10 in the ⍺N 
helix as a key contributor to the decreased activity towards receptors, as the presumably 
hyperphosphorylated T10A variant exhibited the same activity as GRK5 purified from insect 
cells which lacks phosphorylation at this site. Restoration of catalytic activity upon mutation of 
Thr10 is in line with what is hypothesized about GRK-GPCR docking interactions (Huang and 
Tesmer, 2011). Phosphorylation of Thr10 would introduce a bulky charged group in a region of 
the kinase that is proposed to dock into or near the hydrophobic core of activated GPCRs. 
Interestingly, bacterially expressed, hyperphosphorylated GRK5 displays a significantly 
decreased apparent Km for ATP indicating a higher affinity for ATP than minimally 
!120
phosphorylated GRK5 from insect cells potentially explaining the significant enhancement in 
thermal stability in the presence of ATP. The prevalence of canonical AST loop 
autophosphorylation in GRK5 purified from bacteria, which activates AGC family kinases 
(Kunapuli et al., 1994), may explain the increase in apparent Km and thermal stability since 
GRK5 purified from insect cells generally lacks AST loop phosphorylation unless stimulated by 
phospholipids. 
 The described construct and purification scheme will facilitate diverse future studies of 
GRK5. Bacterial expression and purification enables the incorporation of unnatural amino acids 
via amber stop codons into GRK5 (Chin et al., 2002). The incorporation of photocrosslinking 
unnatural amino acids may enable the capture and study of novel GRK5 binding partners or 
substrates in cells (Dumas et al., 2015). Furthermore, selective crosslinking may aid in the 
trapping and determination of a GRK5-GPCR structure by capturing the transient interaction 
with a greater amount of homogeneity than obtained with other crosslinking strategies. NMR 
studies involving GRKs have been limited due to the difficulty of producing isotopically labeled 
kinase in insect cells and their large size (65-80 kDa). As isotope labeling methods are well 
established in bacterial systems, obtaining GRK5 suitable for NMR studies will be more easily 
attainable, facilitating the study of GRK5 dynamics and protein-protein interactions. Beyond the 
aforementioned technical advantages, bacterial expression of GRK5 is simply faster and cheaper 
which is advantageous when studying GRK5 with limited resources.  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Chapter 6: Conclusions and Future Directions 
 6.1. Development of inhibitors targeting IKKε and TBK1. The identification of the non-
canonical inflammatory kinases IKKε and TBK1 as key regulators of obesity and the 
development of type 2 diabetes has lead to interest in the pharmacologically targeting of both 
kinases. Preliminary work identified IKKε and TBK1 as targets of the unrelated FDA-approved 
drug amlexanox. Treatment with amlexanox improved insulin sensitivity, among other beneficial 
effects, in clinical trials with obese and diabetic patients. My aim was to use structural biology to 
characterize the binding of amlexanox to its target kinases to facilitate the design of analogs with 
improved potency, selectivity, and efficacy.  
 To this end, I solved the TBK1·amlexanox structure which revealed type I, ATP-
competitive binding along the kinase hinge. The structure revealed an important interaction 
between the carboxylate on amlexanox and Thr156 in the kinase. SAR established that this 
interaction was essential for potent inhibition of only TBK1, alluding to a mechanism for the 
development of IKKε selective inhibitors. Furthermore, modification of solvent exposed regions 
of the kinase improved potency, through unusual interactions with the neighboring dimerization 
domain, and also efficacy in cellular and animal models of obesity.  
 Of more than 100 analogs, we identified several with potencies as low as 200 nM and 
enhanced efficacy, though these two properties appear to be mutually exclusive. While not 
uncommon in therapeutic development, questions still remain as to the disconnect between in 
vitro kinase inhibition and cellular response. Generally, inhibitor solubility correlated well with 
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potency but not efficacy, suggesting undesirable pharmacokinetic properties. As adipocytes 
contain large fat deposits, lipophilic inhibitors may accumulate in the cells to produce a greater 
response. Indeed, the most efficacious compounds bear lipophilic groups such as cyclohexyl and 
iso-pentyl. Exploration of variants of the amlexanox pharmacophore, such as the two ring 
inhibitor series described here, may yield inhibitors with improved efficacy in animals. Future 
studies and inhibitor development should include permeability assays, such as PAMPA or Caco-2 
cells, to screen compounds prior to extensive in vivo studies. Despite significant improvements 
in potency in vitro, no analogs display superior efficacy to amlexanox in animals. As inhibitors 
targeting TBK1 and IKKε affect both the obese and diabetic phenotypes, a combination of 
readouts, such as IL-6 secretion and p-p38, for efficacy are considered when examining efficacy. 
Some amlexanox analogs produced greater efficacy in select readouts in cultured adipocytes but 
failed to elicit a greater response in obese mice. Such an observation is not uncommon, as 
inhibitor distribution and metabolism is more complex in vivo than in cell culture. Perhaps, the 
response achieved with amlexanox or select analogs represents the ceiling for efficacy for 
engagement of the targets TBK1 and IKKε which would necessitate the identification and 
targeting of novel members of thermogenic and insulin signaling cascades.  
 Emerging evidence suggests that IKKε and TBK1 play different roles in metabolic 
disease (Chiang et al., 2009; Zhao et al., 2018). Despite characterizing more than 100 analogs, 
none with exquisite selectivity were identified. Given that IKKε and TBK1 are >70% in 
sequence in their kinase domains, improving upon inhibitor selectivity will likely require the 
elucidation of an IKKε crystal structure of which none have been reported despite extensive 
efforts on my own part. Such structure could enable the identification of subtle structural 
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differences from TBK1 which may be exploited in future inhibitor analogs. Attempts to 
crystallize IKKε were complicated by the tendency of IKKε to aggregate during purification. 
Because extensive screening of buffer conditions and constructs including the isolate kinase 
domain, kinase-ubiquitin-like domains, and C-terminally truncations analogous to the 
crystallized TBK1 construct have already been performed without success, alternative 
approaches such as the identification of new constructs by proteolytic digestion or the 
introduction of binding partners may aid in stabilizing the protein. However, many interacting 
partners require polyubiquitination of IKKε for binding (Chau et al., 2008; Tu et al., 2013; Zhou 
et al., 2013; Rajsbaum et al., 2014), adding another layer of complexity for crystallographic 
studies. Because IKKε functions as a 160 kDa homodimer (Huynh et al., 2002; Chau et al., 
2008), atomic-resolution structure determination should now be feasible by cryo-EM which does 
not require highly concentrated protein samples. 
 6.2. Characterization and targeting of the Ca2+·CaM–GRK5 complex. Recent 
identification of the role of Ca2+·CaM-mediated nuclear GRK5 translocation in the progression 
of cardiac hypertrophy has renewed interest in a this protein-protein interaction that was first 
described more than two decades ago. Here, I described the architecture of the complex and use a 
variety of peptide and natural product probes to interrogate the interactions between the proteins 
and their effects on kinase regulation. Ca2+·CaM interacts with GRK5 along the membrane 
binding surface of the kinase and RH domains, most likely through simultaneous interactions 
with the N- and C-terminal helices and the PIP2 binding patch, with the net effect of dissociating 
GRK5 from membranes and permitting its nuclear translocation. 
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 Our current understanding of the precise molecular interactions between GRKs and 
Ca2+·CaM is limited by the low resolution of SAXS and negative stain EM, necessitating the 
elucidation of higher resolution structures. Co-crystallization of the complex has been 
unsuccessful possibly due to the dynamic nature of Ca2+·CaM and the interacting regions of 
GRK5. Indeed, the ⍺N helix, basic phospholipid binding patch, and C-terminus where Ca2+·CaM 
binds are not resolved in most GRK crystal structures or are trapped in crystal contacts (Tesmer 
et al., 2005; Lodowski, Tesmer, Benovic, et al., 2006; Komolov et al., 2015; Homan, 
Waldschmidt, et al., 2015; Allen et al., 2015). Furthermore, the 90 kDa size of the Ca2+·CaM–
GRK5 complex poses challenges for structural analysis by EM, however recent advances in data 
processing software and physical technology, such as the implementation of phase plates and 
energy filters, will alleviate these size restrictions in the near future. 
 Future studies of the Ca2+·CaM–GRK5 complex should focus on connecting biochemical 
and biophysical characterization of the interaction to cellular physiology and in vivo pathologies. 
We have shown that the binding of Ca2+·CaM generally activates GRK5 toward soluble 
substrates and thus, whole-cell phosphoproteomic analysis may reveal new cytosolic targets of 
Ca2+·CaM-activated GRK5. Furthermore, the identification of the natural product 
malbrancheamide, which is likely cell permeable, as a partial inhibitor of the bitopic Ca2+·CaM–
GRK5 interaction will enable selective probing of the protein-protein interaction in cells. The 
bitopic nature of the interaction and the selective disruption of one half of the interaction sheds 
light on a possible route for therapeutic intervention. Our data suggest that disruption of the 
Ca2+·CaM C-lobe interaction with GRK5 may maintain membrane localization and attenuate the 
cardiac hypertrophic response. The effect of the common Ca2+·CaM inhibitor calmidazolium, 
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which completely blocks Ca2+·CaM binding, on the hypertrophy in cells revealed therapeutic 
potential for targeting this interaction but may lead to adverse side effects as calmidazolium also 
inhibits a plethora of ion channels (Gold et al., 2013). Future efforts should examine the effects 
of other natural product Ca2+·CaM inhibitors related to malbrancheamide as potential therapeutic 
leads for cardiac hypertrophy because such compounds will expand efforts to target Ca2+·CaM 
into new chemical space.  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